A Human Study on the Intra- and Interindividual Variation in Absorption and Metabolism of Coffee Chlorogenic Acids and Effects on Biomarkers of Health in Humans by Kraut, Nicolai U
A Human Study on the Intra- and Interindividual 
Variation in Absorption and Metabolism of Coffee 
Chlorogenic Acids and Effects on Biomarkers of 
Health in Humans  
 
Nicolai Ulrich Kraut 
 
 
Submitted in accordance with the requirements for the degree of 
Doctor of Philosophy 
 
 
The University of Leeds 
School of Food Science and Nutrition 
 
 
November, 2014 
  
- ii - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Let food be thy medicine and medicine thy food. 
 
Hippocrates, 460-370 BC 
 
  
- iii - 
The candidate confirms that the work submitted is his own, except where work which has 
formed part of jointly-authored publications has been included. The contribution of the 
candidate and the other authors to this work has been explicitly indicated below. The 
candidate confirms that appropriate credit has been given within the thesis where reference 
has been made to the work of others. 
 
 
Paper 
 
da Encarnação, Joana Amarante; Farrell, Tracy L.; Ryder, Alexandra; Kraut, Nicolai U. and 
Williamson, Gary, 2014. In vitro enzymic hydrolysis of chlorogenic acids in coffee. 
Molecular Nutrition & Food Research, 10-1002/mnfr201400498 
 
 
Conference presentations 
 
Kraut, Nicolai U.; Kerimi, Asimina and Williamson, Gary. Quantitation of novel glycine 
conjugates of chlorogenic acid from coffee after consumption by volunteers, Oral 
presentation, VI International Conference on Polyphenols and Health, Buenos Aires, 
Argentina, 2013 
 
Kraut, Nicolai U.; Kerimi, Asimina; Poquet, Laure and Williamson, Gary. Urinary markers 
of coffee consumption detected by LC-MS, Poster presentation, V International Conference 
on Polyphenols and Health, Sitges, Spain, 2011 
 
This copy has been supplied on the understanding that it is copyright material and that no 
quotation from the thesis may be published without proper acknowledgement. 
© 2014 The University of Leeds and Nicolai Ulrich Kraut 
- iv - 
Acknowledgement 
 
First and foremost, I would like to thank my PhD supervisor, Prof Gary Williamson, for 
providing the opportunity of studying towards a PhD in his group and for offering and 
securing a generous studentship. Gary, you were always willing to share your broad 
knowledge and genuine enthusiasm for science. Thank you for your praise, constructive 
criticism, abundant time for discussion, advise concerning daily laboratory issues, but above 
all for being a great companion during the last four years.  
I would like to express my sincere gratitude to Prof Philip Kocienski for his selfless support 
with the chemical synthesis of the glycine and sulphate conjugates of hydroxycinnamic 
acids and for sharing his passion for world literature.  
Thanks to Dr Asimina Kerimi for her support, encouragement, endless time for discussion 
and advice. Mina, thank you for your Mediterranean temperament and spreading your 
energy. 
Special thanks to Miss Joana Encarnaçao, my fellow PhD student, with whom I spent 
numerous hours planning and performing the human study. At the beginning it was not 
always easy to work together, but over time we became a good team.  
Thanks a lot to all my fellow PhD students, especially to Miss Reyna Gutierrez Rivera, for 
the great teamwork on LC-MS, Miss Kerstin Ziegler and Dr Rui Pimpão for the 
controversial, but scientifically stimulating discussions and the practical assistance.  
A very warm thank you to Mrs Helgard Sofie Shaw for everything she has meticulously 
managed for me over the last years. Your life is a true inspiration to future generations. 
I am very grateful to my extended Blenheim family for making me feel at home in Leeds. 
I thank my family for their generous support – financially and emotionally – their constant 
encouragement, sympathy, and for bringing me up as a fair-minded person.  
Kathrin, thank you for your encouragement, sympathy and unconditional love.  
  
- v - 
Abstract 
 
Coffee is a rich source of caffeoylquinic acids, esters of caffeic or ferulic acid and quinic 
acid and its consumption is associated with various health benefits. However, upon 
ingestion of coffee, caffeoylquinic acids are abundantly absorbed, widely metabolised and 
extensively excreted in humans.  
The first part of this thesis addresses the synthesis and subsequent analysis of several 
glycine conjugates of hydroxycinnamic acid in urine collected by six participants of a pilot 
human study. For the first time vanilloylglycine has been quantified in urine for the first 
time after coffee consumption in similar amounts to feruloylglycine, whereas 3,4-
dimethoxycinnamoylglycine, 3,4-dimethoxydihydrocinnamoylglycine, 3,4-
dimethoxybenzoylglycine and dihydroferuloylglycine have only been detected in trace 
amounts.  
The second part of this thesis describes the chemical synthesis of several hundred 
milligrams of dihydrocaffeic acid-3-O-sulfate, ferulic acid-4-O-sulfate, and dihydroferulic 
acid-4-O-sulfate, the development of a rapid LC-MS method for the analysis of the five 
most excreted urinary metabolites of caffeoylquinic acids, the design and performance of a 
human study investigating the intra- and interindividual absorption of caffeoylquinic acids 
in humans and linking these results to biomarkers of health and food intake.  
Among 62 participants, an 8-fold variation in excretion of the total amount of the five most 
abundant, urinary metabolites excreted over 36 hours after coffee consumption was 
calculated and the intraindividual variation between repeated visits was the highest for 
colonic metabolites. A moderate, negative correlation of the absorption of caffeoylquinic 
acids with the weekly consumption of coffee was established. The data suggests a strong 
impact of colonic catabolism on the absorption and metabolism of caffeoylquinic acids and 
a reducing effect of heavy coffee consumption on the absorption of caffeoylquinic acids in 
humans.  
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Chapter 1: Introduction 
 
1.1 Coffee 
Coffee is the world’s third most consumed beverage after water and tea, and is prepared from 
roasted coffee beans grown on shrubs of the Rubiaceae family [1] in the latitude of the tropics 
and subtropics. The species Coffea Arabica L. and Coffea canephora, commonly referred to as 
Arabica and Robusta coffee, are of main economical interest. Less known species are Coffea 
liberica (Liberica coffee) and Coffea dewevrei (Excelsa coffee) [2]. The Arabica coffee plant 
was first botanically described by Linnaeus in 1753, although coffee beans have been cultivated, 
harvested and used to brew coffee in the Middle East since the 15
th
 century.  
After flowering it takes nine to eleven months to grow the ripe, deep-red fruit known as the 
coffee cherry [3]. As coffee is grown in mountainous areas, coffee cherries are still mainly 
hand-picked, a very labor-intensive work. A coffee picker can harvest 100-200 pounds of coffee 
fruits a day, yielding up to 20 pounds of coffee beans a day [3]. There are two coffee beans 
located side by side to each other covered by a silver skin, an endocarp, a mesocarp and a red 
exocarp. Prior to processing, in order to yield roasted coffee beans for sale, the fruit needs to be 
dried. The drying process is mainly performed underneath the sun, by spreading the coffee 
beans on cotton cloth or just on stone or concrete patios. The drying process can take up to 4 
weeks during which the beans are turned by raking [4].  
In 2009, Brazil (2,432,904 t), Vietnam (1,176,000 t) and Colombia (887,661 t) were the world’s 
largest producers of green, unroasted coffee beans [5]. Green coffee beans are shipped, mainly 
to Western countries, for large-scale, industrial coffee roasting. Various roasting processes yield 
the roasted coffee beans needed to prepare several types of coffee brews ranging from mixtures 
with herbs, such as cardamom, known as Arabic-style coffee, Italian-invented espresso to paper-
filtered or percolated coffee [3]. Green coffee beans contain up to 14% (dry weight) of phenolic 
compounds and roasting reduces the phenolic compound content significantly [6].  
Coffee consumption varies considerably from several cups of coffee a day in Scandinavian 
countries down to two cups per year in China [3].  
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1.2 Caffeoylquinic acid and its derivatives in coffee 
Coffee contains various plant-derived compounds, generally known as plant secondary 
metabolites of which some are known to exert certain beneficial effects to health. 
Beside caffeine, melanoidins, and the diterpenes (cafestol and kahweol), caffeoylquinic acid and 
its derivatives are some of the plant bioactive compounds found in coffee beans [1].  
Chlorogenic acids (CGA) are a group of compounds consisting of various esters of trans-caffeic 
and/or trans-ferulic acid with quinic acid. Stalmach et al. detected 13 caffeoylquinic acid and its 
derivatives in instant coffee, which are illustrated in Figure 1.1, consisting of 3-O-
caffeoylquinic acid, 4-O-caffeoylquinic acid, 5-O-caffeoylquinic acid, 3-O-feruloylquinic acid, 
4-O-feruloylquinic acid, 5-O-feruloylquinic acid 3,4-O-dicaffeoylquinic acid, 3,5-O-
dicaffeoylquinic acid, 4,5-O-dicaffeoylquinic acid, 3-O-caffeoyl-1,5-quinide, 4-O-caffeoyl-1,5-
quinide and 4-O-p-coumaroylquinic acid and 5-O-p-coumaroylquinic acid [7]. All chemical 
structures are depicted according to IUPAC numbering [8]. 
5-Caffeoylquinic acid is most abundant with 25-30% molar of the total caffeoylquinic acid and 
its derivatives content, whereas other derivatives have relative abundances of 4-CQA > 3-CQA 
> 5-FQA > 4-FQA > 3-FQA > diCQAs [9]. The detrimental effect of roasting, accompanied by 
pyrolysis and maillard reactions, on the total caffeoylquinic acid and its derivatives content was 
demonstrated by Mills et al. [9].  
  
- 3 - 
Figure 1.1: Caffeoylquinic acid and its derivatives detected in coffee according to 
Stalmach et al., 2009 
 
3-O-caffeoylquinic acid      4-O-caffeoylquinic acid        5-O-caffeoylquinic acid 
 
3-O-feruloylquinic acid        4-O-feruloylquinic acid        5-O-feruloylquinic acid 
 
3,4-O-dicaffeoylquinic acid   3,5-O-dicaffeoylquinic acid   4,5-O-dicaffeoylquinic acid  
 
3-O-caffeoyl-1,5-quinide     4-O-caffeoyl-1,5-quinide     4-O-p-coumaroylquinic acid 
5-O-p-coumaroylquinic acid 
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Clifford et al. reported of twelve new derivatives of caffeoylquinic acid found in green coffee 
beans including 3-O-dimethoxycinnamoylquinic acid; 4-O-dimethoxycinnamoylquinic acid; 5-
O-dimethoxycinnamoylquinic acid; 3-O-dimethoxycinnamoyl, 4-O-caffeoylquinic acid; 3-O-
dimethoxycinnamoyl, 5-O-caffeoylquinic acid; 4-O-dimethoxycinnamoyl, 5-O-caffeoylquinic 
acid; 3,4-O-diferuloylquinic acid, 3,5-O-diferuloylquinic acid; 4,5-O-diferuloylquinic acid; 3-O-
dimethoxycinnamoyl, 4-O-feruloylquinic acid; 3-O-dimethoxycinnamoyl, 5-O-feruloylquinic 
acid; 4-O-dimethoxycinnamoyl, 5-O-feruloylquinic acid [10] which are depicted in Figure 1.2.  
Figure 1.2: Minor derivatives of caffeoylquinic acid detected in green coffee beans 
according to Clifford et al., 2006 
  
3-O-DMCQA                               4-O-DMCQA                       5-O-DMCQA 
 
3-O-DMC, 4-O-CQA           3-O-DMC, 5-O-CQA                4-O-DMC, 5-O-CQA 
 
3,4-O-diFQA                            3,5-O-diFQA                       4,5-O-diFQA 
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3-O-DMC, 4-O-FQA            3-O-DMC, 5-O-FQA             4-O-DMC, 5-O-FQA 
 
According to Clifford [11] a cup of coffee contains 70-350 mg of caffeoylquinic acid and its 
derivatives, thus coffee consumers in the UK ingest up to 1 g of caffeoylquinic acid and its 
derivatives per day. However, the content of caffeoylquinic acid and its derivatives in espresso 
coffee varies substantially, by 18-fold (24 to 422 mg/cup), between different coffee shops 
according to Crozier et al. [12]. Similar findings were reported by Ludwig et al [13] who 
quantified caffeoylquinic acid and its derivatives ranging from 6-188 mg per cup of coffee. 
Nonetheless, for habitual coffee drinkers, coffee is the major source of caffeoylquinic acid and 
its derivatives. 
Recently, Nestle S.A. developed and launched an instant coffee, the commercially available 
Nescafé Green Blend [14], which is manufactured from a blend of green and roasted coffee 
beans in order to increase the caffeoylquinic acid and its derivatives content, which was 
independently analysed by Mills et al. [9]. In comparison with other Nescafé instant coffees, 
Nescafé Green Blend, contains about a 2.4-fold higher amount of caffeoylquinic acid and its 
derivatives. 
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1.3 Absorption, metabolism and excretion 
Following ingestion of coffee, caffeoylquinic acid and its derivatives are abundantly absorbed, 
extensively metabolized, and widely excreted in urine.  
 
1.3.1 Absorption 
Several previous studies investigated the absorption and subsequent metabolism of 
caffeoylquinic acid and its derivatives in humans [7, 15-21]. Co-consumption of milk and coffee 
did not delay or reduce the absorption of caffeoylquinic acid and its derivatives in contrast to 
non-dairy creamer according to Renouf et al. [22]. 
Within half an hour, minor amounts of intact 5-caffeoylquinic acid reach the circulatory system 
and show a Tmax of 1h according to Stalmach et al. [7]. However, most early detected 
caffoylquinic acid and its derivatives derived compounds were found to be in their metabolised 
form, i.e. the ester bond between caffeic or ferulic acid and quinic acid has been cleaved and the 
free hydroxycinnamic acid has been conjugated with, e.g. sulphate. In fact, caffeic acid-3-O-
sulphate and ferulic acid-4-O-sulphate are the first metabolites of caffeoylquinic acid and its 
derivatives to be detected in substantial concentrations in plasma after the ingestion of coffee. 
Prior to the absorption of caffeoylquinic acid and its derivatives, the cleavage of the ester bond 
between caffeic or ferulic acid and quinic acid is attributed to pancreatic and brush border 
esterases in the small intestine [15] and microbial esterases in the colon [17].  
After passing through the stomach, the first important site of absorption is the small intestine 
where the free hydroxycinnamic acids are absorbed through the intestinal epithelium. The 
mechanism of transport is somewhat controversial. According to Konishi and Kobayashi [23] 
caffeic acid and 5-caffeoylquinic acid pass through the intestinal epithelium through 
paracellular diffusion and to a lesser extend through active transport via monocarboxylic acid 
transporters (MCT) in the Caco-2 cell monolayer absorption model, whereas Poquet et al. 
reported that ferulic acid is mainly transported through the intestinal epithelium by passive 
transcellular diffusion rather than via MCT [24].  
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Studies with ileostomists, participants who underwent surgical removal of the colon, showed 
that only 8-10 % of the ingested dose of caffeoylquinic acid and its derivatives are excreted in 
urine collected up to 24 hours after coffee consumption [15] and 76.2 % of the ingested dose of 
caffeoylquinic acid and its derivatives were detected in the ilea fluid [19]. Additionally, Erk et 
al. found that due to the high pH in the upper gastrointestinal tract (pH ~ 6.8), the 
hydroxycinnamic acids are present in their ionic form (-COO
-
) and therefore not well absorbed 
[19]. In contrast, studies including healthy participants showed that the colon is the key site for 
absorption, since the highest plasma concentrations of metabolites of caffeoylquinic acid and its 
derivatives were found between 4.5-5.2 hours after coffee consumption [7, 16]. 
Figure 1.3 depicts the main sites for cleavage of the ester bond in the gastrointestinal tract, the 
absorption and subsequent release into the systemic circulation of humans derived from da 
Encarnação et al [25].  
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Figure 1.3: Main sites of cleavage of ester bond of 5-caffeoylquinic acid and 5-
feruloylquinic acid and absorption into the systemic circulation, derived from da 
Encarnação et al., 2014 
 
1.3.2 Metabolism 
In addition to the cleavage of the ester bond between caffeic acid or ferulic acid and quinic acid, 
several other phase II conjugation reactions and reduction of the aliphatic double bond occur in 
the gastrointestinal tract after consumption of caffeoylquinic acid and its derivatives.  
After coffee consumption, the ileal fluid of ileostomists has been collected and several phase II 
metabolites have been found, e.g. inter alia ferulic acid-4-O-sulfate, caffeic acid-3-O-sulfate, 
caffeic acid and ferulic acid [15]. Moreover, in vitro incubation of coffee with fecal slurries over 
six hours at 37ºC yielded metabolites including caffeic acid and ferulic acid with peak 
concentrations at 1 hour, and dihydrocaffeic acid and dihydroferulic acid with peak 
concentrations at 6 hours [26]. Additionally, phenolic acids with shorter side chains have been 
detected. These include 3,4-dihydroxybenzoic acid, 3-phenylpropionic acid, 3-(4’-
hydroxyphenyl)propionic acid, benzoic acid, 3,4-dihydroxybenzoic acid and phenylacetic acid. 
These results indicated the presence of microbial esterases, reductases, dehydrogenases, 
demethoxyesterases and CoA-mediated decarboxylation.  
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Upon absorption, hydroxycinnamic acids, and to a certain extent, caffeoylquinic acid and their 
derivatives pass into the liver through the hepatic portal vein. Xenobiotics undergo the first pass 
effect before they enter the systemic circulation. During the first pass effect several phase II 
conjugations occur e.g. sulphation (sulfuryl-O-transferase), glucuronidation (UDP-
glucuronyltransferase), methylation (catechol-O-methyltransferase) and addition of glycine 
(CoA mediated, glycine N-acyltransferase). Wong et al. [27] performed several in vitro and in 
vivo experiments to test the effect of liver S9 and intestinal S9 homogenates on 
hydroxycinnamic acids. Sulphation of hydroxycinnamic acids is favoured over glucuronidation. 
After the incubation of caffeic acid with liver S9 and intestinal S9 homogenates caffeic acid-3-
O-sulfate and caffeic acid-4-O-sulphate were detected. When incubating ferulic acid, isoferulic 
acid, dihydrocaffeic acid and dihydroferulic acid with liver S9 and intestinal S9 homogenates, 
ferulic acid-4-O-sulphate, isoferulic acid-3-O-sulphate, dihydrocaffeic acid-3-O-sulphate and 
dihydroferulic acid-4-O-sulphate, respectively, were analysed.  
Figure 1.4: Metabolites of caffeoylquinic acid and its derivatives detected in human 
plasma after consumption of coffee by Stalmach et al., 2009 
 
 
5-O-Caffeoylquinic acid         3-O-CQAL-O-Sulph          4-O-CQAL-O-Sulph 
 
3-O-Feruloylquinic acid             4-O-Feruloylquinic acid         5-O-Feruloylquinic acid 
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Caffeic acid-3-O-Sulph Ferulic acid-4-O-Sulph Dihydroferulic acid Dihydroferulic-4-O-Sulph  
 
Dihydrocaffeic acid   Dihydrocaffeic acid-3-O-Sulph   
 
Stalmach et al. administered coffee containing 412 µmol caffeoylquinic acid and its derivatives 
to eleven, healthy volunteers and collected plasma samples at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 
hours and urine samples from 0-2, 2-5, 5-8, and 8-24 hours [7]. Figure 1.4 depicts all 12 plasma 
metabolites. The first eight metabolites had a maximum plasma concentration within the first 
hour after coffee consumption, whereas the peak concentrations of the four dihydro forms were 
between 4.5-5.2 hours. The time to reach maximum plasma concentration indicates the site of 
absorption, thus the first eight metabolites are absorbed in the stomach and upper part of the 
small intestine, whereas the dihydro forms are absorbed in the colon. The only metabolite which 
showed a biphasic behavior was ferulic acid-4-O-sulfate with a Tmax at 0.6 and 4.3 hours. The 
major plasma metabolites were dihydroferulic acid, dihydrocaffeic acid-3-O-sulphate, 
dihydroferulic acid-4-O-sulphate, caffeic acid-3-O-sulphate, and ferulic acid-4-O-sulphate with 
a Cmax of 385, 325, 145, 92, and 76 nM, respectively. In addition, Nagy et al. [28] detected 3,4-
dimethoxycinnamic acid (Tmax 60 minutes, Cmax ~380 nM) and 3,4-dimethoxy-dihydrocinnamic 
acid (Tmax 600 minutes, Cmax ~80 nM) in plasma post coffee consumption. The data suggests 
that caffeoylquinic acid and its derivatives are highly absorbed and extensively metabolized 
within the human body.  
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1.3.3 Excretion 
Once metabolites of caffeoylquinic acid and its derivatives circulate in the vascular system they 
will be cleared via the renal system.  
Using in vitro digestion, Wong et al. [29] demonstrated that organic anion transporters, OAT1, 
OAT3 and OAT4, but not ATP-binding cassette transporters, are responsible for the uptake of 
hydroxycinnamic acid conjugates, in particular dihydroferulic acid-4-O-sulphate, dihydrocaffeic 
acid-3-O-sulphate, ferulic acid-4-O-sulphate and caffeic acid-3-O-sulphate, into the renal 
system.  
Stalmach et al. [7] quantified metabolites accounting for 29% of the ingested dose of 
caffeoylquinic acid and its derivatives in urine collected up to 24 hours after coffee consumption 
in healthy volunteers. Seventeen urinary metabolites were detected in urine which are shown in 
Figure 1.5. 
Figure 1.5: Metabolites of caffeoylquinic acid and its derivatives detected in urine after 
consumption of coffee by Stalmach et al., 2009 
 
 
3-O-CQAL-O-Sulph             4-O-CQAL-O-Sulph 
 
 
     3-O-FQA                                   4-O-FQA                                        5-O-FQA 
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FA-4-O-Sulph                        FA-Gly                      DHFA              DHFA-4-O-Sulph 
 
DHFA-4-O-GlucA            iFA-3-O-Sulph           iFA-3-O-GlucA        DHiFA-3-O-GlucA 
 
CA-3-O-Sulph      CA-4-O-Sulph        DHCA-3-O-Sulph       DHCA-3-O-GlucA 
 
In contrast, only 8% of the ingested dose of caffeoylquinic and its derivatives were found in 0-
24 hour urine of ileostomists [15].Two metabolites of caffeoylquinic acid and its derivatives 
were uniquely detected in urine, and not in plasma, i.e. feruloylglycine and 
dihydroisoferulicacid-3-O-glucuronide. This finding indicates that the conjugation with glycine 
and glucuronide occurs along with the excretion in the kidney and/or that these conjugates are 
immediately cleared from the systemic circulation and therefore cannot be detected in plasma. 
The data demonstrates that caffeoylquinic acid and its derivatives are well absorbed, extensively 
metabolised and widely excreted in urine post coffee consumption. A major pathway of 
excretion of caffeoylquinic acid and its derivatives is via the renal system [7].  
Recent scientific advances, including the synthesis of sulphate and glucuronide conjugates of 
hydroxycinnamic acid [30], subsequent development and validation of LC-MS based analytical 
methods for biological fluids such as urine and plasma [16-19], have improved the quality of the 
analytical and therefore absorption, metabolism and excretion data substantially.  
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Figure 1.6 provides a general overview of the fate of 5-caffeoylquinic acid after ingestion. 
Figure 1.6: Fate of 5-caffeoylquinic acid in the human body. Derived and adapted from 
Spencer, 2003 
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1.4 Bioavailability 
To this date, several studies have been performed to assess the absorption and overall 
bioavailability of caffeoylquinic acid and its derivates from coffee in humans. In 2002, Naradini 
et al. performed a study including ten human volunteers drinking a single dose of coffee 
containing 96 mg of caffeoylquinic acid and its derivates [31]. A maximum plasma 
concentration of caffeic acid of 505 nmol/L was analysed. However, venepuncture, to obtain 
plasma, was only performed at 1 and 2 hours after coffee consumption, thus no precise 
calculation of the overall bioavailability could have been undertaken [31]. Rechner et al. 
conducted a human study on five participants who consumed two cups of coffee three times: at 
the beginning of the study, at one hour and two hours. Overall, 898 mg of caffeoylquinic acid 
and its derivatives were ingested and urine was collected up to 24 hours after the first 
consumption. Only 5.9 % of the ingested dose was excreted via urine [32].  
Monteiro et al. published a human study with six subjects. In 2007, the subjects ingested 190 
mL of freshly brewed coffee containing 1.202 g of caffeoylquinic acid and its derivatives. 
Plasma and urine were collected over four hours after ingestion and two plasma peaks were 
detected, the first one at 0.5-1.0 hours and the second one at 1.5-4.0 hours. The first peak 
indicates absorption in the small intestine and the second peak in the colon, probably promoted 
through colonic fermentation, however the overall bioavailability was not calculated [21]. In 
2008, Farah et al. reported on a human study where ten participants consumed green coffee 
extracts and blood and urine were collected for up to eight hours post coffee intake. The 
ingested caffeoylquinic acid and its derivatives content was standardized to 170 mg and the 
bioavailability determined to be 33.1% in plasma [20]. 
In a more detailed study, Stalmach et al. reported various biomarkers of coffee consumption [7]. 
The study comprised eleven volunteers who consumed a 200 mL cup of coffee containing 412 
µmol caffeoylquinic acid and its derivatives. Plasma and urine samples were collected over the 
next 24 hours without enzymatic hydrolysis of plasma and urinary metabolites of caffeoylquinic 
acid and its derivatives, thus providing a very detailed profile of the absorption, metabolism, 
and excretion. About 29% of the ingested dose of caffeoylquinic acid and its derivatives was 
recovered in urine. Caffeoylquinic acid and its derivatives were found in small amounts in 
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plasma with a Tmax of 0.5-1 hours. Caffeic acid 3-O-sulfate and ferulic acid-4-O-sulfate were 
detected in up to 10-fold higher concentrations compared to unhydrolised caffeoylquinic acid 
and its derivatives, however, with a similar Tmax.  Reduced dihydro forms of hydroxycinnamic 
acids showed a Tmax of 4.3-5.2 hours, indicating absorption after microbial catabolism in the 
colon. The Cmax of these compounds was up to 100-fold higher compared to unhydrolysed 
caffeoylquinic acid and its derivatives. At 24 hours most metabolites of hydroxycinnamic acid 
had returned to baseline level. In urine mainly conjugates and hydrolysed forms of 
caffeoylquinic acid and its derivatives were detected. The main urinary metabolites were 
dihydrocaffeic acid-3-O-sulfate, feruloylglycine, dihydroferulic acid-4-O-sulfate, ferulic acid-4-
O-sulfate, dihydroferulic acid, dihydroferulic acid-4-O-glucuronide, caffeic acid-3-O-sulfate 
and isoferulic acid-3-O-sulfate.  
In 2009, Renouf et al. reported on quantitative, LC-MS based analysis of hydroxycinnamic acid 
conjugates in plasma post coffee consumption. Nine human volunteers consumed a coffee 
containing 335 mg caffeoylquinic acid and its derivatives and blood samples were collected up 
to 12 hours thereafter and at 24 hours [33]. All metabolites of caffeoylquinic acid and its 
derivatives were enzymatically hydrolysed using chlorogenate esterase, glucuronidase and 
sulfatase. Renouf et al. confirmed previous results with plasma peak times for ferulic, caffeic 
and isoferulic acids at Tmax 1-2 hours after coffee ingestion and for the dihydro forms at Tmax 6-8 
hours in plasma. Additionally, substantial interpersonal variations in Cmax and Tmax were 
described.  
 
In 2011, Williamson et al. [34] critically assessed the quality of previous human studies with 
focus on the absorption of caffeoylquinic acid and its derivatives and their plasma appearance 
by normalising the Cmax to the dose of intake. Nardini et al. [31] reported up to four times higher 
values for the normalised Cmax for caffeic acid. Monteiro et al. [21] reported about 200 times 
higher values for the normalised Cmax for intact caffeoylquinic acid and its derivatives in 
plasma. 
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Summarising the previous studies on the absorption and metabolism of caffeoylquinic acid and 
its derivatives from coffee, it can be concluded that several hydroxycinnamic acids of 
caffeoylquinic acid and its derivatives are absorbed in the small intestine at a Tmax of 0.5-1.0 
hours and only a very minor amount of caffeoylquinic acid and its derivatives, whereas in the 
colon caffeoylquinic acid and its derivatives are hydrolysed by colonic microflora derived 
esterases and the free hydroxycinnamic acids are reduced to their dihydro forms leading to a 
Tmax of 5-7 hours.  
 
However, data on the overall bioavailability of coffee caffeoylquinic acid and its derivatives is 
limited in humans. In order to assess the bioavailability, blood samples need to be drawn at 
several time points after coffee consumption for a detailed description of the plasma 
concentration curve of metabolites of caffeoylquinic acid and its derivatives and subsequent 
meticulous calculation of the area under the curve. In addition, all metabolites of caffeoylquinic 
acid and its metabolites need to be detected and ideally chemically synthesised for subsequent 
development and validation of LC-MS based quantitative analytical methods. 
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1.5 Coffee and health 
Coffee has long been thought of as detrimental to consumer’s health, however, recent research 
indicates potential health benefits including reduced risk of cancer, cardiovascular disease, and 
diabetes [35-37]. 
 
1.5.1 Cardiovascular health 
Globally cardiovascular diseases (CVD) are the main cause of death with over 17.1 million 
deaths in 2004 – 29% of all deaths. About 7.2 million deaths were attributed to coronary heart 
disease and 5.7 million were associated with stroke. CVDs will be the cause of 23.6 million 
deaths by 2030 [38]. CVDs are initiated by intermediate reasons such as a lack of physical 
activity, overweight and obesity, diabetes mellitus type II, tobacco use, unhealthy diet leading to 
high blood glucose levels, high blood lipid levels, sodium-rich diet and therefore high blood 
pressure [38].  
Despite reporting of cholesterol raising effects of coffee consumption independent of the 
brewing method (paper filtered vs unfiltered), via randomized control trials [39, 40], 
caffeoylquinic acid demonstrated an inhibitory effect on LDL cholesterol oxidation ex vivo [41] 
and a single dose of coffee can increase plasma antioxidant activity by 5.5% according to 
Natella et al. [42]. Additionally, the ingestion of a single cup of coffee ameliorated endothelial 
function measured by flow-mediated dilation according Buscemi et al. [43], whereas a another 
study found that habitual, boiled coffee consumption has a beneficial effect on flow-mediated 
dilation in elderly participants [44]. In another randomized control trial, chronic coffee 
consumption was associated with a rise in blood pressure, however, the increase of the systolic 
and diastolic blood pressure was minor only 2.04 mmHg and 0.73 mmHg, respectively [45]. A 
paper reported the inverse correlation of coffee, not green tea consumption, on arterial stiffness, 
assessed using brachial-ankle pulse wave velocity, in Japanese men [46]. Moreover, Andersen 
et al. presented an epidemiological study including more than 40,000 post-menopausal women 
linking coffee consumption to improved anti-inflammatory status and protection against 
cardiovascular diseases reducing death incidence [47]. The current data suggests that moderate 
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coffee consumption as part of a healthy and balanced life style maybe associated with improved 
cardiovascular health. 
 
1.5.2 Diabetes mellitus type II 
Worldwide, 387 million people have been diagnosed with diabetes, indicating a prevalence rate 
of 8.6%, whereas an estimated 46.3% of cases have not been diagnosed according to the 
International Diabetes Foundation [48]. In the UK, numbers are similar with a prevalence rate of 
6.0% indicating that 3.2 million British citizen suffer from diabetes [49]. Physical inactivity, 
overweight/obesity and a diet high in sugar and fat is considered to trigger diabetes mellitus 
type II [48, 49]. 
In a follow-up study of 126,210 health professionals in the UK over twelve years, a beneficial 
effect of long-term coffee consumption on the risk of diabetes mellitus type II was reported by 
Salazar-Martinez et al. in 2004 [50] and Ranheim et al. concluded from a literature study that 
there is a reduced risk of diabetes mellitus type II associated with the consumption of CGA [51]. 
In a Chinese study population of 2,332 participants, habitual coffee drinkers had a 38-46 % 
lower risk of diabetes mellitus type II compared to non-drinkers [52]. In 2009, Pimentel et al. 
reviewed several longitudinal studies and found that long-term, moderate coffee consumption (~ 
4 cups per day) is associated with a reduced risk of diabetes [37]. A Norwegian study found that 
consumption of caffeoylquinic acid enriched coffee reduces glucose absorption by 6.9%, 
compared to a control, and elicits a reduction of the body mass in a randomized, double-blind, 
12-week study including twelve obese participants [53]. In a prospective study including 18,417 
men and 39,740 women, performed by Lopez-Garcia et al. [54] from 1986 to 1998, increases of 
caffeine intake of 213 and 143 mg/d for men and women was negatively associated with long-
term weight gain with -0.43 kg and -0.35 kg for men and women, respectively. Additionally, in 
2011, a German group published results from a prospective cohort study including 30 subjects, 
compared the effects of dark and light roast coffee, differing in their caffeoylquinic acid and its 
derivatives and N-methylpyridinium content, indicating that the dark roast coffee reduced the 
body weight significantly and improved the antioxidant status of erythrocytes, i.e. superoxide 
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dismutase and glutathione peroxidase, by 5.8 and 15%, respectively, and increased plasma 
tocopherol and glutathione concentrations by 41 and 14%, respectively [55]. 
In conclusion it can be stated that the current data indicates a beneficial effect of coffee 
consumption on insulin sensitivity and prevalence of diabetes. However, the relationship 
between the plant secondary metabolites in coffee and health remains unclear and further 
investigation on the in vivo bioactive properties of these compounds is required.  
 
1.5.3 Other beneficial effects of coffee caffeoylquinic acid and its derivatives 
In vitro antioxidant effects of coffee were shown using several tests including oxygen radical 
absorbance capacity (ORAC) [56], fluorescence recovery after photobleaching (FRAP) [57] and 
trolox equivalence antioxidant capacity (TEAC) [58]. However, in 2012, the US Department of 
Agriculture removed all data of the ORAC database on food, since no in vivo effects of the in 
vitro data could be established [59]. 
Strong antibacterial effects of coffee extracts on enterobacteria in vitro were demonstrated by 
Almeida et al. [60]. Santos et al. proved anti-inflammatory effect of caffeoylquinic acid and its 
derivatives in rats, however, the mechanism of action is not fully understood and requires 
further studies [61]. Andersen et al. reported the anti-inflammatory effects of coffee 
consumption assessed by the Iowa Women’s Health Study including 41,836 post-menopausal 
women [62]. A review of 500 papers summarized the outcome and reported a protective effect 
of coffee consumption on hepatocellular, endometrial and colorectal cancer, whereas heavy 
coffee consumption was associated with bladder cancer [35]. Another review confirms the 
hepatoprotective effects and additionally the protective effect against liver cirrhosis [63]. The 
data suggests that further studies concerning the in vivo effect of metabolites of caffeoylquinic 
acid and its derivatives are needed in order to draw conclusions on the bioactivity.   
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1.6 Aims 
Numerous studies have been performed to assess the in vitro and in vivo effect of coffee, coffee-
derived potentially bioactive compounds or a mixture of both. However, to our knowledge, no 
human study has been performed to assess the connection between absorption, metabolism and 
excretion of coffee caffeoylquinic acid and its derivatives, biomarkers of health, i.e. 
cardiovascular health status, diabetes and food intake, i.e. coffee consumption, tea consumption 
and fruit and vegetable intake. 
The specific aims of the studies of this thesis were:  
1) Synthesis and subsequent detection and quantitation of novel, urinary glycine 
conjugates of hydroxycinnamic acids, especially of the recently described plasma 3,4-
dimethoxycinnamic acid and 3,4-dimethoxy-dihydrocinnamic acid [28], in urine after 
coffee consumption 
2) Synthesis of major urinary metabolites of caffeoylquinic acid and its derivatives in 
urine, e.g. dihydrocaffeic acid-3-O-sulphate, dihydroferulic acid-4-O-sulphate and 
ferulic acid-4-O-sulphate and subsequent development and validation of a quick, 
quantitative method based on LC-MS 
3) Design and performance of a human study linking the absorption of caffeoylquinic acid 
and its derivatives, by means of assessing the total urinary excretion, to biomarkers of 
health, e.g. plasma thiols, uric acid, fasting insulin and glucose, and to food intake, e.g. 
coffee consumption, tea consumption, fruit and vegetable intake 
4) Data analysis including correlation of absorption of caffeoylquinic acid and its 
derivatives to biomarkers of health and food intake 
Hypothesis: Coffee consumption and absorption of coffee caffeoylquinic acid and its derivatives 
have a positive impact on biomarkers of health and are correlated with food intake.
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Chapter 2: Chemical synthesis and analysis of novel glycine 
conjugates in urine after coffee consumption 
 
2.1 Abstract 
Chapter 2 describes the chemical synthesis of novel glycine conjugates of cinnamic acid 
derivatives, the performance of a human study and the qualitative and quantitative LC-MS 
analysis of six glycine conjugates, e.g. 3,4-dimethoxycinnamoylglycine, 3-(3,4-
dimethoxyphenyl)propionylglycine, vanilloylglycine, 3,4-dimethoxybenzoylglycine, 
feruloylglycine and dihydroferuloylglycine. Beside the previously reported feruloylglycine, 
vanilloylglycine (33 µmol, equivalent to 4.5% of the ingested dose) was detected and quantified 
in urine after coffee consumption for the first time in similar, high amounts as feruloylglycine 
(39 µmol, equivalent to 5.3% of the ingested dose). Other glycine conjugates were only detected 
in trace amounts suggesting that these must be further modified by phase II metabolism or 
undergo another metabolic pathway than conjugation with glycine.  
 
2.2 Introduction  
In the mid 19
th
 century Friedrich Woehler, a German chemist, was the first scientist to analyse 
organic constituents of urine. In 1841 Alexander Ure, a Scottish physician performed the first 
metabolism study in humans. He administered benzoic acid to a human subject and analysed  
hippuric acid in urine. Later, in 1845, Dessaignes demonstrated that hippuric acid is a glycine 
conjugate of benzoic acid [64].  
More than a century later, in 1957, Booth et al.[3] reported the finding of p-hydroxyhippuric 
acid in human urine after consumption of coffee. Moreover he also performed studies with 
individual compound namely caffeic acid and chlorogenic acid which he administered to 
humans and analysed their urine. After consumption of caffeic acid they detected at least nine 
metabolites in urine e.g. feruloylglycine and dihydroferulic acid. After ingestion of 5-
caffeoylquinic acid they found caffeic acid, m-hydroxyhippuric acid, m-coumaric acid 
conjugated with glucoronic acid and dihydroferulic acid. They also suggested a complex 
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pathway of metabolism including conjugation, e.g. methylation and glucuronidation and chain 
shortening due to β-oxidation. 
In the next two decades several animal studies, mainly on rats, were performed. In 1963 
Dirscherl et al. [65] perfused rat liver with vanillic acid and found vanilloylglycine (3-methoxy-
4-hydroxy hippuric acid) in the perfusate. Similar results were later presented by Strand et al. 
[66] when they found vanilloylglycine and isovanilloylglycine (3-hydroxy-4-methoxy hippuric 
acid) as  urinary metabolites of vanillin in rats. In 1975, Solheim et al. demonstrated that 3,4-
dimethoxycinnamic acid is metabolised to 3,4-dimethoxycinnamoylglycine and 3,4-
dimethoxybenzoylglycine in rats and excreted in urine collected up to 24 hours after 
administration. 3,4-dimethoxycinnamoylglycine together with m-methoxyhippuric acid and 
hippuric acid was also found in urine collected for 24 hours after the consumption of garlic and 
onions in humans [32].  
The mechanism of glycine conjugation is associated with beta-oxidation and therefore located in 
the mitochondria in particular in liver and kidney cells [64]. The following scheme (Figure 2.1) 
depicts the mechanism of glycine conjugation, starting with the activation through ATP, the 
addition of CoASH and the conjugation of glycine mediated by the enzyme glycine N-
acyltransferase (EC 2.3.1.13) which was first isolated and described by Mawal et al. in 1994 
[67]. 
Figure 2.1: Glycine conjugation via activation with ATP followed by addition of CoA and 
finally conjugation with glycine catalysed by glycine N-acyltransferase (EC 2.3.1.13) in 
mitochondria, derived and adapted from Knights et al., 2007 
 
More recently, Stalmach et al. detected feruloylglycine in human urine post coffee 
consumption. Feruloylglycine is the second most abundant metabolite of coffee caffeoylquinic 
acid in urine, but it is also the only glycine conjugate detected by Stalmach et al. [7]. 
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Recently, 3,4-dimethoxycinnamoylquinic acid was determined in roasted coffee beans [10]. 
Since the 3,4-positions of the compound are blocked for phase II modification, e.g. sulphate and 
glucuronide addition, therefore it is hypothesised that the compound is prone to glycine 
conjugation on the carboxylic function. In order to tested this hypothesis, a six subject human 
study was performed where participants consumed a cup of coffee with known content of 
caffeoylquinic acid and its derivatives after a 36 hours washout, thereafter urine was collected 
for 36 hours in time periods of 0-4, 4-8, 8-12, 12-24 and 24-36 hours and several potential and 
chemically synthesised derivatives of cinnamic acid and benzoic acid conjugated with glycine 
were qualitatively and quantitatively analysed, e.g. vanilloylglycine, feruloylglycine, 
dihydroferuloylglycine, 3,4-dimethoxybenzoylglycine, 3,4-dimethoxybenzoylglycine and 3,4-
dihydrodimethoxybenzoylglycine.  
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2.3 Materials and methods 
 
2.3.1 Materials 
3,4-Dimethoxycinnamic acid (99%), 3-(3,4-dimethoxyphenyl)propionic acid (99%), glycine 
methyl ester hydrochloride and ethyl acetate were purchased from Fisher Scientific Ltd. 
(Loughborough, UK). 3,4-Dimethoxybenzoylchloride, 3,5-dimethoxy-4-hydroxycinnamic acid, 
vanillic acid, 3-(4-hydroxy-3-methoxyphenyl)propionic acid, 4-methylmorpholine, 1-
hydroxybenzotriazole hydrate, O-(benzotriazole-1-yl)-N,N,N`,N`-tetramethyluronium 
tetrafluoroborate, acetic acid anhydride, pyridine and thionyl chloride  were acquired from 
Sigma-Aldrich (St. Louis, MO, USA). Acetonitrile (LC-MS grade) was delivered by VWR 
International (Lutterworth, UK). Alfa Aesar (Ward Hill, MA, USA) provided anhydrous N,N- 
dimethylformamide (packed under Argon atmosphere). Water was purified using a Millipore 
Elix system (Millipore, MA, USA). 3-Caffeoylquinic acid was purchased from Purify Chengdu 
Biopurify Phytochemicals, Chengdu, China, 4-caffeoylquinic acid was purchased from HWI 
Analytik, Rülzheim, Germany and 5-caffeoylquinic acid was obtained from Sigma-Aldrich (St. 
Louis, MO, USA). Nestle Green Blend™ was purchased from a local supermarket. 
Feruloylglycine was a generous gift from Prof Alan Crozier, University of Glasgow, UK. 
 
2.3.2 Methods 
The chemical synthesis was performed in collaboration with Prof Philip Kocienski in the iPDR 
laboratory at the Department of Chemistry at the University of Leeds, UK. The structure of all 
intermediates and final compounds was determined by 
1
H-NMR. 
2.3.2.1 Synthesis of 3,4-dimethoxycinnamoylglycine and 3-(3,4-dimethoxyphenyl)-
propionylglycine 
1.07 g of 3,4-dimethoxycinnamic acid (5 mmol, 1.0 equiv.) or 1.05 g of 3-(3,4-
dimethoxyphenyl)propionic acid were weighed in together with 0.65g (5 mmol, 1.0 equiv.) of 
glycine methyl ester hydrochloride, 0.69 g of 1-hydroxybenzotriazole (5 mmol, 1.0 equiv.), 1.62 
- 25 - 
g O-(benzotriazole-1-yl)-N,N,N’,N’-tetramethyluronium hexafluoroborate (5 mmol, 1.0 equiv.) 
and were dissolved in 18 mL of anhydrous N,N-dimethylformamide under nitrogen atmosphere. 
To start the reaction, 1.65 mL (15 mmol, 3.0 equiv.) of 4-methylmorpholine were added 
dropwise through a septum under stirring. After 24 hours the reaction mix was poured onto 150 
mL of purified water and extracted three times with a small amount of ethyl acetate. Combined 
organic phases were washed with 1 M HCl, purified water, saturated sodium hydrogen 
carbonate solution, purified water and brine. Prior to reduction to dryness in vacuo ethyl acetate 
was dried over sodium sulphate. 
Methyl (E)-2-(3-(3,4-dimethoxyphenyl)acrylamido)acetate 
 
 
 
1
H-NMR (500 MHz, CDCl3, ppm): δ 3.76 (3H, s, methoxy OCH3-1), 3.87 (3H, s, methoxy 
OCH3 -3b or 4b), 3.88 (3H, s, methoxy OCH3 -3b or 4b), 4.18 (2H, d, J=5.3 Hz, CH2-2), 6.39 
(1H, d, Jtrans =15.6 Hz, olefinic CH=C-2'), 6.56 (1H, bs, NH), 6.82 (1H, d, Jortho=8.3 Hz, 
CarH-5b), 7.00 (1H, d, Jmeta=1.8 Hz, CarH-2b), 7.05 (1H, dd, J1=8.3 Hz, J2=1.8 Hz, CarH-6b), 
8.53 (1H, d, Jtrans =15.64 Hz, olefinic CH=C-3') 
 
Methyl 2-(3-(3,4-dimethoxyphenyl)propanamido)acetate 
 
 
 
1
H-NMR (300 MHz, CDCl3, ppm): δ 2.55 (2H, t, J=7.4 Hz, CH2-3'), 2.95 (2H, t, J=7.4 Hz, 
CH2-2'), 3.78 (3H, s, methoxy OCH3-1), 3.87 (3H, s, methoxy OCH3-3b or 4b), 3.88 (3H, s, 
methoxy OCH3 -3b or 4b), 4.04 (2H, d, J=5.1 Hz, CH2-2), 5.97 (1H, br s, NH), 6.84-6.73 (3H, 
m) 
 The intermediate was dissolved in 30 mL methanol and 6 mL 1 M NaOH and left at room 
temperature overnight. The solution was concentrated in vacuo and acidified with 25 mL of 1 M 
HCl to pH 2. The solution was extracted four times with ethyl acetate. Combined organic phases 
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were washed with water and dried over sodium sulphate prior to reduction to dryness to yield 
fine crystalline powder. The solid was recrystallised from acetronitrile. The overall yields were 
18.1% and 17.1% and the melting points 192-193°C and 114-117°C for 3,4-
dimethoxycinnamoylglycine and 3-(3,4-dimethoxyphenyl)propionylglycine, respectively.  
(E)-2-(3-(3,4-Dimethoxyphenyl)acrylamido)acetic acid 
 
 
 
1
H-NMR (300 MHz, d6-DMSO, ppm): δ 3.78 (3H, s, methoxy OCH3 -3b or 4b), 3.80 (3H, s, 
methoxy OCH3 -3b or 4b), 3.89 (2H, d, J=5.85 Hz, CH2-2), 6.61 (1H, d, Jtrans =15.7 Hz, olefinic 
CH=C-2'), 6.99 (1H, d, Jortho=8.3 Hz, CarH-5b), 7.14 (1H, dd, J1=8.3 Hz, J2=1.7 Hz, CarH-6b), 
7.19 (1H, d, Jmeta=1.6 Hz, CarH-2b), 7.38 (1H, d, Jtrans =15.64 Hz, olefinic CH=C-3'), 8.29 (1H, t, 
J=5.9 Hz, NH), 12.6 (1H, bs, carboxylic CO2H) 
2-(3-(3,4-Dimethoxyphenyl)propanamido)acetic acid 
 
 
 
1
H-NMR (500 MHz, CD3OD, ppm): δ 2.55 (2H, t, J=8.0 Hz, CH2-3'), 2.89 (2H, t, J=8.0 Hz, 
CH2-2'), 3.82 (3H, s, methoxy OCH3 -3b or 4b), 3.84 (3H, s, methoxy OCH3-3b or 4b), 3.91 (2H, 
s, CH2-2), 6.79 (1H, dd, J1=5.3 Hz, J2=2.0 Hz, CarH-6b), 6.86 (1H, bs, CarH-2b), 6.87 (1H, d, 
Jortho=5.3 Hz, CarH-5b) 
2.3.2.2 Synthesis of 3,4-dimethoxybenzoylglycine 
1.00 g of 3,4-dimethoxybenzoylchloride (5 mmol, 1.0 equiv.) and 0.933 g of glycine methyl 
ester hydrochloride (7.5 mmol, 1.5 equiv.) were dissolved in 20 mL of dichloromethane. 1.1 mL 
of 4-methylmorpholine (10 mmol, 2.0 equiv.) were added dropwise and the solution was left for 
24 hours.  
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The reaction mixture was poured onto 100 mL of purified water and acidified slightly prior to 
triplicate extraction with ethyl acetate. Combined organic phases were neutralised over sodium 
hydrogencarbonate and dried over sodium sulphate prior to recrystallisation from ethyl acetate.  
 
Methyl 2-(3,4-dimethoxybenzamido)acetate 
 
 
 
1
H-NMR (500 MHz, CDCl3, ppm): δ 3.79 (3H, s, methoxy OCH3-1), 3.91 (6H, 2 x s, methoxy 
OCH3-3b and 4b), 4.22 (2H, d, J=5.3 Hz, CH2-2), 5.51 (1H, d, Jortho=8.35 Hz, CarH-5b), 6.80 
(1H, dd, J1=8.3 Hz, J2=2.1 Hz, CarH-6b), 7.64 (1H, d, Jmeta=2.0 Hz, CarH-2b 
The dried product was dissolved in 30 mL of methanol containing 8 mL of 1 M NaOH and left 
at room temperature overnight. The solution was acidified with 1 M HCl to pH 2 and extracted 
four times with ethyl acetate. The compound was recrystallised from water to yield fine, shiny 
plates. The yield was 28.3% and the melting point 190-195°C.  
2-(3,4-Dimethoxybenzamido)acetic acid 
 
 
 
1
H-NMR (500 MHz, CD3OD, ppm): δ 3.33 (1H, s, fine splitting, NH), 3.91 (6H, 2 x s, methoxy 
OCH3-3b and 4b), 4.11 (2H, s, CH2-2), 4.89 (1H, bs, NH), 7.04 (1H, d, Jortho=8.4 Hz, CarH-5b), 
7.5 (1H, d, Jmeta=2.0 Hz, CarH-2b), 7.52 (1H, dd, J1=8.35 Hz, J2=2.0 Hz, CarH-6b) 
 
2.3.2.3 Synthesis of vanilloylglycine  
Under stirring acetic acid anhydride (83 mmol, 2.8 equiv) was added to a solution of vanillic 
acid (29.7 mmol) in pyridine (10 mL). The mixture was stirred for 3 h at room temperature and 
poured onto ice water (150 mL). The viscous product was extracted with ethyl acetate (100 
mL). The solution was washed with 2 M HCl (100 mL) and water (50 mL). The extract was 
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dried using sodium sulphate and concentrated in vacuo. The pale yellow solid was recrystallised 
from ethyl acetate and methyl-tert-butylether yielding a beige solid (19.5 mmol, 65%). The 
melting point was 146-149°C.  
 
4-Acetoxy-3-methoxybenzoic acid 
 
 
 
1
H-NMR (500 MHz, CDCl3, ppm): δ 2.37 (3H, s), 3.95 (3H, s, methoxy OCH3-3b), 7.17 (1H, d, 
Jortho=8.2 Hz, CarH-5b), 7.74 (1H, d, Jmeta=1.8 Hz, CarH-2b), 7.78 (1H, dd, J1=8.2 Hz, J2=1.8 Hz, 
CarH-6b) 
The above product was dissolved in chloroform (25 mL) at ambient temperature with a small 
amount of dimethylformamide. Thionyl chloride (20 mmol, 1.2. equiv.) was added and heated 
under reflux. After half an hour the solvent was removed in vacuo. The yellow, oily product was 
dissolved in pyridine (10 mL) in an ice bath and glycine methyl ester hydrochloride (20 mmol, 
1.2 equiv.) was added under stirring. After 1 hour the mixture was poured into water (150 mL) 
and the product extracted with ethyl acetate (75 mL). Combined organic layers were washed 
with 2 M HCl (100 mL), water (50 mL), saturated aqueous sodium hydrogen carbonate (25 mL) 
and brine (25 mL). The organic layer was dried over sodium sulphate and concentrated in 
vacuo. The yellow-orange oil was purified chromatographically using silica gel and ethyl 
acetate and petrol. The yield was 10.7 mmol equivalent to 63% yield.  
Methyl 2-(4-acetoxy-3-methoxybenzamido)acetate 
 
 
 
1
H-NMR (500 MHz, CDCl3, ppm): δ  2.33 (3H, s, methoxy OCH3-1), 3.79 (3H, s, methoxy 
OCH3-4b), 3.86 (3H, s, methoxy OCH3-3b), 4.20 (2H, d, J=5.2 Hz, C2H2), 6.92 (1H, br t, J=4.7 
Hz, NH), 7.07 (1H, d, J=8.2 Hz, CarH-5b), 7.32 (1H, dd, J1=8.2 Hz, J2=1.7 Hz, CarH-6b), 7.50 
(1H, d, J=1.7 Hz, CarH-2b) 
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The estrified product (10.7 mmol) was solved in methanol (15 mL) and potassium hydroxide 
(30 mmol, 2.8 equiv.) was added dropwise in 2 mL of water. The solution was left at room 
temperature for 24 hours. Methanol was evaporated in vacuo and 6 M HCl (6 mL) were added 
prior to extraction with ethyl acetate (100 mL). Combined organic layers were washed with 
water (2 x 10 mL), dried over sodium sulphate and the solvent removed in vacuo. Methyl-tert-
butyl ether was added to the yellow oil for solidification. The colour was removed by solving 
the product in methanol (20 mL) which was run over a charcoal filter. Methanol was removed in 
vacuo and the solid was dissolved in ethyl acetate and methyl-tert-butyl ether (20 mL 1:1). 
Overnight the product was kept at -20ºC which induced the formation of white fine crystals. The 
product was dried under vacuum at 80ºC. The yield was 4.9 mmol equivalent to 46%. The 
melting point was 165-168ºC. 
2-(4-Hydroxy-3-methoxybenzoamido)acetic acid 
 
 
 
1
H-NMR (500 MHz, DMSO-d6, ppm): δ  3.82 (3H, s, methoxy OCH3), 3.91 (2H, d, J=5.85 Hz, 
C2H2),  6.83 (1H, dd, J1=8.2 Hz, J2=1.0 Hz, C
ar
H-6b), 7.37 (1H, d, J=8.55 Hz, C
ar
H-5b), 7.44 
(1H, app s, C
ar
H-2b), 8.62 (1H, br t, J=4.9 Hz, NH), 9.60 (1H, br s, OH) 12.54 (1H, br s, 
COOH) 
 
2.3.2.4 Synthesis of dihydroferuloylglycine  
0.98 g of 3-(4-hydroxy-3-methoxyphenyl)propionic acid (5 mmol, 1.0 equiv.) was weighed 
along with 0.65g (5 mmol, 1.0 equiv.) of glycine methyl ester hydrochloride, 0.69 g of 1-
hydroxybenzotriazole (5 mmol, 1.0 equiv.), 1.62 g O-(benzotriazole-1-yl)-N,N,N’,N’-
tetramethyluronium hexafluoroborate (5 mmol, 1.0 equiv.) and were solved in 18 mL of 
anhydrous N,N-dimethylformamide in a nitrogen atmosphere. To start the reaction, 1.65 mL (15 
mmol, 3.0 equiv.)  of 4-methylmorpholine was added dropwise through a septum whilst 
magnetically stirring. After 24 hours the reaction mix was poured onto 50 mL of purified water 
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and extracted with ethyl acetate (5 x 15 mL). Combined organic phases were washed with 2 M 
HCl, saturated sodium hydrogen carbonate solution, purified water and brine. Prior to 
evaporation to dryness in vacuo ethyl acetate was dried over sodium sulphate.  
 Methyl 2-(3-(4-hydroxy-3methoxyphenyl)propanamido)acetate 
 
 
 
1
H-NMR (500 MHz, CDCl3, ppm): δ 2.45 (2H, t, J=7.5 Hz, CH2-3’), 2.84 (2H, t, J=7.5 Hz, 
CH2-2’), 3.68 (3H, s, methoxy OCH3), 3.79 (3H, s, methoxy OCH3), 3.96 (2H, d, J=5.2 Hz, CH2-
2), 5.88 (1H, broad singlet), 6.62 (1H, dd, J1= 8.8 Hz, J2= 1.9 Hz, C
ar
H-6b), 6.65 (1H, d, Jmeta= 
1.8 Hz, CarH-2b), 6.76 (1H, d, Jortho=8.8 Hz, CarH-5b) 
The ester (4.6 mmol) was solved in methanol (10 mL) and 5 M sodium hydroxide solution (2 
mL) were added. The solution was kept at ambient temperature for 24 hours, thereafter the 
solvent was removed in vacuo and the pH was adjusted to 2-3 with 5 M HCl. The product was 
extracted with ethyl acetate (5 x 5 mL). Combined organic phases were dried over sodium 
sulfate and the solvent evaporated in vacuo. The product crystallised at -20°C and was 
recrystallised from ethyl acetate and purified with a charcoal filter. The yield was 38% with a 
melting point of 148-150°C. 
2-(3-(4-Hydroxy-3-methoxyphenyl)propanamido)acetic acid 
 
 
 
1
H-NMR (500 MHz, CD3OD, ppm): δ  2.54 (2H, t, J=8.1 Hz, CH2-3’), 2.87 (2H, t, J=8.1 Hz, 
CH2-2’), 3.86 (3H, s, methoxy OCH3-1), 3.91 (3H, s, methoxy OCH3-3b), 6.67 (1H, dd, J1=8.0 
Hz, J2= 1.9 Hz, CarH-6b), 6.72 (1H, d, Jortho=8.0 Hz, CarH-5b), 6.82 (1H, d, Jmeta=1.7 Hz, CarH-
2b 
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2.3.2.5 Study design 
Six subjects (n=6), three female and three male, age 21 to 54 years, body mass index 22.9 +/- 
2.4 kg/m
2
, gave their written informed consent prior to the beginning of the human study. They 
were all in good health, non-smokers and did not take any medication as assessed by a health 
questionnaire (Appendix D: Health assessment and food frequency questionnaire).  
Volunteers were asked to abstain from polyphenol-rich food for 36 hours prior to the study 
(wash-out) and 36 hours during the study. After an overnight fast for 10 hours, participants 
consumed 4 g of instant coffee solved in 200 mL of hot, but not boiling, water with a 
standardised breakfast consisting of two slices of toast with margarine and cheese. Water was 
allowed ad libitum. 
The study design was approved by the University of Leeds Joint Faculty Ethics Committee 
(MEEC 10-035). 
 
2.3.2.6 Sample collection and storage 
Six subjects collected a baseline urine sample prior to the consumption of the coffee. Thereafter 
all urine was collected in time increments of 0-4, 4-8, 8-12, 12-24 and 24-36 hours in urine 
collection containers containing 3 g of ascorbic acid. Urine was centrifuged at 800 g and 4°C for 
10 minutes within 48 hours after collection. The supernatant was stored at -20°C in aliquots of 
13 mL containing 130 µL of a 10% aqueous sodium azide solution. 
 
2.3.2.7 Sample preparation  
Instant coffee (2 g) was dissolved in 200 mL demineralised water (90-95ºC). The coffee 
solution was diluted 1:5 with mobile phase A (95% demineralised water, 5% acetonitrile, 0.1% 
formic acid) and chilled at 4°C. Aliquots were centrifuged at 17,000 g and 4°C for 10 minutes. 
The supernatant was filtered through 0.2 m syringe-driven PTFE filters. Three stock solutions 
of coffee were prepared and two aliquots were taken for the analysis.  
Urine samples were thawed at 4°C and two aliquots of 990 µL were taken for each time point. 
10 µL of internal standard solution (dihydrodimethoxycinnamoyl glycine, final concentration 10 
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µM), 10 µL of 50% formic acid and 1 mL of ethyl acetate were added prior to vortexing the 
samples for 1 minute. The samples were left for 15 minutes, vortexed for 1 minute and 
centrifuged at 2000 g at 4°C for 1 minute. 750 µL of the organic layer was taken. The extraction 
was repeated a second time. Combined organic layers were dried at ambient temperature under 
a gentle stream of nitrogen. The sample was reconstituted in 100 µL mobile phase A (95% 
ultrapure water, 5% acetonitrile and 0.1% formic acid) by sonication for 5 minutes. 
Samples were prepared to determine the extraction efficiencies of six glycine conjugates. 
Therefore pooled urine collected from six participants collected after a 36 hours washout period, 
which is described in detail in chapter 4, was used for spiking. Urine (950 µL) and 50 µL of the 
standard solution to yield concentrations of 1, 5 and 10 µM was mixed. All samples were 
prepared in triplicate and processed as described above.  
 
2.3.2.8 High performance liquid chromatography-mass spectrometry 
The high performance liquid chromatography system was the Agilent 1200 series (Waldbronn, 
Germany) with a degasser, binary pump, temperature controlled autosampler and column 
compartment, and a diode array detector.  
The Agilent 1200 series HPLC was coupled through a divert valve and a heated electrospray 
ionisation source to an Agilent 6410 A triple quadrupole mass spectrometer (Wokingham, UK). 
The drying gas was nitrogen generated by a PEAK Scientific nitrogen generator (Inchinnan, 
UK). 
Chromatographic settings for caffeoylquinic acid were used from a previously published 
method by T. Farrell et al., 2011[68]. In brief, chromatographic separation was achieved on an 
Agilent ZORBAX Eclipse Plus Rapid Resolution C18 100 mm x 2.1 mm i.d., 1.8 µm using a 
reverse phase method consisting of mobile phase A (95% demineralised water, 5% acetonitrile, 
0.1% formic acid) and mobile phase B (95% acetonitrile, 5% demineralised water, 0.1% formic 
acid) at a flow rate of 0.26 mL/min at 30°C. Elution was achieved using a gradient of 0% B for 
the first 17.3 minutes, up to 51.0 minutes B was increased to 25%, from 51.1 to 56.0 minutes 
the gradient was kept at 100% B for washing the column, prior to reequilibration from 56.1 to 
65.0 minutes at 0% B. Samples were kept at 4°C and 5 L injected onto the column in triplicate.  
- 33 - 
Chromatographic separation of glycine conjugates was achieved on an Agilent ZORBAX 
Eclipse Plus Rapid Resolution C18 100 mm x 2.1 mm i.d., 1.8 µm using a reverse phase method 
consisting of mobile phase A (95% demineralised water, 5% acetonitrile, 0.1% formic acid) and 
mobile phase B (95% acetonitrile, 5% demineralised water, 0.1% formic acid) at a flow rate of 
0.3 mL/min at 30°C. Elution was achieved using a gradient from 0-35% B in 3 minutes, 35 % B 
from 3 to 6 minutes, 100% B from 6-11 minutes and reequilibration at 0% B form 11-17 
minutes. Samples were kept at 4°C and 10 L injected onto the column in triplicate. 
 
2.3.2.9 Mass spectrometry 
For the ionisation of caffeoylquinic acids the heated electrospray ionisation source was operated 
in negative mode with the gas flow set to 10 L/min, a nebuliser pressure of 60 psi at a 
temperature of 350°C. Multiple reaction monitoring (MRM) settings were optimised using 
commercially available standards at a concentration of 10 µg/mL. The following table (Table 
2.1) shows the optimised settings for the individual compounds.  
Table 2.1: Multiple reaction monitoring settings optimized for the individual 
caffeoylquinic acid 
Compound Retention 
time 
(min) 
Precursor 
ion 
(m/z) 
Fragmentor 
energy 
Product 
ion 
(m/z) 
Collision 
energy 
3-Caffeoylquinic acid  6.2 353 120 191 
179 
20 
20 
5-Caffeoylquinic acid 14.1 353 120 191 
179 
10 
20 
4-Caffeoylquinic acid  19.4 353 120 179 
173 
15 
15 
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The first four minutes of the LC flow were sent to waste, from 4-8 minutes the settings for 3-
CQA, from 8-16 minutes the settings for 5-CQA and from 16 to 55 minutes the settings for 4-
CQA were used, respectively. After 55 minutes the polarity was switched to positive to 
neutralise a potential charge accumulation in the ion capillary. 
The heated electrospray ionisation source was operated in negative mode at optimised settings 
for feruloylglycine with the gas flow set to 13 L/min, a nebuliser pressure of 60 psi at a 
temperature of 350°C. Multiple reaction monitoring (MRM) settings were optimised using 
synthesised standards at a concentration of 10 µg/mL. The following table (Table 2.2) shows the 
optimised settings for the individual compounds.  
Table 2.2: Multiple reaction monitoring settings optimised for the individual glycine 
conjugate 
Compound Retention 
time 
(min) 
Precursor 
ion 
(m/z) 
Fragmentor 
energy  
(V) 
Product 
ion 
(m/z) 
Collision 
energy 
(V) 
Vanilloylglycine 4.2 224 130 100 
123 
6 
10 
Dihydroferuloylglycine 4.6 252 110 74 
121 
12 
28 
3,4-Dimethoxybenzoylglycine 5.0 238 110 194 
122 
5 
25 
Feruloylglycine 5.0 250 100 206 
134 
6 
16 
3-(3,4-
Dimethoxyphenyl)propionyl-
glycine 
5.4 266 160 74 
149 
12 
18 
3,4-
Dimethoxycinnamoylglycine 
5.8 264 160 220 
103 
5 
15 
 
2.3.2.10 Quantitative analysis caffeoylquinic acids 
External calibration was used to quantify the three caffeoylquinic acids. Calibration curves were 
run on day 1 and day 3 including nine calibrants (0.5, 1, 2.5, 5, 10, 25, 50, 100 and 200 M) 
prepared on the individual days. The linarity was R
2 ≥ 0.99. The limit of detection (LOD) and 
the limit of quantitation (LOQ) are calculated by LOD=(3.3*intercept)/slope and 
LOQ=(10*intercept)/slope, respectively. The values are presented in Table 2.3.  
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Table 2.3: Summary of limit of detection and limit of quantitation of 3-, 4-, and 5-
caffeoylquinic acid in pmol 
Compound Limit of detection (pmol) Limit of quantitation (pmol) 
3-Caffeoylquinic acid 3.0 9.1 
4-Caffeoylquinic acid 2.0 5.9 
5-Caffeoylquinic acid 14.8 44.7 
 
Three coffee samples were prepared and two aliquots taken for each samples which were 
injected in triplicate on day 2. 
 
2.3.2.11 Quantitative analysis glycine conjugates 
Calibration curves were prepared on the day of the analysis and included nine calibrants (0.1, 
0.5, 1, 5, 10, 20, 40, 60, 80 and 100 µM). 10 µL of each calibrant was injected in triplicate. The 
calibration curves were run on three different days (Day 1, 3 and 5) with a linearity of R
2 ≥ 0.99. 
The limit of detection (LOD) and the limit of quantitation (LOQ) are calculated by 
LOD=(3.3*intercept)/slope and LOQ=(10*intercept)/slope, respectively. The values are 
presented in Table 2.4.  
Table 2.4: Summary of limit of detection and limit of quantitation of vanilloylglycine, 
dihydroferuloylglycine, 3,4-dimethoxybenzoylglycine, feruloylglycine, 3-(3,4-
dimethoxyphenyl)propionylglycine and 3,4-dimethoxycinnamoylglycine in pmol 
Compound Limit of detection 
(pmol) 
Limit of quantitation 
(pmol) 
Vanilloylglycine 6.6 20.0 
Dihydroferuloylglycine 37.2 112.6 
3,4-Dimethoxybenzoylglycine 128.9 390.7 
Feruloylglycine 5.1 15.4 
3-(3,4-Dimethoxyphenyl)propionyl-
glycine 
2.6 7.9 
3,4-Dimethoxycinnamoylglycine 74.0 224.2 
 
Urine samples were prepared in duplicate and 10 µL of each sample was injected in triplicate on 
two different days (Day 2 and 4).  
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2.4 Results 
 
2.4.1 Synthesis 
Several hundred milligrams of 3,4-dimethoxycinnamoylglycine, 3-(3,4-
dimethoxyphenyl)propionylglycine, 3,4-dimethoxybenzoylglycine, dihydroferuloylglycine and 
vanilloylglycine were chemically synthesised and characterised by 
1
H-NMR and MS/MS with a 
purity of ≥95% derived from the 1H-NMR spectra. According to our knowledge 3-(3,4-
dimethoxyphenyl)propionylglycine and dihydroferuloylglycine are new compounds and have 
never been described in literature.  
3,4-dimethoxycinnamoylglycine, 3,4-dimethoxybenzoylglycine, dihydroferuloylglycine, 
feruloylglycine and vanilloylglycine were used as standards for the preparation of calibration 
curves for external calibration and quantitation. The amounts synthesised are practical for 
weighing, i.e. several milligram (2-3 mg), providing high accuracy.  
 
2.4.2 Caffeoylquinic acid content in instant coffee 
3-, 4- and 5-caffeoylquinic acids were quantitatively analysed in instant coffee.  
Figure 2.2 depicts the individual amounts of caffeoylquinic acid in 4 g of instant coffee. The 
amount of 3-, 4- and 5-caffeoylquinic acids is 160 ± 8.4, 103 ± 6.0 and 467 ± 9.2 mol, 
respectively. Participants ingested a total amount of caffeoylquinic acids of 730 ± 23.7 mol. 
The quantified amounts of caffeoylquinic acids are in line with previous findings [16].  
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 Figure 2.2: Caffeoylquinic acid content in µmol in 4g instant coffee equivalent to one cup 
of coffee which was consumed by the participant, n=18 (three samples, two aliquots, three 
injections), mean ± standard deviation 
 
 
2.4.3 Novel glycine conjugates in urine post coffee consumption 
The synthesised glycine conjugates serve as standards for unequivocal qualitative and 
quantitative analysis of caffeoylquinic acid metabolites in urine post coffee consumption. 
Therefore the compounds were used to determine the retention times, optimise multiple reaction 
monitorings and for quantitation by external calibration.  
Figure 2.3 depicts the chromatographic separation of the total ion chromatogram. 
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Figure 2.3: Total ion chromatogram for six glycine conjugates including the internal 
standard, 10 µL injected of a solution of 1 µmol/L of vanilloylglycine (1), 
dihydroferuloylglycine (2), 3,4-dimethoxybenzoylglycine (3), feruloylglycine (3), 3,4-
dimethoxycinnamoylglycine (4), and 3-(3,4-dimethoxyphenyl)propionylglycine (5, internal 
standard). 
 
The total ion chromatogram shows five peaks, however, six compounds were analysed. 3,4-
dimethoxybenzoylglycine and feruloylglycine coelute, but can be distinguished using their 
specific multiple reaction monitoring which are (M-H)
-
 m/z 238-194 and 250-134, respectively. 
 
Figure 2.4 depicts the single reaction monitoring of vanilloylglycine m/z 224-100 which was 
used as the quantifier transition since it yielded the highest intensity transition.  
Figure 2.4: Single reaction monitoring for vanilloylglycine (M-H)
- 
m/z 224-100, 10 µL 
injected of a solution of 1 µmol/L 
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Figure 2.5 depicts the product ion spectrum of vanilloylglycine. The peak at m/z 100 is the 
glycine with the acid-amide bond fragment, the peak m/z 123 is the phenol moiety with a 
methoxy group. The single reaction monitoring m/z 224-123 is used as the qualifier transition. 
The minor peaks could not have been identified.  
Figure 2.5: Product ion spectrum of vanilloylglycine showing the precursor peak at (M-H)
- 
 
m/z 224 and the two product ions at m/z 123 and 100, respectively, at a collision energy of 
5 V 
 
Figure 2.6 shows the single reaction monitoring of dihydroferulic acid m/z 252-74 which was 
used as the quantifier transition.  
Figure 2.6: Single reaction monitoring for dihydroferuloylglycine (M-H)
-
 m/z 252-74 
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In Figure 2.7 the product ion spectrum of dihydroferulic acid is depicted. The peak at m/z 74 is 
the glycine moiety. The underlying structure of peak at m/z 121 has not been identified, but is 
used as the qualifier transition.  
Figure 2.8 depicts the single reaction monitoring of dimethoxybenzoylglycine m/z 238-194 
which was used as the quantifier transition. 
 
Figure 2.7: Product ion spectrum of dihydroferuloylglycine depicting the precursor peak 
at (M-H)
-
 m/z 252 and two product ions at m/z 121 and 74, respectively, at a collision 
energy of 5 V 
 
Figure 2.8: Single reaction monitoring for dimethoxybenzoylglycine (M-H)
-
 m/z 238-194 
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In Figure 2.9 the product ion spectrum of dimethoxybenzoylglycine is depicted. The peak at m/z 
194 is the precursor molecule minus the m/z 44 which indicates decarboxylation. The qualifier 
peak at m/z 122 was not identified.  
Figure 2.9: Product ion spectrum of dimethoxybenzoylglycine depicting the precursor 
peak at (M-H)
-
 m/z 238 and two product ions at m/z 194 and 122, respectively, at a 
collision energy of 5 V 
 
Figure 2.10 shows the single reaction monitoring of feruloylglycine m/z 250-134, the quantifier 
transition. The retention time is the same as of dimethoxybenzoylglycine. As the the peaks 
coelute there is a need to distinguish them, based on the different single reaction monitoring.  
Figure 2.10: Single reaction monitoring of feruloylglycine (M-H)
-
 m/z 250-134 
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Figure 2.11 shows the product ion spectrum of feruloylglycine with the quantifier peak at m/z 
206 and the qualifier peak at m/z 134. The peak at m/z 206 is the precursor structure which has 
been decarboxylated (-CO2), the qualifier peak’s structure has not been identified.  
Figure 2.11: Product ion spectrum of feruloylglycine with a completely depleted precursor 
ion at (M-H)
-
 m/z 250 and two product ions at m/z 206 and 134, respectively, at a collision 
energy of 5 V 
 
The following figure shows the single reaction monitoring of the 3-(3,4-
dimethoxyphenyl)propionyl glycine, the dihydro form of 3,4-dimethoxycinnamoyl glycine with 
m/z 266-74.  
Figure 2.12: Single reaction monitoring of 3-(3,4-dimethoxyphenyl)propionylglycine (M-
H)
-
 m/z 266-74 
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The product ion spectrum (Figure 2.13) depicts the two major fragment peaks at m/z 149 and 
m/z 74. The latter is the quantifier peak at m/z 74 which is the glycine fragment. The qualifier 
peak at m/z 149 is the phenol ring with the C3-tail.  
Figure 2.13: Product ion spectrum of 3-(3,4-dimethoxyphenyl)propionylglycine depicting 
the precursor peak at (M-H)
-
 m/z 266 and two product peaks at m/z 149 and 74, 
respectively, at a collision energy of 5 V 
 
Figure 2.14 shows the single reaction monitoring of 3,4-dimethoxycinnamoylglycine m/z 264-
220, the quantifier transition. 
Figure 2.14: Single reaction monitoring for 3,4-dimethoxycinnamoylglycine (M-H)
-
 m/z 
264-220 
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Figure 2.15 shows the product ion spectrum of 3,4-dimethoxycinnamoyl glycine. The quantifier 
peak at m/z 220 and the qualifier peak at m/z 103. The first peak is the decarboxylated form of 
the precursor peak and the latter is the benzene ring with a C2 tail. The precursor peak 
(m/z=264) is completely depleted.  
Figure 2.15: Product ion spectrum of 3,4-dimethoxycinnamoylglycine with a completely 
depleted precursor ion at (M-H)
-
 m/z 264 and two product ions at m/z 220 and 103, 
respectively, at a collision energy of 5 V 
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2.4.4 Glycine conjugates in urine 
The recovery of six glycine conjugated urinary metabolites of caffeoylquinic acid and its 
derivatives were assessed and the results are depicted in Table 2.5.  
Table 2.5: Recovery (%) of six urinary metabolites and internal standard at 1, 5, 10 µM, 
n=9 (three samples, three injections), mean ± standard deviation 
 VA-
GLY 
DHFA-
GLY 
DMB-
GLY 
FA-GLY DHDM-
GLY 
DMCA-
GLY 
1 µM 71.4 ± 
1.4 
67.3 ± 
1.4 
67.5 ± 
1.5 
112.5 ± 
1.3 
65.2 ± 
2.3 
117.2 ± 
3.6 
5 µM 63.2 ± 
1.5 
62.3 ± 
2.1 
72.5 ± 
1.9 
115.8 ± 
1.8 
72.3 ± 
1.5 
109.8 ± 
2.7 
10 µM 67.4 ± 
1.5 
75.4 ± 
2.0 
79.6 ± 
2.2 
114.1 ± 
1.5 
81.1 ± 
2.5 
115.9 ± 
3.1 
 
There is an overall tendency that the recovery rates are below the spiked amount, which could 
be due to insufficient extraction or ion suppression effects in the electrospray ionisation source. 
However, the recovery for feruloylglycine and dimethoxycinnamoylglycine are overall higher 
and exceed the spiked amount in the sample. This could be due to ion enhancement effects in 
the electrospray ionisation source. 
Five of six participants completed the human study. One participant was excluded due to non-
compliance with the study guidelines since its excretion exceeded 100% of the ingested dose of 
caffeoylquinic acids. Vanilloylglycine and feruloylglycine were detected and quantified as the 
only glycine metabolites. Dihydroferuloylglycine, 3,4-dimethoxybenzoylglycine, and 3,4-
dimethoxycinnamoylglycine were detected, but not quantified as their concentrations were 
below the limit of quantitation. Feruloylglycine is the highest metabolite followed by 
vanilloylglycine. Vanilloylglycine has been reported for the first time as an urinary metabolite 
of coffee consumption or caffeoylacid intake.  
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Figure 2.16: Urinary excretion of vanilloylglycine (µmol) for individual subject (n=5) for 0-4, 4-8, 8-12, 12-24, and 24-36 hours post coffee consumption, 
n=6 (two biological replicates, triplicate injections), mean ± standard deviation 
 
Figure 2.17: Urinary excretion of feruloylglycine (µmol) for individual subject (n=5) for 0-4, 4-8, 8-12, 12-24, and 24-36 hours post coffee  
Consumption, n=6 (two biological replicates, triplicate injections), mean ± standard deviation 
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Graph (Figure 2.16) depicts the vanilloylglycine excretion in urine per collection interval per 
subject. Most vanilloylglycine was excreted between 12-24 hours post coffee consumption, 
however, substantial amounts have also been excreted between 8-12 and 24-36 hours. 
Hypothetically, more vanilloylglycine would be excreted after 36 hours, however, only small 
amounts of vanilloylglycince have been detected in the baseline urine sample. The graph also 
depicts the interindividual variation of the amounts excreted.  
Graph (Figure 2.17) shows the feruloylglycine excretion in urine per collection interval per 
subject. Most feruloylglycine was excreted between 8-12 hours post coffee consumption, 
however, substantial amounts were also excreted between 12-24 hours.  
Graph (Figure 2.18) shows the cumulated vanilloylglycine for the five subjects for the 
individual urine collection intervals. The average total amount excreted for the five subjects is 
33.0 ± 32.4 mol for 0-36 hours post coffee consumption. The amount accounts for 4.5% molar 
of the ingested dose. 
Graph (Figure 2.19) depicts the cumulated feruloylglycine for the five subjects for the 
individual urine collection intervals. The average cumulated amount excreted for the five 
subjects is 38.8 ± 8.7 mol for 0-36 hours post coffee consumption. The amount accounts for 
5.3% of the ingested dose.  
The total amount of glycine conjugates excreted for 0-36 hours post coffee consumption 
account for 9.8% of the dose ingested.  
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Figure 2.18: Cumulated, mean excretion of vanilloylglycine (µmol) for individual subject (n=5) for 0-4, 4-8, 8-12, 12-24, and 24-36 hours post coffee  
consumption, n=6 (two biological replicates, triplicate injections), mean 
 
Figure 2.19: Cumulated, mean excretion of feruloylglycine (µmol) for individual subject (n=5) for 0-4, 4-8, 8-12, 12-24, and 24-36 hours post coffee  
consumption, n=6 (two biological replicates, triplicate injections), mean 
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2.5 Discussion 
Several new cinnamic acid and phenolic acid glycine conjugates were chemically synthesised, 
their structures confirmed by 
1
H-NMR and MS
2
 and their physicochemical properties 
determined. The glycine conjugates were identified and quantitatively analysed in urine post 
coffee consumption by comparison of their specific retention time and multiple reaction 
monitoring on a high pressure liquid chromatography coupled via electrospray ionisation to a 
triple quadrupole mass spectrometer with the synthesised standards. Two of the synthesised 
glycine conjugates have never been described in literature – dihydroferuloylglycine and 3-(3,4-
dimethoxyphenyl)propionylglycine.  
After coffee consumption only feruloylglycine was previously reported as a urinary metabolite 
of chlorogenic acids. The urinary excretion of feruloylglycine accounted for 5.0% of the 
ingested dose according to Stalmach et al. [7]. It was the second most excreted metabolite after 
dihydrocaffeic acid-3-O-sulphate which accounted for 9.0 % of the ingested dose. However, for 
the first time vanilloylglycine has been detected and quantified as a urinary metabolite of coffee 
chlorogenic acids in humans and it accounts for 4.5% of the ingested dose. It is one of the most 
excreted metabolites of coffee chlorogenic acids in urine and of importance when calculating 
the absorption of coffee chlorogenic acids via the excretion rate in the human body.  
Vanilloylglycine differs from feruloylglycine by a C2-unit. The chain shortening is attributed to 
the β-oxidation process in the hepatic mitochondria described for the first time in greater detail 
in Dr A. Kerimi’s doctoral thesis, 2011 [69]. Prior to conjugation with glycine the 
hydroxycinnamic acid derivative is introduced into the β-oxidation process. During the β-
oxidation the propionyl tail is shortened by two carbon atoms and either two or four hydrogen 
atoms depending on the oxidation stage of the compound. The loss of molecular weight 
facilitates the urinary excretion which is further enhanced by the subsequent conjugation with 
glycine. Both catalysed reactions are located in the mitochondrial matrix of liver and kidney 
cells [64]. A suggested metabolic pathway is shown in Figure 2.20.  
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Figure 2.20: Suggested metabolic pathway of coffee chlorogenic acids in the body with 
focus on glycine conjugation. Sulphation and glucuronidation are not shown. Derived and 
adapted from Olthof et al., 2003 
 
 
3,4-dimethoxycinnamic acid linked to quinic acid via an ester bond has been reported as a 
coffee constituent [10] and 3,4-dimethoxycinnamic acid was found in plasma [28], recently. As 
the 3- and 4- positions are protected by a methoxy group, no functional group, e.g. sulfate or 
glucuronide can be attached during phase II metabolism. Therefore we hypothesised that the 
compound is prone to conjugation with glycine at the carboxylic tail and thus excreted in urine. 
However, we only found trace amounts of 3,4-dimethoxycinnamoyl glycine in urine. This leads 
to the assumption that the 4-position is demethylated during metabolism and feruloylglycine is 
the main metabolite. The demethylation step would also explain the occurrence of only trace 
amounts of 3,4-dimethoxybenzoylglycine, but substantial amounts of vanilloylglycine (4-
hydroxy-3-methoxy-benzoylglycine) in urine. 
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Alternatively, 3,4-dimethoxycinnamic acid could undergo conjugation with glutathione by 
glutathione-S-transferase and thereafter it might enter the mercapturic acid pathway implying 
further modifications to the tripeptide tail including loss of glutamic acid and glycine, followed 
by acetylation of the remaining cysteine [70]. Conjugation with glutathione has also been 
reported during the incubation of ferulic acid with rat hepatocytes [71]. Further studies should 
investigate the presence of 3,4-dimethoxycinnamoyl-N-acetylcysteine which is potentially 
excreted in urine after coffee consumption. The conjugate with N-acetylcysteine of 
sulforaphane, an isothiocyanate present in cruciferous vegetables, was found in urine after 
ingestion of broccoli sprouts for example [72]. The dihydro form of feruloylglycine has only 
been detected in trace amounts and no dihydroform of 3,4-dimethoxycinnamoylglycine was 
found. The reduction of the double bond occurs in the colon and is attributed to microbial 
reductases [15].  
We have shown that hydroxycinnamic acid, the hydrolysis products of chlorogenic acids, is 
decarboxylated and subsequently undergoes conjugation with glycine associated with the β-
oxidation in mitochondria. Vanilloylglycine, differing by the loss of C2H2 compared to 
feruloylglycine, and was found to be the second most excreted urinary metabolite of 
caffeoylquinic acid and its derivatives.   
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Chapter 3:  Synthesis of hydroxycinnamic acid sulphates, 
development of a LC-MS method for highest urinary metabolites of 
caffeoylquinic acid and its derivatives, analysis of caffeoylquinic acid 
and its derivatives in coffee, and digestion of coffee and caffeoylquinic 
acid and its derivatives with porcine pancreatin 
 
3.1 Abstract 
This chapter summarises the synthesis chemical standards, the subsequent development and 
validation of a LC-MS method for the analysis of major urinary metabolites of caffeoylquinic 
acid and its derivatives, the analysis of caffeoylquinic acid and its derivatives in a standardised 
coffee beverage and the digestion of coffee and caffeoylquinic acid and its derivatives by 
porcine pancreatin.  
The first part describes the synthesis of three hydroxycinnamic acid sulphates, e.g. 
dihydrocaffeic acid-3-O-sulphate, ferulic acid-4-O-sulphate and dihydroferulic acid-4-O-
sulphate in hundred milligram amounts for use as standards for LC-MS based quantitation via 
external calibration. Additionally, a rapid sample procedure and LC-MS method was developed 
for the quantitative analysis of five major urinary metabolites of caffeoylquinic acid and its 
derivatives, i.e., vanilloylglycine, dihydrocaffeic acid-3-O-sulphate, dihydroferulic acid-4-O-
sulphate, ferulic acid-4-O-sulphate, and dihydroferulic acid. The method was used to assess the 
absorption of caffeoylquinic acid and its derivatives in urine obtained from volunteers in a 
human study described in detail in chapter 4. Moreover, caffeoylquinic acid and its derivatives, 
e.g. 3-, 4-, 5-caffeoylquinic acid, 3-, 4-, 5-feruloylquinic acid and 3,4-dicaffeoylquinic acid and 
3,5-dicaffeoylquinic acid were quantified in coffee which is consumed by the participants in the 
human study described in chapter 4. Furthermore, coffee, 3-, 4- and 5-caffeoylquinic acid and 3-
,4- and 5-feruloylquinic acid have been incubated individually over 60 minutes with porcine 
pancreatin, a mixture of digestive enzymes released by the pancreas into the duodenum. Caffeic 
acid concentration increased the most during the incubation of coffee, however, a small increase 
in ferulic acid concentration was also observed during the incubation of 3-,4- and 5-
caffeoylquinic acid. No release of ferulic acid was observed when 3-, 4- and 5-feruloylquinic 
acid have been incubated with porcine pancreatin. The data indicate that pancreatin has a 
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substantial contribution to the hydrolysis of the ester bond between caffeic acid and the quinic 
acid moiety in caffeoylquinic acids, in particular on 5-caffeoylquinic acid, in the small intestine. 
 
3.2 Introduction 
Coffee caffeoylquinic acid and its derivatives are well absorbed, extensively metabolised and 
abundantly excreted in urine post coffee consumption. The major urinary metabolites are 
dihydrocaffeic acid-3-O-sulphate, feruloylglycine, dihydroferulic acid-4-O-sulphate, ferulic 
acid-4-O-sulphate and dihydroferulic acid according to Stalmach et al. [7]. In chapter 2, 
vanilloylglycine was reported for the first time as a metabolite of caffeoylquinic acid and its 
derivatives, excreted in similar amounts to feruloylglycine in urine.  
Previously, Fumeaux et al. [30] described the synthesis of several hydroxycinnamic acid phase 
II metabolites including dihydrocaffeic acid-3-O-sulphate, dihydroferulic acid-4-O-sulphate and 
ferulic acid-4-O-sulphate. In order to assess the absorption of coffee caffeoylquinic acids and its 
derivatives, the excretion of urinary metabolites can be quantified after coffee consumption. 
Therefore dihydrocaffeic acid-3-O-sulphate, dihydroferulic acid-4-O-sulphate and ferulic acid-
4-O-sulphate were synthesised using a modified protocol of Fumeaux et al. [30] to obtain 
practical amounts of these chemical standards for the LC-MS based quantitation of the major 
urinary metabolites via external calibration.  
Earlier, several analytical methods for the quantitation of urinary metabolites of caffeoylquinic 
acid and its derivatives have been reported [7, 15, 17]. These methods aimed to quantify all the 
known urinary metabolites of caffeoylquinic acid and its derivatives and run over a long time of 
sixty minutes and are therefore not suitable for the screening of excretion of a larger study 
populations (>10). Therefore a new and quick method of sample preparation and LC-MS based 
quantitation using external calibration for the major urinary metabolites was developed and is 
described in this chapter.  
Several caffeoylquinic acids and its derivatives have been quantitatively analysed in coffee [7, 
9, 15, 17, 73]. The major ones are 3-, 4-, and 5-caffeoylquinic acid, 3-, 4-, and 5-feruloylquinic 
acid and 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid and 4,5-dicaffeoylquinic acid. For 
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the assessment of the absorption of caffeoylquinic acid and its derivatives their amount was 
quantified in commercially available instant coffee which was administered in the human study 
described in chapter 4. The method for the quantitation was previously described by Farrell et 
al. [74].  
Previous studies assessed the absorption, metabolism and excretion of caffeoylquinic acid and 
its derivatives in ileostomists, patients who underwent removal of their colon due to medical 
conditions [15, 17, 19]. The absorption of caffeoylquinic acids and its derivatives in ileostomists 
is attenuated compared to healthy people. Ileostomists only excreted 8 ± 1% of the ingested 
dose of caffeoylquinic acids and its derivatives [15] whereas healthy subjects excreted 29 ± 4%. 
The cleavage of the ester bond between caffeic acid and quinic acid in caffeoylquinic acid is 
partially located in the small intestine [15, 19], however, only a moderate hydrolysis has been 
observed in the upper gastrointestinal tract and major esterases were located in the colon [19]. 
Pancreatin, a complex mixture of various digestive enzymes including lipases, trypsin, 
peptidases, proteases, RNAses, DNAses, amylases and unspecific carboxylesterases is excreted 
by the pancreas into the duodenum, the upper part of the small intestine. In order to better 
understand the hydrolyzing effects of pancreatin on coffee, caffeoylquinic acid and its 
derivatives were incubated at 37ºC for 60 minutes with porcine pancreatin and caffeic acid and 
ferulic acid, respectively, and were quantified at 0, 10, 20, 40 and 60 minutes of incubation.  
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3.3 Materials and methods 
 
3.3.1 Materials 
Vanilloylglycine was synthesised as described in chapter 2. Feruloylglycine was generously 
donated by Prof Alan Crozier, University of Glasgow, UK. 3,4-dicaffeoylquinic acid was a gift 
from Dr Thomas Erk, University of Kaiserslautern, Germany and 3,5-dicaffeoylquinic acid was 
kindly provided by Prof Mike Clifford, University of Surrey, UK. 3-Caffeoylquinic acid was 
purchased from Purify Chengdu Biopurify Phytochemicals, Chengdu, China and 4-
caffeoylquinic acid was purchased from HWI Analytik, Rülzheim, Germany. 3-Feruloyquinic 
acid and 4-feruloylquinic acid were purchased from Purify Chengdu Biopurify Phytochemicals, 
Chengdu, China.  
All other chemicals were purchased from Sigma-Aldrich, St. Louis, MO, USA. Chemicals for 
the synthesis were reagent grade, chemicals which served as standards for LC-MS quantitation 
or enzymatic digestion were LC-MS grade or of HPLC grade ≥ 99%. 
Demineralised water was prepared using a Millipore water purification system, Millipore 
Corporation, Billerica, MA, USA.  
The MPLC (Thomson Single Step, 16.5 g C18 Flash Column) was purchased from Biotage, 
Uppsala, Sweden.  
 
3.3.2 Methods 
The chemical synthesis was performed in collaboration with Prof Philip Kocienski in the iPDR 
laboratory at the Department of Chemistry at the University of Leeds, UK. The structure of all 
intermediates and final compounds was determined by 
1
H-NMR, 
13
C-NMR, and IR. 
3.3.2.1 Synthesis of dihydrocaffeic acid-3-O-sulphate 
The synthesis of dihydrocaffeic acid-3-O-sulphate consists of five individual synthesis steps. 
The first step introduced a benzyl group as a protecting group at the 4-position of 3,4-
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dihydrobenzaldehyde. The subsequent step inserted a neopentyl sulphate group at the 3-
position.  
At the third step the aldehyde tail was extended by addition of a CH-COOEt group, thereafter 
the protecting benzyl group is removed by reduction with gaseous hydrogen, prior to the 
removal of the protecting neopentyl group and formation of the sodium salt. In the following the 
individual procedures are described in detail.  
4-(Benzoyloxy)-3-hydroxybenzaldehyde (2) was prepared according to a procedure of 
Couladorous et al.[75]. 3,4-dihydroxybenzaldehyde (1) (10.0 g, 72.4 mmol, 1.0 equiv) and 
anhydrous potassium carbonate (9.0 g, 65.2 mmol, 0.9 equiv) were suspended in 85 mL 
dimethylformamide and heated at 60ºC for 4 h. The reaction mixture was allowed to cool to 
room temperature, benzyl bromide (9.09 mL, 76.0 mmol, 1.05 equiv) added and the resulting 
dark suspension stirred at room temperature for 18 h. Ethyl acetate (150 mL) and water (150 
mL) were added and the layers allowed to separate and the aqueous layer extracted with ethyl 
acetate (100 mL). The combined organic layers were washed with ammonium chloride 
(saturated aqueous solution, 150 mL) and brine (150 mL). Activated charcoal was used to 
decolourise the solution which was passed through a plug of silica/celite subsequently and the 
filtrate concentrated in vacuo to give an orange/brown oily solid. Recrystallisation from ethyl 
acetate/petrol gave the title compound as an off-white solid (9.89 g, 43.3 mmol, 60%) with a mp 
108-109 ºC. Spectroscopic data [
1
H NMR (500 MHz, CDCl3), 
13
C NMR (75 MHz, CDCl3), and 
IR] are in accordance with those reported [75].  
1
H NMR (500 MHz, CDCl3): δ = 9.83 (1H, s, C3H), 7.48–7.34 (7H, m, C5H/C9H/ArH), 7.04 
(1H, d, J = 8.2, C6H), 5.83 (1H, s, OH), 5.20 (2H, s, PhCH2O).   
13
C NMR (75 MHz, CDCl3): δ = 191.3 (C3), 151.2 (C7), 146.4 (C8), 135.3 (CAr), 130.8 (C4), 
129.0 (2C, CArH), 128.8 (CArH), 128.0 (2C, CArH), 124.6 (C5H), 114.5 (C9H), 111.6 (C6H), 
71.30 (PhCH2O).   
IR (solid): ν = 3600–2400 br s, 1745 m, 1673 s, 1603 s, 1513 s, 1454 s cm−1. 
 
Neopentyl chlorosulfate (4) was prepared from neopentyl alcohol (3) using a modification of 
Widlanski’s procedure [76]. A solution of commercial neopentyl alcohol (3) (25.0 g, 284 mmol, 
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1.0 equiv) and pyridine (22.9 mL, 284 mmol, 1.0 equiv) in diethylether (60 mL) was added 
dropwise to a solution of sulfuryl chloride (23.0 mL, 284 mmol, 1.0 equiv) in diethyl ether (115 
mL) at –78°C. The cooling bath was removed and the reaction mixture allowed to warm to 
room temperature over 20 minutes and then stirred at room temperature for 2 h.  The white 
suspension was filtered, the white solid washed with diethyl ether (2  100 mL) and the filtrate 
concentrated in vacuo to give a colourless liquid. Distillation gave the title compound (50.0 g, 
268 mmol, 94%) as a colorless liquid with a bp of 26–28°C at 0.3 mmHg. Spectroscopic data 
[
1
H NMR (500 MHz, CDCl3), 
13
C NMR (75 MHz, CDCl3), and IR] are in accordance with those 
reported [76] . 
1
H NMR (500 MHz, CDCl3): δ = 4.17 (2H, s, C1H2), 1.05 (9H, s, C2(CH3)3.  
13
C NMR (75 MHz, CDCl3): δ = 85.6 (C1H2), 32.0 C2), 26.0 (3C, C2(CH3)3).   
IR (solid): ν = 2968 s, 2875 w, 1480 m, 1411 s, 1371 m, 1189 s, 950 s, 936 s, 855 s cm−1. 
 
2-(Benzyloxy)-5-formylphenyl neopentyl sulphate (5) was prepared using a modification of the 
procedure of Fumeaux et al. [30]. Neopentyl chlorosulphate (4) (9.81 g, 52.6 mmol, 1.2 equiv) 
in dichloromethane (10 mL) was added dropwise to a yellow solution of phenol (2) (10.0 g, 43.8 
mmol, 1.0 equiv) and diazabicycloundecene (7.86 mL, 52.6 mmol, 1.2 equiv) in 
dichloromethane (90 mL) at room temperature and the resulting yellow/orange solution stirred 
for 21 h. The reaction mixture was washed with 1 M aqueous hydrochloric acid (150 mL), 
sodium hydrocarbonate (saturated aqueous, 150 mL) and brine (150 mL), dried over sodium 
sulphate, filtered and concentrated in vacuo to give an off-white solid. The crude product was 
passed through a plug of silicate, eluted with dichloromethane and crystallised from 
methyltertbutyl ether–petrol to give the title compound (14.7 g, 38.8 mmol, 89%) as a white 
solid, with a mp 58–59°C. Spectroscopic data [1H NMR (500 MHz, CDCl3), 
13
C NMR (75 
MHz, CDCl3), and IR] are in accordance with those reported [30]. 
1
H NMR (500 MHz, CDCl3): δ = 9.88 (1H, s, C3H), 7.91 (1H, d, J = 2.0, C9H), 7.80 (1H, dd, J 
= 8.5, 2.0, C5H), 7.50–7.32 (5H, m, ArH), 7.18 (1H, d, J = 8.5, C6H), 5.22 (2H, s, PhCH2O), 
4.06 (2H, s, OCH2C(CH3)3), 0.89 (9H, s, OCH2C(CH3)3).   
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13
C NMR (75 MHz, CDCl3): δ = 189.6 (C3), 155.7 (C7), 139.5 (C8), 135.1 (CAr), 130.8 (C5H), 
130.1 (C4), 129.0 (2C, CArH), 128.8 (CArH), 127.8 (2C, CArH), 124.0 (C9H), 114.1 (C6H), 84.0 
(OCH2C(CH3)3), 71.43 (PhCH2O), 31.9 (OCH2C(CH3)3), 25.9 (3C, OCH2C(CH3)3).   
IR (solid): ν = 3376 w, 3070 m, 2961 s, 2872, s, 2815 s, 2717 s, 1698 s, 1606 s, 1576 s, 1509 s, 
1465 s, 1430 s, 1380 s, 1298 s cm
−1
. 
(E)-Ethyl 3-(4-(benzyloxy)-3-(((neopentyloxy)sulfonyl)oxy)phenyl)acrylate (7) was prepared 
using the procedure of Fumeaux et al. [30]. Ethyl 2-(triphenylphosphoranylidene)acetate (6) 
(20.1 g, 57.7 mmol, 1.0 equiv) was added in a single portion to aldehyde (5) (21.8 g, 57.7 mmol, 
1.0 equiv) in dichloromethane–tetrahydrofuran (1:1; 90 mL) at room temperature and the 
resulting pale yellow solution stirred for 2.5 h. The reaction mixture was concentrated in vacuo 
to give a white oily solid that was passed through a plug of silicate eluting with petrol/ethyl 
acetate (3:1) and crystallised from methyltertbutyl ether–petrol to give the title compound (23.7 
g, 52.8 mmol, 92%) as colourless needles, with a mp 76–77°C. The E:Z ratio was assigned 
using 
1
H NMR spectroscopy with no (Z)-isomer being observed. Spectroscopic data [
1
H NMR 
(500 MHz, CDCl3)] are in accordance with those reported [30]. 
1
H NMR (500 MHz, CDCl3): δ =7.63–7.54 (2H, m, C3H/C9H), 7.48–7.43 (2H, m, C5H/ArH), 
7.42–7.32 (4H, m, ArH), 7.05 (1H, d, J = 8.6, C6H), 6.32 (1H, d, J = 15.9, C2H), 5.15 (2H, s, 
PhCH2O), 4.25 (2H, q, J = 7.1, OCH2CH3), 4.04 (2H, s, OCH2C(CH3)3), 1.33 (t, J = 7.1, 
OCH2CH3), 0.87 (9H, s, OCH2C(CH3)3).   
13
C NMR (75 MHz, CDCl3): δ = 166.9 (C1), 152.1 (C7), 142.8 (C3H), 139.4 (C8), 135.6 (CAr), 
128.9 (2C, CArH), 128.7 (CArH), 128.6 (C5H), 128.1 (C4), 127.9 (2C, CArH), 122.4 (C9H), 
118.0 (C2H), 114.4 (C6H), 83.9 (OCH2C(CH3)3), 71.2 (PhCH2O), 60.7 (OCH2CH3), 31.8 
(OCH2C(CH3)3), 25.9 (3C, OCH2C(CH3)3), 14.5 (OCH2CH3).   
IR (solid): ν = 3047 w, 2968 m, 2903 m, 2874 m, 1697 s, 1632 s, 1603 s, 1515 s, 1478 m, 1463 
m, 1420 m, 1398 s 1313 s, 1287 s cm
−1
. 
 
Ethyl 3-(4-hydroxy-3-(((neopentyloxy)sulfonyl)oxy)phenyl)propanoate (8) was prepared using 
a modification of Fumeaux et al.[30] method. A suspension of palladium on activated carbon 
(10% dispersion; 500 mg) and compound (7) in ethanol (150 mL) was degassed with gaseous 
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hydrogen five times and stirred at room temperature under an atmosphere of hydrogen for 4 h. 
The reaction mixture was filtered through a pad of celite, the dark residue washed with 
dichloromethane (2  100 mL) and the combined filtrate concentrated in vacuo. The residual 
yellow/orange oil was purified by column chromatography on silicate eluting with petrol/ethyl 
acetate (5:1) to give the title compound (7.91 g, 21.9 mmol, 98%) as a colourless oil that 
solidifies on storage at ca –20°C.  Spectroscopic data [1H NMR (500 MHz, CDCl3), 
13
C NMR 
(75 MHz, CDCl3), and IR] are in accordance with those reported [30]. 
1
H NMR (500 MHz, CDCl3): δ = 7.13 (1H, d, J = 2.1, C9H), 7.05 (1H, dd, J = 8.3, 2.1, C5H), 
6.97 (1H, d, J = 8.4, C6H), 4.13 (2H, s, OCH2C(CH3)3), 4.12 (2H, q, J = 7.2, OCH2CH3), 2.89 
(2H, t, J = 7.6, C3H2), 2.59 (t, J = 7.7 Hz, C2H2), 1.23 (t, J = 7.2 Hz, OCH2CH3), 1.01 (9H, s, 
OCH2C(CH3)3).   
13
C NMR (75 MHz, CDCl3): δ = 173.2 (C1), 146.2 (C7), 137.6 (C8), 133.5 (C4), 128.5 (C5H), 
122.2 (C6H), 118.3 (C9H), 84.3 (OCH2C(CH3)3), 60.9 (OCH2CH3), 36.0 (C2H2), 32.0 
(OCH2C(CH3)3), 30.0 (C3H2), 25.9 (3C, OCH2C(CH3)3), 14.3 (OCH2CH3). 
IR (solid): ν = 3900–2900 br s, 2965 s, 2873 s, 1708 br s, 1624 m, 1594 m, 1519 s, 1398 s, 1297 
s cm
−1
. 
 
Dihydrocaffeic acid 3-O-sulphate (9) was prepared using a modified procedure of Fumeaux et 
al.[30]. A solution of phenol (8) (2.5 g, 6.94 mmol, 1.0 equiv) and sodium azide (902 mg, 13.9 
mmol, 2.0 equiv) in dimethylformamide (21 mL) was heated at 60°C for 24 h. The reaction 
mixture was allowed to cool to room temperature and the solvent removed using distillation (ca 
40°C at ca 1 mmHg) to give a off-white gummy residue that was dissolved in methanol, dry 
loaded onto silicate and passed through a plug of silicate eluting with dichloromethane/ethanol 
(5:1) to give a pale yellow oil. Methanol (14 mL) and 1 M aqueous sodium hydroxide (28.0 mL, 
28.0 mmol, 4.0 equiv) was added and the resulting solution stirred at room temperature for 4 h.  
Amberlite CG-50 (3.0 g) was added to the reaction mixture and stirred at room temperature for 
30 min. Filtration and concentration in vacuo gave an off-white solid that was purified using 
Biotage MPLC (Thomson Single Step, 16.5 g C18 Flash Column) using a gradient of methanol 
in water as eluent to give the title compound (1.92 g, 6.27 mmol, 90%) as a hydroscopic off-
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white solid. Spectroscopic data [
1
H NMR (500 MHz, DMSO-d6) and 
13
C NMR (75 MHz, 
DMSO-d6)] are in accordance with those reported [30]. 
1
H NMR (500 MHz, DMSO-d6): δ = 6.93 (1H, d, J = 2.2, C9H), 6.78 (1H, dd, J = 8.2, 2.2, 
C5H), 6.69 (1H, d, J = 8.1, C6H), 2.65 (2H, t, J = 7.6, C3H2), 2.17 (2H, t, J = 7.6, C2H2).   
13
C NMR (75 MHz, DMSO-d6): δ = 177.3 (C1), 147.1 (C7), 140.4 (C8), 133.9 (C4), 124.6 
(C5H), 122.9 (C9H), 116.9 (C6H), 39.8 (C2H2), 31.6 (C3H2). 
Figure 3.1: Synthesis of dihydrocaffeic acid-3-O-sulphate 
 
3.3.2.2 Synthesis of ferulic acid-4-O-sulphate 
The synthesis of ferulic acid-4-O-sulphate consists of three individual synthesis steps. In the 
first step the carboxylic group of ferulic acid is protected by the formation of a methyl ester. In 
the second step neopentyl sulphate is introduced at the 4-position of the phenyl ring which is 
followed by the last step where the neopentyl unit split off due to hydrolysis followed by the 
addition of a sodium cation. In the following the individual synthesis steps are described in 
experimental detail.  
 
1. K2CO3 (0.9 equiv)
DMF, 60ºC, 4 h
2. Add BnBr (1.05 equiv)
rt, 18 h
60%
(72.4 mmol scale)
1
2
mp 108-109ºC
5
mp 58-59ºC
3 (1.2 equiv)
DBU (1.2 equiv)
CH2Cl2, rt
89%
(43.8 mmol scale)
SO2Cl2 (1.0 equiv)
Py (1.0 equiv)
Et2O, -78ºC→ rt, 2 h)
43
6 (1.0 equiv)
CH2Cl2-THF (1:1)
rt, 2.5 h
92%, E:Z ≥ 10:1
(57.7 mmol scale)
7
mp 76-77ºC
98%
(22.3 mmol scale)
H2 (g)
EtOH, rt, 4h
89
2. 1M NaOH
MeOH, rt, 4 h
90%
(6.94 mmol scale)
1. NaN3 (2.0 equiv)
DMF, 60ºC, 24 h
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(E)-Methyl 3-(4-hydroxy-3-methoxyphenyl)acrylate (11) was prepared using a modification of 
the procedure of Voisin-Chiret et al.[77]. Trimethyl orthoformate (38.0 mL, 348 mmol, 1.35 
equiv) followed by concentrated sulfuric acid (1.38 mL, 25.8 mmol, 10 mol%) in methanol (40 
mL) was added to a solution of ferulic acid (10) (50.0 g, 258 mmol, 1.0 equiv) in methanol (215 
mL) at room temperature and the resulting yellow solution heated under reflux for 20 h. The 
reaction mixture was allowed to cool to room temperature, pyridine (6.26 mL, 77.4 mmol, 30 
mol%) added and the mixture concentrated in vacuo. Methyltertbutyl ether (250 mL) was 
added, the solution washed with 1 M aqueous hydrochloric acid (2  150 mL), sodium 
bicarbonate (saturated aqueous, 100 mL) and brine (100 mL), dried over sodium sulfate, filtered 
and concentrated in vacuo to give a colourless oil. The title compound (43.8 g, 210 mmol, 82%) 
was crystallised as a white solid by the addition of diethylether (50 mL) and the addition of 
petrol (ca 50 mL) until cloud point was observed with stirring at 400 rpm for 20 h, with a 
melting point at (diethylether/petrol) 59–60 °C; Lit.[77] melting point of 68°C. Spectroscopic 
data [
1
H NMR (500 MHz, CDCl3), 
13
C NMR (75 MHz, CDCl3), and IR] are in accordance with 
those reported [77]. 
1
H NMR (500 MHz, CDCl3): δ = 7.62 (1H, d, J = 15.9, C3H), 7.07 (1H, dd, J = 8.2, 2.0, C5H), 
7.02 (1H, d, J = 1.8, C9H), 6.92 (1H, d, J = 8.1, C6H), 6.29 (1H, d, J = 15.8, C2H), 5.91 (1H, s, 
OH), 3.92 (3H, s, OCH3), 3.80 (3H, s, OCH3).   
13
C NMR (75 MHz, CDCl3): δ = 167.9 (C1), 148.1 (C8), 146.9 (C7), 145.1 (C3H), 126.9 (C4), 
123.1 (C5H), 115.1 (C2H), 114.9 (C6H), 109.5 (C9H), 56.0 (OCH3). 51.8 (OCH3).   
IR (solid): ν = 3700–2700 br s, 3074 s, 2944 s, 2846 s, 1730 br m, 1605 m, 1512 m, 1227 m 
cm
−1
. 
 
(E)-Methyl 3-(3-methoxy-4-(((neopentyloxy)sulfonyl)oxy)phenyl)acrylate (12) was prepared 
using Fumeaux et al. modified procedure [30]. Neopentyl chlorosulphate (4) (20.0 g, 107 mmol, 
1.2 equiv) in dichloromethane (20 mL) was added dropwise to a yellow solution of ester (11) 
(18.6 g, 89.3 mmol, 1.0 equiv) and diazabicycloundecene (16.0 mL, 107 mmol, 1.2 equiv) in 
dichloromethane (180 mL) at room temperature and the resulting yellow/orange solution stirred 
for 21 h. The reaction mixture was washed with 1 M aqueous hydrochloric acid (200 mL), 
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sodium bicarbonate (saturated aqueous, 200 mL) and brine (200 mL), dried over sodium 
sulphate, filtered and concentrated in vacuo to give an off-white solid. The crude product was 
passed through a plug of silicate, eluted with dichloromethane and crystallised from 
methyltertbutyl ether to give the title compound (28.7 g, 80.1 mmol, 90%) as a white solid, with 
a melting point of 105–106 °C. 
1
H NMR (500 MHz, CDCl3): δ = 7.64 (1H, d, J = 16.0, C3H), 7.38 (1H, d, J = 8.4, C6H), 7.14 
(1H, d, J = 2.0, C9H), 7.13–7.10 (1H, m, C5H), 6.41 (1H, d, J = 15.9, C2H), 4.17 (2H, s, 
OCH2C(CH3)3), 3.92 (3H, s, OCH3), 3.82 (3H, s, OCH3), 1.01 (9H, s, OCH2C(CH3)3).   
13
C NMR (75 MHz, CDCl3): δ = 167.1 (C1), 151.6 (C8), 143.6 (C3H), 140.4 (C7), 134.6 (C4), 
123.3 (C6H), 121.1 (C5H), 119.2 (C2H), 111.9 (C9H), 83.7 (OCH2C(CH3)3), 56.1 (OCH3), 52.0 
(OCH3), 32.0 (OCH2C(CH3)3), 26.1 (3C, OCH2C(CH3)3).   
IR (solid): ν = 3081 w, 2970 s, 2872 m, 1708 s, 1645 m, 1634 m, 1599 m, 1505 s, 1464 m, 1449 
m, 1409 s, 1370 m cm
−1
. 
Ferulic acid-4'-O-sulphate (13) was prepared using a modified procedure of Fumeaux et al.[30]. 
A solution of ester (12) (2.5 g, 6.98 mmol, 1.0 equiv) and sodium azide (907 mg, 14.0 mmol, 
2.0 equiv) in dimethylformamide (21 mL) was heated at 60°C for 24 h. The reaction mixture 
was allowed to cool to room temperature and the solvent removed using distillation (ca 40°C at 
ca 1 mmHg) to give a off-white gummy residue that was dissolved in methanol, dry loaded onto 
silicate and passed through a plug of silicate eluting with dichloromethane/ethanol (5:1) to give 
an off-white solid. Methanol (14 mL) and 1 M aqueous sodium hydroxide (28.0 mL, 28.0 
mmol, 4.0 equiv) was added and the resulting solution stirred at room temperature for 4 h. 
Amberlite CG-50 (3.0 g) was added to the reaction mixture and stirred at room temperature for 
30 min. Filtration and concentration in vacuo gave an off-white solid that was purified using 
Biotage MPLC (Thomson Single Step, 16.5 g C18 Flash Column) using a gradient of methanol 
in water as eluent to give the title compound (2.0 g, 6.29 mmol, 90%) as a hydroscopic white 
solid. Spectroscopic data [
1
H NMR (500 MHz, DMSO-d6) and 
13
C NMR (75 MHz, DMSO-d6)] 
are in accordance with those reported [30]. 
- 63 - 
1
H NMR (500 MHz, DMSO-d6): δ = 7.42 (1H, d, J = 8.3, C6H), 7.14 (1H, d, J = 15.9, C3H), 
7.09 (1H, d, J = 1.9, C9H), 6.96 (1H, dd, J = 8.4, 2.0, C5H), 6.35 (1H, d, J = 15.8, C2H), 3.77 
(3H, s, OCH3).   
13
C NMR (75 MHz, DMSO-d6): δ = 171.6 (C1), 150.5 (C8), 143.0 (C7), 136.9 (C3H), 131.7 
(C4), 127.4 (C5H), 120.8 (C6H), 119.6 (C2H), 110.6 (C9H), 55.6 (OCH3). 
3.3.2.3 Synthesis of dihydroferulic acid-4-O-sulphate 
The synthesis of dihydroferulic acid-4-O-sulphate consists of four individual synthesis steps. In 
the first step the carboxylic group of ferulic acid is protected by the formation of a methyl ester. 
In the second step neopentyl sulphate is introduced at the 4-position of the phenyl ring which is 
followed by reduction of the double bond with hydrogen, prior to the last step where the 
neopentyl unit is split off due to hydrolysis followed by the addition of a sodium cation.  
In the following the individual synthesis steps are described in experimental detail.  
 
Methyl 3-(3-methoxy-4-(((neopentyloxy)sulfonyl)oxy)phenyl)propanoate (14) was prepared 
using a modification of the procedure of Fumeaux et al.[30]. A suspension of palladium on 
activated carbon (10% dispersion; 500 mg) and compound (12) in methanol (150 mL) was 
degassed with gaseous hydrogen five times and stirred at room temperature under an 
atmosphere of hydrogen for 4 h. The reaction mixture was filtered through a pad of celite, the 
dark residue washed with dichloromethane (2  100 mL) and the combined filtrate concentrated 
in vacuo to give the title compound (9.86 g, 27.3 mmol, 98%) as a colourless oil that solidifies 
on storage at ca –20°C and was used in the subsequent step with no further purification. 
1
H NMR (500 MHz, CDCl3): δ = 7.26 (1H, d, J = 8.2, C6H), 6.84 (1H, d, J = 2.0, C9H), 6.78 
(1H, dd, J = 8.2, 2.0, C5H), 4.15 (2H, s, OCH2C(CH3)3), 3.87 (3H, s, OCH3), 3.68 (3H, s, 
OCH3), 2.94 (2H, t, J = 7.7, C3H2), 2.63 (2H, t, J = 7.7, C2H2) 1.00 (9H, s, OCH2C(CH3)3).   
13
C NMR (75 MHz, CDCl3): δ = 173.0 (C1), 151.0 (C8), 141.2 (C7), 137.5 (C4), 122.7 (C5H), 
120.4 (C6H), 113.1 (C9H), 83.3 (OCH2C(CH3)3), 55.9 (OCH3), 51.7 (OCH3), 35.4 (C2H2), 31.8 
(OCH2C(CH3)3), 30.7 (C3H2), 25.9 (OCH2C(CH3)3).   
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IR (solid): ν = 2962 s, 2873 m, 1738 s, 1604 m, 1509 s, 1437 m, 1399 s, 1369 s, 1271 s, 1207 s, 
1183 s cm
−1
. 
 
Dihydroferulic acid-4-O-sulphate (15) was prepared using a modification of the procedure of 
Fumeaux et al.[30]. A solution of ester (14) (2.5 g, 6.94 mmol, 1.0 equiv) and sodium azide 
(902 mg, 13.9 mmol, 2.0 equiv) in dimethylformamide (21 mL) was heated at 60°C for 24 h. 
The reaction mixture was allowed to cool to room temperature and the solvent removed using 
distillation (ca 40°C at ca 1 mmHg) to give a off-white gummy residue that was dissolved in 
methanol, dry loaded onto silicate and passed through a plug of silicate, eluted with 
dichloroemethane/ethanol (5:1) to give a pale yellow oil. Methanol (14 mL) and 1 M aqueous 
sodium hydroxide (28.0 mL, 28.0 mmol, 4.0 equiv) was added and the resulting solution stirred 
at room temperature for 4 h. Amberlite CG-50 (3.0 g) was added to the reaction mixture and 
stirred at room temperature for 30 min. Filtration and concentration in vacuo yielded an off-
white solid that was purified using Biotage MPLC (Thomson Single Step, 16.5 g C18 Flash 
Column) using a gradient of methanol in water as eluent to give the title compound (1.76 g, 5.50 
mmol, 79%) as a hydroscopic white solid. Spectroscopic data [
1
H NMR (500 MHz, DMSO-d6) 
and 
13
C NMR (75 MHz, DMSO-d6)] are in accordance with those reported [30]. 
1
H NMR (500 MHz, DMSO-d6): δ = 7.28 (1H, d, J = 8.1 Hz, C6H), 6.79 (1H, d, J = 2.0 Hz, 
C9H), 6.64 (1H, dd, J = 8.3, 2.0 Hz, C5H), 3.70 (3H, s, OCH3), 2.71 (2H, t, J = 7.9 Hz, C3H2), 
2.23 (2H, t, J = 7.9, C2H2).   
13
C NMR (75 MHz, DMSO-d6): δ = 177.1 (C1), 150.4 (C8), 140.3 (C7), 138.5 (C4), 121.1 
(C5H), 119.6 (C6H), 112.8 (C9H), 55.6 (OCH3), 39.7 (C2H2), 32.2 (C3H2). 
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Figure 3.2: Synthesis of ferulic acid-4-O-sulphate and dihydroferulic acid-4-O-sulphate 
 
3.3.2.4 Sample Preparation 
Instant coffee (Nestle Green Blend™) was purchased from one batch at a local supermarket in 
Leeds, UK. The coffee was kept sealed until the analysis and stored in a dark, cool place.  
Instant coffee (5 g) was taken from three different jars and mixed by stirring prior to weighing 
and dissolution.  
500 mg of instant coffee mixture was weighed and 50 mL of demineralised water (90-95ºC) was 
added and stirred. The coffee was immediately chilled on ice and diluted 1:5 with mobile phase 
A consisting of 95% demineralised water, 5% acetonitrile (LC-MS grade) and 0.1% fromic acid 
(LC-MS grade) containing 1 mM ascorbic acid. The solution was centrifuged at 17,000 g for 10 
minutes and the supernatant filtered through 0.22 µm PTFE. The sample was prepared in 
triplicate and 5 µL of each sample was injected onto the column in triplicate. 
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Urine samples were collected into sterilised unisex urine collection containers containing 1 g 
ascorbic acid for 0, 0-4, 4-8 and 8-12 h and 3 g ascorbic acid for 12-24 and 24-36 h, 
respectively. Within 48 h after collection the urine volume was determined by weight, an 
aliquote of 45 mL centrifuged at 4ºC for 10 minutes and 12 mL of the supernatant taken and an 
aqueous solution of sodium azide added with a final concentration of 0.1% prior to freezing the 
sample at -20ºC.  
Urine samples were prepared according to a modification of a procedure described by Stalmach 
et al. [7].  
Prior to LC-MS analysis urine samples were defrosted in a fridge overnight and one aliquot of 
900 µL from each sample taken, 100 µL 100 µM sinapic acid in mobile phase A containing 1 
mM ascorbic acid was added as an internal standard, vortexed for ten seconds, inverted twice, 
and centrifuged at 20,000 g at 4ºC for 10 minutes. The supernatant was filtered through 0.22 µm 
PTFE into amber vials.  
Samples were prepared to determine the recovery rates of the six urinary metabolites. Therefore 
pooled urine collected from six participants collected after a 36 hours washout period, which is 
described in detail in chapter 4, was used for spiking. Urine (850 µL) and 50 µL of the standard 
solution to yield concentrations of 2, 5, and 50 µM, and 100 µL of 100 µM sinapic acid as an 
internal standard. Additionally, 900 µL of blank urine were mixed with 100 µL of 100 µM 
sinapic acid. All samples were prepared in triplicate and processed as previously described.  
 
For the pancreatic digestion, 100 mg porcine pancreatin was suspended in 1 mL 20 mM 
potassium phosphate buffer pH 7.4. The suspension was briefly vortexed, and centrifuged at 
20,000 g, prior to separating the supernatant. The protein content of the pancreatic solution was 
determined using a Bradford protein assay kit including a 96 well plate which was inserted into 
a PHERAstar, BMG LABTECH (Ortenberg, Germany) operated at 595 nm.  
3-, 4-, and 5-caffeoylquinic acid and 3-, 4-, and 5-feruloylquinic acid were individually 
dissolved in potassium phosphate buffer to give 100 µM stock solutions. 1 g instant coffee was 
dissolved in 50 mL hot, but not boiling demineralised water. Prior to the incubation for the 
pancreatic digestion all solutions were heated at 37ºC. Potassium phosphate buffer (0.4 mL, 20 
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mM) was mixed with either 0.5 mL of coffee, 100 µM 3-, 4-, 5-caffeoylquinic acid, or 3-, 4-, 5-
feruloylquinic acid and 0.1 mL pancreatin solution. Each solution was prepared in duplicate and 
one control with heat-deactivated pancreatic solution.  
The samples were incubated at 37ºC for 60 minutes in an electrothermal incubator (Eppendorf, 
Hamburg, Germany). Aliquots of 100 µL were taken at the beginning, at 10, 20, 40 and 60 
minutes and acidified with 10 µL 10 % aqueous hydrochloric acid, vortexed and cooled on ice, 
prior to be centrifuged at 20,000 g at 4ºC for 10 minutes. 
3.3.2.5 High pressure liquid chromatography  
The high performance liquid chromatography system was an Agilent 1200 series (Waldbronn, 
Germany) with a degasser, binary pump, temperature controlled autosampler and column 
compartment, and a diode array detector fitted with an Agilent ZORBAX Eclipse Plus Rapid 
Resolution C18 100 mm x 2.1 mm i.d., 1.8 µm. 
Mobile phase A consisted of 95% demineralised water, 5% acetonitrile (LC-MS grade) and 
0.1% formic acid (LC-MS grade), mobile phase B of 95% acetonitrile (LC-MS grade), 5% 
demineralised water and 0.1% formic acid (LC-MS grade). Both solvents were degassed using 
an ultrasonic bath (Clifton, Nickel Electro Ltd., Weston-super-Mare, UK). 
 
For the liquid chromatography  of coffee, chromatographic settings were derived and adapted 
from a method developed by Farrell et al. [68]. In brief, coffee samples were kept at 4ºC and 5 
µL were injected in duplicate. The flow rate was set to 0.26 mL/min for a total run time of 65.1 
minutes. The gradient started with 0% mobile phase B for 17.3 minutes, was increased to 25% 
up to 51.0 minutes, further increased to 100% from 51.1 to 56.0 minutes and dropped to 0% 
from 56.1 minutes for ten minutes for reequilibration. The column was thermostated at 30ºC. 
 
Urine samples were kept at 4ºC and 10 µL were injected in duplicate. Chromatographic settings 
were optimized using synthesised (vanilloylglycine, feruloylglycine, dihydrocaffeic acid-3-O-
sulphate, ferulic acid-4-O-sulphate and dihydroferulic acid-4-O-sulphate) and commercially 
available standards (dihydroferulic acid and sinapic acid as an internal standard).  
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The flow rate was set to 0.4 mL/min, total run time of the method was 25 minutes with a 
gradient kept at 0% mobile phase B for the first 12 minutes, increased to 40% up to 16 minutes, 
further increased up to 100% at 16.5 minutes until 19.5 minutes and dropped to 0% from 20.0 
minutes for 5 minutes for reequilibration. The column was thermostated at 35ºC.  
 
Pancreatic digestion samples were kept at 4ºC and 5 µL injected in duplicate. The flow rate was 
set to 0.3 mL/min and separation with a 30 minutes gradient starting with 0% mobile phase B, 
increased to 8% over 14 minutes, increased to 19% up to 14.1 minutes and kept until 20.0 
minutes, increased to 100% from 20.1 to 24.0 minutes and dropped to 0% at 24.1 minutes for 6 
minutes for reequilibration. The column was thermostated at 30ºC.  
3.3.2.6 Mass spectrometry 
The Agilent 1200 series HPLC (Waldbronn, Germany) was coupled through a divert valve and 
a heated electrospray ionisation source to an Agilent 6410 A triple quadrupole mass 
spectrometer (Wokingham, UK). 
 
For the mass spectrometric analysis of coffee caffeoylquinic acid and its derivatives, the heated 
electrospray ionisation source was operated in negative mode with a source temperature set to 
350ºC, a nebulizer pressure of 10 L/min and a pressure of 60 psi. Multiple reaction monitoring 
(MRM) settings were optimised using commercially available standards at a concentration of 10 
µg/mL. Table 3.1 shows the optimised settings for the individual compounds. The flow of the 
first 4 minutes was diverted into waste.  
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Table 3.1: Chromatographic settings and multiple reaction monitoring of caffeoylquinic 
acid and its derivatives 
Compound Time 
window 
(min) 
Retention 
time 
(min) 
Precursor 
ion  
(m/z) 
Fragmentor 
energy 
(V) 
Product 
ion 
(m/z) 
Collision 
energy 
(V) 
3-Caffeoylquinic 
acid  
4.0- 
8.0 
6.2 353 120 191 
179 
20 
20 
5-Caffeoylquinic 
acid 
8.0- 
16.0 
14.1 353 120 191 
179 
10 
20 
3-Feruloylquinic 
acid 
 
4-Caffeoylquinic 
acid 
16.0- 
23.0 
 
16.4 
 
 
19.4 
 
367 
 
 
353 
120 
 
 
120 
193 
134 
 
179 
173 
20 
20 
 
15 
15 
5-Feruloylquinic 
acid 
 
4-Feruloylquinic 
acid 
28.0- 
39.0 
 
 
 
30.8 
 
 
31.8 
 
367 
 
 
367 
 
120 
 
 
120 
 
191 
134 
 
193 
173 
15 
20 
 
10 
10 
3,4-
Dicaffeoylquinic 
acid 
 
3,5-
Dicaffeoylquinic 
acid 
39.0- 
55.0 
41.6 
 
 
 
42.2 
515 
 
 
 
515 
150 
 
 
 
150 
 
353 
173 
 
 
191 
134 
20 
20 
 
 
20 
20 
 
After 55 minutes the polarity was switched to positive to neutralise a potential charge 
accumulation in the ion capillary. 
For the mass spectrometric analysis of urinary metabolites of caffeoylquinic acid and its 
derivatives, the heated electrospray ionisation source was operated in negative mode with a 
source temperature set to 350ºC, a nebulizer nitrogen flow of 13 L/min and a pressure of 60 psi. 
Multiple reaction monitoring (MRM) settings were optimised using synthesised 
(vanilloylglycine, feruloylglycine, dihydrocaffeic acid-3-O-sulphate, ferulic acid-4-O-sulphate 
and dihydroferulic acid-4-O-sulphate) and commercially available standards (dihydroferulic 
acid and sinapic acid as an internal standard) at a concentration of 10 µg/mL. Table 3.2 shows 
the optimised settings for the individual compounds. The eluent flow of the first 3 minutes was 
diverted into waste. 
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Table 3.2: Chromatographic settings and multiple reaction monitoring of vanilloylglycine, 
dihydrocaffeic acid-3-O-sulphate, dihydroferulic acid-4-O-sulphate, ferulic acid-4-O-
sulphate, feruloylglycine, dihydroferulic acid and sinapic acid (internal standard) 
Compound Time 
window 
(min) 
Retention 
time 
(min) 
Precursor 
ion  
(m/z) 
Fragmentor 
energy 
(V) 
Product 
ion 
(m/z) 
Collision 
energy 
(V) 
Vanilloylglycine 3.0- 
4.5 
4.2 
 
224 90 100 
123 
108 
6 
10 
22 
Dihydrocaffeic 
acid-3-O-
sulphate 
 
4.5- 
7.0 
5.8 
 
 
261 
 
 
90 
 
 
181 
137 
109 
12 
18 
26 
Dihydroferulic 
acid-4-O-
sulphate 
 
Ferulic acid-4-O-
sulphate 
7.0- 
15.0 
 
8.6 
 
 
 
10.7 
275 
 
 
 
273 
 
100 
 
 
 
90 
 
195 
136 
80 
 
193 
178 
134 
10 
16 
14 
 
8 
16 
26 
Feruloylglycine 15.0-
16.0 
15.6 250 90 206 
163 
134 
6 
20 
18 
Dihydroferulic 
acid 
16.0-
16.5 
16.2 195 90 136 
121 
93 
12 
26 
30 
Sinapic acid 
(internal 
standard) 
16.5-
19.5 
16.7 223 90 208 
193 
164 
6 
16 
10 
 
After 19.5 minutes the polarity was switched to positive mode to neutralise a potential charge 
accumulation in the ion capillary. 
For the mass spectrometric analysis of the pancreatic digestion samples, the heated electrospray 
ionisation source was operated in negative mode with a source temperature set to 350ºC, a 
nebulizer nitrogen flow of 13 L/min and a pressure of 60 psi. Multiple reaction monitoring 
settings were optimised using commercially available standards at a concentration of 10 µg/mL. 
The following table shows the optimised settings for the individual compounds. The eluent flow 
of the first 3 minutes was diverted into waste. 
  
- 71 - 
Table 3.3: Chromatographic settings and multiple reaction monitoring of caffeic acid and 
ferulic acid 
Compound Retention 
time 
(min) 
Precursor 
ion  
(m/z) 
Fragmentor 
energy (V) 
Product 
ion 
(m/z) 
Collision 
energy 
(V) 
Caffeic acid 9.9 179 80 135 
89 
15 
30 
Ferulic acid 17.6 193 90 134 
178 
8 
12 
 
After 25.0 minutes the polarity was switched to positive mode to neutralise a potential charge 
accumulation in the ion capillary. 
3.3.2.7 Quantitation through external calibration 
Caffeoylquinic acids and its derivatives in coffee were quantified using external calibration with 
eight calibrants including 0.5, 1, 2, 5, 10, 20, 50 and 100 µM for each individual compound. The 
calibrants were prepared in mobile phase A containing 1 mM ascorbic acid. The linearity was 
R
2≥0.99 over the entire range. The limit of detection (LOD) and the limit of quantitation (LOQ) 
are calculated by LOD=(3.3*intercept)/slope and LOQ=(10*intercept)/slope, respectively. The 
values are presented in Table 3.4.  
Table 3.4: Summary of the limit of detection and limit of quantitation caffeoylquinic acid 
and its derivatives, 5 µL injected 
Compound Limit of detection (µM) Limit of quantitation (µM) 
3-Caffeoylquinic acid 5.8 17.5 
4-Caffeoylquinic acid 1.4 4.3 
5-Caffeoylquinic acid 6.3 19.2 
3-Feruloylquinic acid 0.6 1.9 
4-Feruloylquinic acid 1.1 3.3 
5-Feruloylquinic acid 4.8 14.8 
3,4-Dicaffeoylquinic acid 0.45 1.4 
3,5-Dicaffeoylquinic acid 0.1 0.2 
 
Urinary metabolites of caffeoylquinic acid and its derivatives were quantified using external 
calibration. The first calibration curves with twelve calibrants including 10, 20, 50, 500 nM, 1, 
2, 4, 6, 8, 10, 20 and 50 µM. Further calibration curves were run, including five calibrants 0.5, 
1, 5, 10 and 50 µM. The calibrants were prepared in mobile phase A containing 1 mM ascorbic 
acid. The linearity for the first and following calibration curves were R
2≥0.99 and R2≥0.999, 
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respectively. The limit of detection (LOD) and the limit of quantitation (LOQ) were calculated 
by LOD=(3.3*intercept)/slope and LOQ=(10*intercept)/slope, respectively. The values are 
presented in Table 3.5.  
Table 3.5: Summary of the limit of detection and limit of quantitation of urinary 
metabolites of caffeoylquinic acid and its derivatives, 10 µL injected 
Compound Limit of detection (µM) Limit of quantitation (µM) 
Vanilloylglycine 0.4 1.2 
Dihydrocaffeic acid-3-O-
sulphate 
0.6 1.7 
Dihydroferulic acid-4-O-
sulphate 
0.4 1.3 
Ferulic acid-4-O-sulphate 0.5 1.6 
Feruloylglycine 0.1 0.2 
Dihydroferulic acid 0.5 1.5 
Sinapic acid  0.3 0.8 
 
The first calibration curve was run on day 1 thereafter samples of six subjects were run and a 
calibration curve with five calibrants followed by samples of six subjects. The cycle was 
repeated for 11, 8 and 7 times for the first visit (n=62), the second visit (n=47) and the third visit 
(n=40), respectively. Urinary concentration and subsequent total amounts excreted, have been 
corrected using the recovery factor of the internal standard.  
 
In the pancreatic digestion samples, caffeic acid and ferulic acid were quantified through 
external calibration. Calibration curves included eight calibrants, e.g. 10, 250, 500 nM, 1, 2, 5, 
10 and 20 µM with a linearity of R
2≥0.999. The limit of detection (LOD) and the limit of 
quantitation (LOQ) are calculated by LOD=(3.3*intercept)/slope and 
LOQ=(10*intercept)/slope, respectively. Table 3.6 presents the values. The calibrants have been 
prepared in 20 mM potassium phosphate buffer (pH=7.4).  
Table 3.6: Summary of the limit of detection and limit of quantitation of caffeic acid and 
ferulic acid, 10 µL injected 
Compound Limit of detection (µM) Limit of quantitation (µM) 
Caffeic acid 0.01 0.04 
Ferulic acid 0.04 0.13 
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3.4 Results 
 
3.4.1 Synthesis of hydroxycinnamic acid sulphates 
Several hundred milligrams of dihydrocaffeic acid-3-O-sulphate, dihydroferulic acid-4-O-
sulphate and ferulic acid-4-O-sulphate were chemically synthesised and their quality and purity 
confirmed by NMR, IR and LC-MS. The compounds served as analytical standards for the 
quantitation of urinary metabolites of caffeoylquinic acid and its derivatives. For the first time 
these sulphates have been synthesised in amounts visible to the human eye. Subsequently, their 
appearance was described and their melting points determined.  
 
3.4.2 Coffee caffeoylquinic acid and its derivatives content 
Eight caffeoylquinic acid and its derivatives have been analysed in commercially available 
instant coffee. The following graph (Figure 3.3) shows the amounts of the individual compound 
in 4 g instant coffee, the amount which was ingested in a subsequent study described in 4.3.3.  
Figure 3.3: Caffeoylquinic acid and its derivatives content in µmol in 4g instant coffee, n=9 
(three biological samples, three injections), mean ± standard deviation 
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The total amount of caffeoylquinic acid and its derivatives is 881.8 +/- 27.2 µmol and were 
about two-fold higher when compared with other publications [7, 20, 31], however, green, 
unroasted coffee beans were intentionally used to prepare the coffee by the manufacturer.  
3-, 4-, and 5-Caffeoylquinic acid account for 68.5% with 5-CQA accounting for 33.0% of the 
total caffeoylquinic acid and its derivatives content on a molar basis.  
 
3.4.3 Urine 
Six major urinary metabolites of caffeoylquinic acids were separated with a newly developed 
reverse phase, gradient method. Baseline separation was achieved for most compounds within 
17 minutes depicted in Figure 3.4. However, there is a slight overlap of dihydroferulic acid-4-O-
sulphate and ferulic acid-4-O-sulphate. These compounds can be distinguished using their 
specific multiple reaction monitoring.  
Figure 3.4: Total ion chromatogram of six major urinary CQA metabolites and the 
internal standard, vanilloylglycine (1), dihydrocaffeic acid-3-O-sulphate (2), 
dihydroferulic acid-4-O-sulphate (3), ferulic acid-4-O-sulphate (4), feruloylglycine (5), 
dihydroferulic acid (6) and sinapic acid (7) 
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Sulphate conjugates tend to yield broader peaks which could be due to incomplete protonisation 
[68], however, the pH cannot be dropped further due to incompatibility with the column, the 
HPLC and the mass spectrometer.  
The recovery of six urinary metabolites of caffeoylquinic acid and its derivatives were assessed 
and the results are depicted in Table 3.7.  
Table 3.7: Recovery (%) of six urinary metabolites and internal standard at 2, 5, 50 µM, 
n=6 (three samples, two injections), mean ± standard deviation 
 VA-
GLY 
DHCA-
3-O-S 
DHFA-
4-O-S 
FA-4-O-
S 
FA-GLY DHFA SA  
2 µM 84.4 ± 
1.2 
76.7 ± 
0.8 
65.2 ± 
3.2 
48.5 ± 
0.3 
80.4 ± 
0.9 
62.1 ± 
0.6 
30.1 ± 
11.9 
5 µM 105.8 ± 
1.4 
126.9 ± 
1.2 
115.4 ± 
2.4 
96.8 ± 
1.8 
102.1 ± 
1.5 
93.6 ± 
1.2 
101.6 ± 
1.9 
50 µM 94.9 ± 
0.4 
111.9 ± 
0.9 
103.4 ± 
1.0 
99.7 ± 
0.5 
95.4 ± 
1.3 
92.0 ± 
0.9 
86.6 ± 
1.1 
 
There is an overall tendency that the recovery rates of 2 µM concentration are very low, 
whereas the recovery for 5 and 50 µM are overall higher and closer to the amount spiked in the 
sample. However, the recovery for the sulphates, especially the dihydro forms at 5 µM 
concentration tend to be above the amount spiked in urine. This could be due to ion 
enhancement effects in the electrospray ionisation source [68].  
 
3.4.4 Pancreatic digestion of coffee, caffeoylquinic acid and its derivatives  
The presented data has been published by da Encarnaçao et al., 2014 [25]. 
Incubation of the coffee solution with porcine pancreatin at 8.5 mg protein/mL led to hydrolysis 
of caffeoylquinic acid and its derivatives present in the coffee to give free caffeic acid, with a 
rate of 203 pmol/mg protein/min as shown in Figure 3.5. Pure caffeoylquinic acids (50 µM 
each) were tested as pancreatin substrates. Linear rates over 60 min were obtained, equivalent to 
1.6, 2.4 and 5.4 pmol/mg protein/min  for 3-CQA, 4-CQA and 5-CQA, respectively, depicted in 
Figure 3.6, Figure 3.7, and Figure 3.8. No significant increase in ferulic acid was observed after 
pancreatin treatment of coffee, and also no ferulic acid was detected after incubation of 
pancreatin with 50 µM 3-FQA, 4-FQA and 5-FQA. The data suggests that CQAs, and in 
- 76 - 
particular 5-CQA, are better substrates for pancreatin, a complex mixture of various lipases, 
peptidases, amylases and non-specific carboxylesterases. No digestion was observed when the 
coffee solution and each of the caffeoylquinic acids were incubated with a heat-inactivated 
pancreatin solution. 
Figure 3.5: Pancreatic digestion of instant coffee with measument of caffeic acid 
concentration over sixty minutes with samples taken at 0, 10, 20, 40, and 60 minutes, n=4 
(two biological samples, two injections), mean ± standard deviation. The enzymatic rate is 
203 pmol/mg protein/min 
 
Figure 3.6: Pancreatic digestion of 3-CQA with measurement of caffeic acid concentration 
over sixty minutes with samples taken at 0, 10, 20, 40, and 60 minutes, n=4 (two biological 
samples, two injections), mean ± standard deviation. The enzymatic rate is 1.6 pmol/mg 
protein/min 
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Figure 3.7: Pancreatic digestion of 4-CQA with measurement of caffeic acid concentration 
over sixty minutes with samples taken at 0, 10, 20, 40, and 60 minutes, n=4 (two biological 
samples, two injections), mean ± SD. The enzymatic rate is 2.4 pmol/mg protein/min 
 
Figure 3.8: Pancreatic digestion of 5-CQA with measurement of caffeic acid concentration 
over sixty minutes with samples taken at 0, 10, 20, 40, and 60 minutes, n=4 (two biological 
samples, two injections), mean ± standard deviation. The enzymatic rate is 5.4 pmol/mg 
protein/min 
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3.5 Discussion 
Dihydrocaffeic acid-3-O-sulphate, dihydroferulic acid-4-O-sulphate and ferulic acid-4-O-
sulphate have been synthesised in hundreds of milligram amounts, purity confirmed by MS
2
, 
1
H-NMR, 
13
C-NMR and IR, and their physicochemical properties determined, which are in line 
with a previous publication of Fumeaux et al. [30]. For the first time these sulphates have been 
synthesised in practical amounts. The synthesised amounts of these non-commercially available 
standards allowed us to develop and validate a new, quick method for the quantitative LC-MS 
analysis of the six highest urinary metabolites of caffeoylquinic acids and its derivatives, e.g. 
vanilloylglycine, feruloylglycine, dihydrocaffeic acid-3-O-sulphate, dihydroferulic acid-4-O-
sulphate, ferulic acid-4-O-sulphate and dihydroferulic acid. Previous methods developed by 
Stalmach et al. [7] and Farrell et al. [68] exceeded a run time of 60 minutes and were therefore 
not suitable for the analysis of several hundred urine samples in a reasonable time period. The 
method consists of a quick sample preparation step followed by a chromatographic method 
which fully separates the six major urinary metabolites of caffeoylquinic acid and its derivatives 
over 17 minutes and takes 30 minutes to finish. The LC-MS method has been validated 
including linearity, limit of detection and quantitation and recovery rates from spiked samples 
and is therefore fit for purpose. The limit of detection and quantitation of the developed LC-MS 
method were up to a factor of 20 higher compared to Farrell et al. [68], however, Farrell et al 
based her calculation on the signal-to-noise-ratio whereas the slope and intercept of the equation 
of the calibration curves to calculate LOD and LOQ, respectively, were used here. The recovery 
rates are very close to the spiked amount for 5 and 50 µM (100 ± 15%) and reasonable for 2 
µM. The method was used to analyse urine samples of participants in a study described in 
chapter 4, where the results are also presented.  
Numerous previous studies described the detection and quantification of caffeoylquinic acid and 
its derivatives in coffee beverages [10, 12, 17, 19, 20, 78]. The major compounds are 3-, 4- and 
5-caffeoylquinic acid whereas 5-caffeoylquinic acid is by far the most abundant [7, 15, 19]. In 
this study, Nescafe Green Blend™, a commercially available instant coffee, was analysed for 
caffeoylquinic acid and its derivatives, e.g. 3-, 4-, and 5-caffeoylquinic acid, 3-, 4-, and 5-
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feruloylquinic acid, 3,4-dicaffeoylquinic acid and 3,5-dicaffeoylquinic acid. However, 4,5-
dicaffeoylquinic acid was not analysed since the chemical standard was not available.  
With 68.5% (molar ratio), 3-, 4-, and 5-caffeoylquinic acid were the major constituents, whereas 
3-, 4-, and 5-feruloylquinic acid accounted for only 19.1% (molar ratio) and 3,4-diCQA and 3,5-
diCQA for only 12.4% (molar ratio) of the total amount of 881.8 µmol of caffeoylquinic acid 
and its derivatives. The ratio of the various caffeoylquinic acid and its derivatives is in 
accordance with previous publications [7, 15], however, the total amount of caffeoylquinic acid 
and its derivatives is more than two-fold higher compared with these publications. In contrast, 
by comparison with Erk et al’s publication [17], the caffeoylquinic acid content in this chapter 
is on the lower end (881.8 µmol vs 1053, 2219 and 4525 µmol).  
Over the past five years, three studies by independent groups have been published on the 
absorption, metabolism and excretion of caffeoylquinic acid and its derivatives in humans who 
underwent ileostomy, removal or by-pass of the colon. The studies were performed to assess the 
role of the stomach and small intestine on the absorption and metabolism of caffeoylquinic acid 
and its derivatives excluding the effect of colonic catabolism. The studies found that the 
absorption is attenuated, as measured as the percentage of ingestion (8 ± 1% [15] and 15 ± 7% 
[17]) in 24 hour urine and the metabolites detected included mainly non-reduced caffeic and 
ferulic acid phase II metabolites. The following reactions are attributed to the small intestine 
cleavage of the ester bond in caffeoylquinic acid and its derivatives, sulphation of the free 
hydroxycinnamic acids and the methylation of caffeic acid yielding isoferulic acid [15]. 
Whereas in the colon the cleavage of the ester bond in caffeoylquinic acid and its derivatives is 
attributed to colonic microbial esterases [26], the cleavage in the small intestine has not yet been 
investigated in detail. Pancreatin, a complex mixture of various digestive enzymes including 
lipases, trypsin, peptidases, proteases, RNAses, DNAses, amylases and unspecific 
carboxylesterases excreted by the pancreas into the duodenum, the upper part of the small 
intestine, is supposed to have a hydrolysing effect on the ester bond of caffeoylquinic acid and 
its derivatives ascribed to the carboxylesterases. The hydrolysing effect of pancreatin was tested 
on coffee, 3-, 4-, and 5-caffeoylquinic acid and 3-, 4-, and 5-feruloylquinic acid. Coffee was the 
best substrate concerning the rate of hydrolysis of caffeoylquinic acid and its derivatives (203 
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pmol/mg protein/min). Results from caffeoylquinic acid and feruloylquinic acid treatment by 
porcine pancreatin indicated that 5-caffeoylquinic acid is the highest substrate with a rate of 
hydrolysis (5.4 pmol/mg protein/min) up to 5-fold higher when compared to 3-CQA (1.6 
pmol/mg protein/min) and 4-CQA (2.4 pmol/mg protein/min). No hydrolysing effect of porcine 
pancreatin was observed on feruloylquinic acids. This indicates that the early plasma 
appearance of ferulic acid phase II metabolites [15, 33] is probably due to the methylation of the 
3-position of caffeic acid after cleavage of the ester bond and further phase II conjugation 
reactions which is in line with the data of Stalmach et al.[15]. The data indicates that pancreatin 
has a substantial contribution to the hydrolysis of the ester bond between caffeic acid and the 
quinic acid moiety in caffeoylquinic acids, in particular on 5-caffeoylquinic acid, in the small 
intestine. 
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Chapter 4: Design and performance of human study and subsequent 
analysis of highest urinary metabolites of caffeoylquinic acid and its 
derivatives 
 
4.1 Abstract 
This chapter reports on the design and performance of the human study, the procedure of the 
urine sample analysis and presents the data of the urinary excretion of metabolites of 
caffeoylquinic acid and its derivatives.  
The study aimed to investigate the intra- and interindividual variation of absorption and 
metabolism of caffeoylquinic acid and its derivatives and the linkage to some biomarkers of 
health. The intra- and interindividual variation of absorption and metabolism of caffeoylquinic 
acid and its derivatives after coffee consumption is described in detail in chapter 4, whereas the 
correlation to biomarkers of health is described in chapter 5. 
The study consisted of three phases and included 63, 47 and 40 participants. During each phase 
participants underwent a wash-out of 36 hours prior to the beginning of the study, consumed a 
cup of standardised coffee (881.8 µmol of caffeoylquinic acid and its derivatives), followed by a 
low polyphenol diet during the 36 hours of urine collection thereafter. A baseline urine sample 
was collected and all urine was collected in time periods of 0-4, 4-8, 8-12, 12-24 and 24-36 
hours. The urine was analysed by LC-MS for the six major metabolites of caffeoylquinic acid 
and its derivatives. The highest excreted metabolites are dihydrocaffeic acid-3-O-sulphate (60.2 
µmol), feruloylglycine (51.7 µmol), vanilloylglycine (41.9 µmol), ferulic acid-4-O-sulphate 
(40.7 µmol), dihydroferulic acid-4-O-sulphate (27.0 µmol), and dihydroferulic acid (19.2 µmol) 
for phase 1. The total amount excreted was 240.6 µmol which is equivalent to 27.3% of the 
ingested dose.  
The inter- and intraindividual variation is also described. In phase 1, phase 2 and phase 3 the 
summed amount of all five metabolites of caffeoylquinic acid and its derivatives excreted over 
36 hours vary by up to 8-fold, 10-fold and 35-fold between the participants, respectively. The 
intraindividual variation for the individual participants who completed all three phases of the 
study was the highest for dihydrocaffeic acid-3-O-sulphate (52.3% CV), vanilloylglycine 
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(51.8% CV), dihydroferulic acid-4-O-sulphate (50.2% CV), dihydroferulic acid (46.1% CV), 
ferulic acid-4-O-sulphate (37.4% CV) and feruloylglycine (35.9% CV). The colonic microbial 
derived metabolites showed the highest coefficient of variation whereas the small intestinal 
metabolites were demonstrated to show a lower coefficient of variation. This leads us to the 
conclusion that the colonic microflora undergoes substantial changes over a time period of six 
to eight weeks in terms of quantity and composition of bacterial strains and their metabolic 
competence might be due to changes.  
 
4.2 Introduction 
Several studies have been performed to investigate the absorption, metabolism and excretion of 
caffeoylquinic acid and its derivatives in healthy humans and ileostomists [7, 15-18, 21, 22, 28, 
30, 31, 33, 73, 79, 80]. Some studies showed the extensive metabolism caffeoylquinic acid and 
its derivatives undergo, when passing through the human body [7, 17]. However, the first 
studies investigating the absorption, metabolism and excretion of caffeoylquinic acid and its 
derivatives in humans used either enzymatic or alkaline hydrolysis to cleave the phase II 
functional groups, e.g. sulfate and glucuronide, to yield the aglycone form of caffeic or ferulic 
acid for quantification, and thus did not provide a full scheme of the potential bioactive forms 
within the circulatory system of the human body. Stalmach et al. were the first to quantify 
plasma and urinary metabolites of caffeoylquinic acid and its derivatives using some chemically 
synthesised standards, e.g. feruloylglycine and isoferuloylglycine for precise LC-MS based 
quantitation [7] in 2009. A year later, Fumeaux et al. chemically synthesised several sulfates 
and glucuronides of caffeic and ferulic acid, the aglycone forms of caffeoylquinic acid and its 
derivatives, and quantified these in urine and plasma post coffee consumption [30]. Moreover, a 
study was performed to investigate the absorption of caffeoylquinic acid and its derivatives in 
ileostomists demonstrating that two third of all ingested compounds reach the colon and only 
8% are excreted as urinary metabolites over 24 hours after coffee consumption [15]. 
Additionally, further studies were performed to investigate the effect of dose of caffeoylquinic 
acid and its derivatives in healthy humans and in ileostomists indicating the reduction of 
absorption of higher doses of caffeoylquinic acid and its derivatives due to enzyme saturation, 
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limitation of substrates, limited transport capacities at the enterocyte (influx and efflux) or an 
influence of the gastrointestinal transit time [16, 17].  
In addition to studies of absorption, metabolism and excretion of caffeoylquinic acid and its 
derivatives from coffee, several epidemiological studies have been performed. An inverse 
correlation was found between coffee consumption and diabetes mellitus type II [37, 52] and 
coffee consumption showed beneficial effects on the prevention of endometrial and 
hepatocellular cancer [35, 63]. Furthermore regular, moderate coffee consumption is indicated 
to prevent Alzheimer and related diseases [81]. 
Previous studies either investigated the absorption, metabolism and excretion of coffee 
caffeoylquinic acid and its derivatives in humans or investigated effects of isolated 
caffeoylquinic acid and its derivatives on cell models, however, until now no study has 
investigated the relationship between absorption of coffee caffeoylquinic acids and its 
derivatives and the health status of participants. The following study aims to link these two 
important factors together. The chosen biomarkers of health chosen are plasma thiols, e.g. 
cysteine, homocysteine, cysteinylglycine and glutathione for cardiovascular health and insulin 
as an indicator for the metabolic syndrome. In urine, the five highest metabolites of 
caffeoylquinic acid and its derivatives according to Stalmach et al. [7] including the newly 
detected and quantified vanilloylglycine, described in 2.4.4, were analysed, e.g. dihydrocaffeic 
acid-3-O-sulphate, feruloylglycine, dihydroferulic acid-4-O-sulphate, ferulic acid-4-O-sulphate 
and dihydroferulic acid.  
This chapter describes the design and execution of the human study, the sample collection, 
storage and analysis of the urine and the presentation of urinary excretion of metabolites of 
caffeoylquinic acid and its derivatives including the display of inter- and intraindividual 
variation. The relationship between absorption of coffee caffeoylquinic acid and its derivatives 
in humans and the biomarkers of health is presented in chapter 5.  
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4.3 Methods 
 
4.3.1 Samples size calculation 
The calculation of the sample size takes the mean and standard deviation of a specific parameter 
of a population into account in order to provide meaningful, statistical data. The samples size 
calculation was performed using various biomarkers of health measured in baseline plasma, e.g. 
thiols (total cysteine, homocysteine, cysteinylglycine, glutathione) and insulin. The sample size 
was calculated using the following website http://www.statisticalsolutions.net/pss_calc.php. 
Table 4.1 depicts the measured mean and standard deviation of a pilot study including six 
subjects in column 2. The mean and standard deviation of previously published data is depicted 
in column 3. The probability of falsely calculating the null hypothesis was set to 0.05 and the 
probability of correctly rejecting the false null hypothesis was set to 0.8. The calculated sample 
size for the individual compound is shown in column 4 and the number of participants is the 
highest for homocysteine with 52, thus the aim was to recruit at least 52 participants. With 62 
participants in phase 1, the target was met.  
 
Table 4.1: Sample size calculation based on the measured biomarkers of health, e.g. thiols 
and insulin form a pilot study population (n=6). The measurement of homocysteine 
indicate a requirement of at least 52 participants in order to obtain, meaningful, 
statistically significant data, whereas for cysteine and insulin only 6 and 15 participants 
were required. Derived and adapted from Miss Joana Amarante Encarnacao’s thesis, 
2015 
Biomarker μ0 ± SD μ1 ± SD n (sample size) 
Total cysteine 251 ± 10 289 ± 31 6 
Total homocysteine 7.4 ± 2 8.1 ± 1.8 52 
Total 
cysteinylglycine 
37 ± 4 28 ± 2 1 
Total glutathione 7.9 ± 0.6 3.71 1 
Insulin 7.3 ± 1.9 9.6 ± 3.1 15 
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4.3.2 Recruitment and personal information  
Healthy participants were recruited by poster advertisement on the campus of the University of 
Leeds and were asked to attend an information session where the course of the human study, the 
inclusion criteria and the risks were explained. Prior to the beginning of the study participants 
gave their written, informed consent and were informed of the possibility to withdraw from the 
study at any time. A subject code was assigned to every participant and their personal data kept 
apart from the data of the study. Thereafter they filled in a health questionnaire to assess their 
conformity with the inclusion criteria. Healthy participants were defined by inclusion criteria 
such as age (18-70 years), body mass index (18-29 kg/m
2
), non-smoker, or weak smoker, 
alcohol consumption (no more than 4 UK units on average on a daily basis), physical health (did 
not suffer from diagnosed chronic diseases, haemophilia, or underwent previous gastrointestinal 
tract surgery), medication (no intake of long term prescription only medicine) and women were 
neither pregnant nor lactating. Additionally, information on physical activity and bowel 
movement was gathered. Participants who fulfilled these inclusion criteria were accepted into 
the study and filled in a food frequency questionnaire in order to assess their food and drink 
intake, covering among others coffee and tea consumption and type, fruit, vegetable and spice 
consumption.  
 
4.3.3 Study design 
After providing their written informed consent and assessment of conformity with the inclusion 
criteria, participants were invited to the first phase of the study and were given a food restriction 
list and a food diary. They were asked not to consume several types of food for 72 hours, 36 
hours prior to their visit (washout) and 36 hours after their visit (urine collection). The 
following foods were included in the restriction list: any type of coffee, tea, chocolate, alcoholic 
beverages, all fruits and fruit-based products with the exception of banana and kiwi, all 
vegetables and vegetable-based products with the exception of mushrooms, cucumber, 
courgette, asparagus, lettuce, pumpkin and fruit or vegetable-based food supplements. The 
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participant’s diet was documented in the food diary during the 72 hours to assure compliance 
with the food restriction.  
The washout started on the evening of day 1 and participants fasted for at least 10 hours 
overnight on day 2. At the next morning (day 3), participants were allowed to void the morning 
urine as normal and drank at least 500 mL of water one hour prior to arriving at the School of 
Food Science and Nutrition between 7:00 and 9:30 am.  
Anthropometric measurements of the height, weight, waist and hip circumference and the blood 
pressure were recorded. Two baseline blood samples of 6 mL were collected by venepuncture of 
the antecubital vein. The blood was immediately processed to yield plasma described in Miss 
Joana Encarnaçao’s thesis, 2015.  
Participants collected a baseline urine sample. Afterwards they drank a cup of coffee containing 
882 µmol of caffeoylquinic acids and its derivatives as described in chapter 3 and were provided 
with a breakfast consisting of toast, hard and spread cheese and milk. They were allowed to add 
water or milk to their coffee according to their preference. They were instructed to collect all 
urine in time periods of 0-4, 4-8, 8-12, 12-24 and 24-36 hours post coffee consumption and to 
report any loss.  
The urine collection finished in the evening of day 4. At the morning of day 5, urine was 
returned and immediately processed and subsequently analysed as described in chapter 3. The 
same procedure (phase 2 and 3) was repeated about six and twelve weeks after the completion 
of the first phase for the assessment of intrapersonal variation in absorption. Participants were 
remunerated with GBP 10 for each completed phase. The individual data is stored separately 
from the participants codes and is kept confidential. The human study was approved by the 
University of Leeds Joint Faculty Ethics Committee (MEEC 10-035) and was registered with 
the clinicaltrials.gov database (NCT01912144). All human study documents can be found in the 
appendix.  
 
- 87 - 
4.3.4 Analysis of human samples 
Human urine samples were stored at –20ºC up to 12 months after the collection. The samples 
were processed and quantitatively analysed by LC-MS as described in detail in 3.3.2.  
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4.4 Results 
 
4.4.1 Description of the study population 
Initally, 63 participants were recruited for the human study, of which 62, 46, and 38 participants 
completed phase 1, phase 2 and phase 3, respectively. 41 female and 21 male volunteers 
participated in phase 1 with an average age of 28.3 years (18-53), an average body mass index 
of 23.3 kg/m
2
 (18.0-29.6) and an average waist to hip ratio of 0.76 (0.67-0.94). Four participants 
were smokers and three former smokers. After completion of phase 1, some participants decided 
to quit the study or were not allowed to enter phase 2 due to time constraints. From the initial 62 
participants, 46 completed phase 2. Participants of the phase 2 of the human study had an 
average age of 29.0 years (19-53), an average body mass index of 23.7 kg/m
2
 (18.8-29.5) and an 
average waist to hip ratio of 0.77 (0.68-0.91). Three participants were smokers and three former 
smokers. Due to time constraints only 38 participants completed phase 3. Participants of phase 3 
had an average age of 28.6 years (19-53), an average body mass index of 23.3 kg/m
2
 (18.4-29.5) 
and an average waist to hip ratio of 0.77 (0.66-0.89). Three participants were smokers and three 
former smokers. None of the participants suffered from diagnosed chronic diseases, 
haemophilia, underwent previous gastrointestinal tract surgery or took prescription only 
medicine during the study.  
 
4.4.2 Excretion of urinary metabolites of caffeoylquinic acid and its derivatives 
The six major urinary metabolites (Figure 4.1) of caffeoylquinic acid and its derivatives were 
analysed in urine before and in time periods of 0-4, 4-8, 8-12, 12-24 and 24-36 hours post 
coffee consumption, e.g. dihydrocaffeic acid-3-O-sulphate, feruloylglycine, vanilloylglycine, 
ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-sulphate and dihydroferulic acid. Only small 
amounts of metabolites of caffeoylquinic acid and its derivatives of 0.8 ± 1.6 µmol 
dihydrocaffeic-acid-3-O-sulphate, 1.2 ± 2.2 µmol feruloylglycine, 0.8 ± 2.4 µmol 
vanilloylglycine, 0.9 ± 2.5 µmol ferulic acid-4-O-sulphate, 0.4 ± 1.0 µmol dihydroferulic acid-
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4-O-sulphate and 0.2 ± 0.4 µmol dihydroferulic acid were detected in baseline urine. These 
amounts are negligible compared to the amounts excreted post coffee consumption.  
Figure 4.1: Excretion of six major urinary metabolites for 36 hours after coffee 
consumption averaged for 62 participants in phase 1. Dihydrocaffeic acid-3-O-sulphate, 
feruloylglycine, vanilloylglycine, ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-
sulphate and dihydroferulic acid account for 60.2 ± 53.5, 51.7 ± 29.5, 41.9 ± 34.7, 40.7 ± 
21.2, 27.0 ± 26.4 and 19.2 ± 15.2 µmol, respectively, n=62, mean ± standard deviation  
 
In the whole urine collected up to 36 hours after coffee consumption, averaged for all 62 
participants, 60.2 ± 53.5 µmol dihydrocaffeic acid-3-O-sulphate, 51.7 ± 29.5 µmol 
feruloylglycine, 41.9 ± 34.7 µmol vanilloylglycine, 40.7 ± 21.1 µmol ferulic acid-4-O-sulphate, 
27.0 ± 26.4 µmol dihydroferulic acid-4-O-sulphate and 19.2 ± 15.2 µmol dihydroferulic acid 
were quantitatively analysed. In accordance with a previous publication [7], dihydrocaffeic 
acid-3-O-sulphate is the highest excreted metabolite followed by feruloylglycine. The third 
most excreted metabolite is vanilloylglycine with 41.9 ± 34.7 µmol which was neither detected, 
nor quantified, in urine after consumption of coffee in any previous studies. In Stalmach’s et al. 
[7] study dihydroferulic acid-4-O-sulphate was the third highest metabolite followed by ferulic-
acid-3-O-sulfate. In our study ferulic acid-4-O-sulphate (40.7 ± 21.1 µmol) is the fourth highest 
metabolite followed by dihydroferulic acid-4-O-sulphate (27.0 ± 26.4 µmol). The lowest 
metabolite from the six metabolites analysed is dihydroferulic acid with 19.2 ± 15.2 µmol.  
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Adding all the metabolites excreted in the urine up to 36 hours, the amount equals to 240.6 ± 
123.8 µmol which accounts for 27.3 % of the ingested dose of 881.8 µmol caffeoylquinic acid 
and its derivatives (compare chapter 3). Dihydrocaffeic acid-3-O-sulphate, feruloylglycine, 
vanilloylglycine, ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-sulphate and dihydroferulic 
acid accounted for 6.8, 5.9, 4.8, 4.6, 3.1 and 2.2 molar % of the ingested dose, respectively. The 
sulphated and glycine conjugate metabolites accounted for 14.5 and 10.6 molar % of the 
ingested dose, respectively.  
Figure 4.2: Total excretion of six major urinary metabolites for 36 hours after coffee 
consumption for 62 participants of phase 1 in µmol. The lowest amount excreted is 82.9 
µmol and the highest amount excreted is 693.2 µmol 
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Figure 4.2 depicts the total amount of six major metabolites excreted for 36 hours after coffee 
consumption of 62 participants of phase 1. The lowest and highest amounts excreted are 82.9 
and 693.2 µmol, respectively. Performing a Saphiro-Wilk test (p=0.000) indicates that the data 
is not normally distributed with a skew towards the upper end including two statistical outliers 
of 535.3 and 693.2 µmol. Since these values are equivalent to 60.7 and 78.6 % of the ingested 
dose of caffeoylquinic acid and its derivatives and therefore hypothetically possible, they were 
not excluded from the set of data for further analysis in chapter 5.  
Since urine was collected in time periods of 0-4, 4-8, 8-12, 12-24 and 24-36 hours, each 
individual sample was quantitatively analysed. The summary of the excretion for dihydrocaffeic 
acid-3-O-sulphate, feruloylglycine, vanilloylglycine, ferulic acid-4-O-sulphate, dihydroferulic 
acid-4-O-sulphate and dihydroferulic acid is depicted in Figure 4.3 and Figure 4.4. The 
excretion peak was at 12-24 hours for dihydrocaffeic acid-3-O-sulphate, feruloylglycine and 
ferulic acid-4-O-sulphate, whereas the excretion peaks for dihydroferulic acid-4-O-sulphate and 
dihydroferulic acid were at 8-12 hours. Only vanilloylglycine showed the excretion peak at 24-
36 hours. Substantial amounts were of dihydrocaffeic acid-3-O-sulphate and feruloylglycine and  
were also excreted at 8-12 hours. Ferulic acid-4-O-sulphate showed biphasic behaviour with the 
second peak being at 4-8 hours. Dihydroferulic acid-4-O-sulphate and dihydroferulic acid were 
also abundantly excreted at 12-24 hours, whereas substantial amounts for vanilloylglycine were 
excreted at 12-24 hours.  
  
- 92 - 
Figure 4.3: Excretion in µmol of dihydrocaffeic acid-3-O-sulphate, feruloylglycine and 
vanilloylglycine for time periods of 0-4, 4-8, 8-12, 12-24, 24-36 hours after the consumption 
of coffee for 62 participants of phase 1, n=62, mean ± standard deviation 
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Figure 4.4: Excretion in µmol of ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-
sulphate and dihydroferulic acid for time periods of 0-4, 4-8, 8-12, 12-24, 24-36 hours after 
the consumption of coffee for 62 participants of phase 1, n=62, mean ± standard deviation 
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Figure 4.5: Excretion of six major urinary metabolites for 36 hours after coffee 
consumption averaged for 46 participants in phase 2. Dihydrocaffeic acid-3-O-sulphate, 
feruloylglycine, vanilloylglycine, ferulic acid-4-O-sulfate, dihydroferulic acid-4-O-sulphate 
and dihydroferulic acid account for 70.7 ± 59.7, 54.5 ± 30.6, 42.1 ± 41.8, 37.6 ± 23.2, 27.7 ± 
28.9 and 16.2 ± 16.4 µmol, respectively, n=46, mean ± standard deviation 
 
Baseline urine of 47 participants was analysed for dihydrocaffeic acid-3-O-sulphate, 
feruloylglycine, vanilloylglycine, ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-sulphate 
and dihydroferulic acid and small amounts of 0.5 ± 0.0, 0.7 ± 0.9, 0.5 ± 0.0, 0.4 ± 0.7, 0.3 ± 0.6 
and 0.1 ± 0.1 µmol, respectively. These amounts are negligible compared to the amounts 
excreted post coffee consumption.  
In phase 2, urine of 47 participants (Figure 4.5) was collected up to 36 hours after coffee 
consumption and dihydrocaffeic acid-3-O-sulphate, feruloylglycine, vanilloylglycine, ferulic 
acid-4-O-sulphate, dihydroferulic acid-4-O-sulphate and dihydroferulic acid quantitatively 
analysed with 70.7 ± 59.7, 54.5 ± 30.6, 42.1 ± 41.8, 37.6 ± 23.2, 27.7 ± 28.9 and 16.2 ± 16.4 
µmol, respectively. The amounts excreted follow the same pattern as in phase 1 and a 
previously published study [7] with the exception of ferulic acid-4-O-sulphate and 
dihydroferulic acid-4-O-sulphate. Again, ferulic acid-4-O-sulphate with 37.6 ± 23.2 µmol is the 
fourth highest metabolite followed by dihydroferulic acid-4-O-sulphate with 27.7 ± 28.9 µmol. 
Data of one participant is excluded from the set of data due to non-compliance with the study 
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guidelines, as the amount of metabolites of caffeoylquinic acid and its derivatives exceeded 
100% of the ingested dose (131%). 
All the metabolites excreted in urine over 36 hours after the consumption of coffee account for 
an amount of 248.7 ± 130.2 µmol which is equivalent to 28.2% of the ingested dose of 881.8 
µmol caffeoylquinic acid and its derivatives. Dihydrocaffeic acid-3-O-sulphate, feruloylglycine, 
vanilloylglycine, ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-sulphate and dihydroferulic 
acid account for 8.0, 6.2, 4.8, 4.6, 4.3 and 1.8% of the ingested dose, respectively. The 
combined sulphate and glycine metabolites account for 15.4 and 11.0% of the ingested dose, 
respectively.  
Figure 4.6: Total excretion of six major urinary metabolites for 36 hours after coffee 
consumption for 46 participants of phase 2 in µmol. The lowest amount excreted is 55.1 
µmol and the highest amount excreted is 562.3 µmol 
 
Figure 4.6 depicts the total amount of six major metabolites excreted for 36 hours after coffee 
consumption of individual participants of phase 2 expressed in µmol. The lowest and highest 
amounts excreted are 55.1 and 562.3 µmol, respectively. Performing a Saphiro-Wilk test 
(p=0.045) indicates that the data is not normally distributed with a light skew towards higher 
values, but without any statistical outliers.  
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The summary of the excretion for dihydrocaffeic acid-3-O-sulphate, feruloylglycine, 
vanilloylglycine, ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-sulphate and dihydroferulic 
acid is depicted in Figure 4.7 and Figure 4.8. 
The excretion peak was at 12-24 hours for dihydrocaffeic acid-3-O-sulphate, feruloylglycine, 
ferulic acid-4-O-sulphate and dihydroferulic acid-4-O-sulphate, whereas the excretion peak for 
dihydroferulic acid was at 8-12 hours. Only vanilloylglycine showed the excretion peak at 24-
36 hours. Substantial amounts of dihydrocaffeic acid-3-O-sulfate and feruloylglycine were also 
excreted at 8-12 hours. In contrast to phase 1, ferulic acid-4-O-sulphate did not show biphasic 
behaviour with the second peak being at 4-8 hours. Dihydroferulic acid-4-O-sulphate and 
dihydroferulic acid were also abundantly excreted at 12-24 hours, whereas substantial amounts 
of vanilloylglycine were excreted at 12-24 hours.  
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Figure 4.7: Excretion in µmol of dihydrocaffeic acid-3-O-sulphate, feruloylglycine and 
vanilloylglycine for time periods of 0-4, 4-8, 8-12, 12-24, 24-36 hours after the consumption 
of coffee for 46 participants of phase 2, n=46, mean ± standard deviation 
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Figure 4.8: Excretion in µmol of ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-
sulphate and dihydroferulic acid for time periods of 0-4, 4-8, 8-12, 12-24, 24-36 hours after 
the consumption of coffee for 46 participants of phase 2, n=46, mean ± standard deviation 
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Figure 4.9: Excretion of six major urinary metabolites for 36 hours after coffee 
consumption averaged for 38 participants in phase 3. Dihydrocaffeic acid-3-O-sulphate, 
feruloylglycine, vanilloylglycine, ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-
sulphate and dihydroferulic acid account for 76.6 ± 74.5, 47.1 ± 29.2, 40.6 ± 41.2, 38.3 ± 
29.6, 24.5 ± 17.4 and 16.1 ± 16.2 µmol, respectively, n=38, mean ± standard deviation 
 
In phase 3, urine of 38 participants was collected after a 36 hours washout and was analysed for 
dihydrocaffeic acid-3-O-sulphate, feruloylglycine, vanilloylglycine, ferulic acid-4-O-sulphate, 
dihydroferulic acid-4-O-sulphate and dihydroferulic acid with 0.8 ± 2.1, 0.7 ± 1.2, 0.5 ± 1.0, 0.3 
± 0.6, 0.4 ± 1.0 and 0.1 ± 0.3 µmol, respectively. As in phase 1 and phase 2, the amounts 
excreted in the baseline urine are negligible compared to the amounts excreted post coffee 
consumption. 
Figure 4.9 depicts the amounts of dihydrocaffeic acid-3-O-sulphate, feruloylglycine, 
vanilloylglycine, ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-sulphate and dihydroferulic 
acid which were analysed in all the urine of 38 participants of phase 3 collected for 36 hours 
post coffee consumption with 76.6 ± 74.5, 47.1 ± 29.2, 40.6 ± 41.2, 38.3 ± 29.6, 24.5 ± 17.4 and 
16.1 ± 16.2 µmol, respectively.  
All the metabolites excreted over 36 hours after the consumption of a cup of coffee averaged for 
38 participants of phase 3 account for a total amount of 243.2 ± 169.2 µmol which is equivalent 
to 27.8 % of the ingested dose of caffeoylquinic acid and its derivatives.  
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Dihydrocaffeic acid-3-O-sulphate, feruloylglycine, vanilloylglycine, ferulic acid-4-O-sulphate, 
dihydroferulic acid-4-O-sulphate and dihydroferulic acid account for 8.7, 5.3, 4.6, 4.3, 2.8 and 
1.8% of the ingested dose. The combined sulphate and glycine metabolites account for 15.8 and 
10.0% of the ingested dose, respectively.  
Figure 4.10: Total excretion of six major urinary metabolites for 36 hours after coffee 
consumption for 38 participants of phase 3 in µmol. The lowest amount excreted is 17.9 
µmol and the highest amount excreted is 631.9 µmol 
 
Figure 4.10 depicts the total amount of six major metabolites excreted for 36 hours after coffee 
consumption of 38 participants of phase 3 expressed in µmol. The lowest and highest amounts 
excreted are 17.9 and 631.9 µmol, respectively. Performing a Saphiro-Wilk test (p=0.002) 
indicates that the data is not normally distributed with a skew towards the upper end including 
three statistical outliers of 587.2, 609.9 and 631.9 µmol. Since these values are equivalent to 
66.6, 69.2 and 71.7% of the ingested dose of caffeoylquinic acid and its derivates and therefore 
hypothetically possible, they were not excluded from the set of data for further analysis in 
chapter 5. 
The summary of the excretion for dihydrocaffeic acid-3-O-sulphate, feruloylglycine, 
vanilloylglycine, ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-sulphate and dihydroferulic 
acid is depicted in Figure 4.11and Figure 4.12. 
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The excretion peak was at 12-24 hours for dihydrocaffeic acid-3-O-sulphate, feruloylglycine, 
vanilloylglycine, ferulic acid-4-O-sulphate and dihydroferulic acid-4-O-sulphate, whereas the 
excretion peak for dihydroferulic acid was at 8-12 hours. Substantial amounts were of 
dihydrocaffeic acid-3-O-sulphate and feruloylglycine were also excreted at 8-12 hours. In 
contrast to phase 2, but in accordance with phase 1, ferulic acid-4-O-sulphate did show biphasic 
behaviour with the second peak being at 4-8 hours. Dihydroferulic acid-4-O-sulphate and 
dihydroferulic acid were also abundantly excreted at 12-24 hours, whereas substantial amounts 
for vanilloylglycine were excreted at 12-24 hours.  
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Figure 4.11: Excretion in µmol of dihydrocaffeic acid-3-O-sulphate, feruloylglycine and 
vanilloylglycine for time periods of 0-4, 4-8, 8-12, 12-24, 24-36 hours after the consumption 
of coffee for 38 participants of phase 3, n=38, mean ± standard deviation 
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Figure 4.12: Excretion in µmol of ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-
sulphate and dihydroferulic acid for time periods of 0-4, 4-8, 8-12, 12-24, 24-36 hours after 
the consumption of coffee for 38 participants of phase 3, n=38, mean ± standard deviation 
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Figure 4.13: Excretion of six major urinary metabolites for 36 hours after coffee consumption of 36 participants for all three phases, n=36, data presented 
as mean values in µmol 
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Figure 4.13 shows the excretion of six major urinary metabolites for 36 hours after coffee 
consumption of 36 particpants who completed all three phases of the study. The data is 
presented as mean values. The data of total urinary excretion of all six major urianry metabolites 
of caffeoylquinic acid and its derivatives shows variation of up to 3-fold between the three 
phases. In order to understand where the intraindividual variation derives from, the individual 
metabolites were also plotted for the three phases of the study in the following graphs (Figure 
4.14, Figure 4.15, Figure 4.16, Figure 4.17, Figure 4.18, and Figure 4.19). 
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Figure 4.14: Excretion of dihydrocaffeic acid-3-O-sulfate for 36 hours after coffee consumption of 36 participants for all three phases, n=36, data presented 
as mean value in µmol 
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Figure 4.15: Excretion of feruloylglycine for 36 hours after coffee consumption of 36 participants for all three phases, n=36, data presented as mean value 
in µmol 
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Figure 4.16: : Excretion of vanilloylglycine for 36 hours after coffee consumption of 36 participants for all three phases, n=36, data presented as mean 
value in µmol 
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Figure 4.17: Excretion of ferulic acid-4-O-sulphate for 36 hours after coffee consumption of 36 participants for all three phases, n=36, data presented as 
mean value in µmol 
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Figure 4.18: Excretion of dihydroferulic acid-4-O-sulphate for 36 hours after coffee consumption of 36 participants for three phases, n=36, data presented 
as mean value in µmol 
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Figure 4.19: Excretion of dihydroferulic acid for 36 hours after coffee consumption of 36 participants for three phases, n=36, data presented as mean value 
in µmol 
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Figures (Figure 4.14 to Figure 4.19) depict the excretion of dihydrocaffeic acid-3-O-sulphate, 
feruloylglycine, vanilloylglycine, ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-sulphate 
and dihydroferulic acid for 36 hours after coffee consumption for 36 particpants who completed 
all three phases of the study in µmol. The intraindividual variation of excretion, i.e. the variation 
of excretion between the three phases, varies by up to a factor of six. In order to better 
understand the intraindividual variation, the average coefficient of variation for each metabolite 
was calculated and is depicted in Table 4.2.  
Table 4.2: Coefficient of variation (%) of the excretion of dihydrocaffeic acid-3-O-
sulphate, feruloylglycine, vanilloylglycine, ferulic acid-4-O-sulphate, dihydroferulic acid-4-
O-sulphate and dihydroferulic acid for 36 hours after coffee consumption of 36 
participants for all three phases, n=36, mean coefficient of variation in per cent ± standard 
deviation 
 DHCA-3-
O-SO4 
FA-GLY VA-GLY FA-4-O-
SO4 
DHFA-4-
O-SO4 
DHFA 
Mean CV 
% ±SD 
52.3 ±24.5 35.9 ± 15.5 51.8 ± 27.7 37.4 ± 18.1 50.2 ± 25.4 46.1 ± 23.8 
 
The mean coefficient of variation was the highest for dihydrocaffeic acid-3-O-sulphate, 
vanilloylglycine and dihydroferulic acid-4-O-sulphate with 52.3, 51.8 and 50.2%, respectively. 
The dihydroforms of the hydroxycinnamic acids are formed by reductases derived from 
microbiota in the colon according to Stalmach et al. 2010 [15]. The mean coefficient of 
variation for feruloylglycine and ferulic acid-4-O-sulphate is 35.9 and 37.4%, respectively. 
These metabolites are not associated with the metabolism of colonic microbiota [7, 15].  
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4.5 Discussion 
Assessing the absorption of coffee caffeoylquinic acid and its derivatives in human subjects can 
be performed by the non-invasive measurement of metabolites in urine collected after coffee 
consumption. Thus the excretion ratio, a quotient of the amount excreted in urine and the 
amount ingested, is determined which is suitable for the assessment of the minimum absorption. 
However, ingestion of xenobiotic compounds is followed by phase I and phase II metabolism in 
order to facilitate excretion from the human body. Coffee caffeoylquinic acids and its 
derivatives are metabolised in a complex pathway of colonic and hepatic metabolites [7]. 
Stalmach et al. [7] quantified 12 and 17 metabolites of caffeoylquinic acid and its derivatives in 
plasma and urine, respectively. The five highest urinary metabolites were dihydrocaffeic acid-3-
O-sulphate, feruloylglycine, dihydroferulic acid-4-O-sulphate, ferulic acid-4-O-sulphate and 
dihydroferulic acid with 37.1, 20.7, 12.4, 11.1 and 9.7 µmol, respectively. Additionally, other 
twelve metabolites were quantified, e.g. dihydroferulic acid-4-O-glucuronide, caffeic acid-3-O-
sulphate, isoferulic acid-3-O-glucuronide, dihydroisoferulic acid-3-O-glucuronide, 3-O-ferulic 
acid, 4-O-ferulic acid, 3-O-caffeoylquinic acid lactone-O-sulphate, 5-O-ferulic acid, 4-O-
caffeoylquinic acid lactone-O-sulphate, dihydrocaffeic acid-3-O-glucuronide, caffeic acid-3-O-
sulphate and isoferulic acid-3-O-sulphate. Stalmach et al. determined the excretion rate with 
29.1% of the dose of caffeoylquinic acid and its metabolites ingested in urine collected for 24 
hours thereafter. Another publication reported similar ranges varying from 16 to 25% depending 
on the dose ingested [16]. Eleven participants ingested three different doses, e.g. 412, 635, 795 
µmol of caffeoylquinic acid and its derivatives and excreted 101, 160 and 125 µmol of 
metabolites equivalent to 24, 25 and 16%. When the higher dose of 795 µmol caffeoylquinic 
acid and its derivatives is ingested, the excretion is about a third lower compared to the 
intermediate dose. This phenomenon could be due to enzyme saturation, limitation of substrates, 
limited transport capacities at the enterocytes (influx and efflux) or an influence on the 
gastrointestinal transit times according to Erk et al.[17].  
The study presented here consisted of three phases, in order to investigate the intraindividual 
variation of absorption and metabolism of caffeoylquinic acid and its derivatives, where 
participants had to follow a washout procedure, consumed a cup of coffee and collected all their 
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urine for 36 hours thereafter in time periods of 0-4, 4-8, 8-12, 12-24 and 24-36 hours. Table 4.3 
depicts the amounts of the individual metabolites excreted, the percentage of the dose ingested 
of the study presented here and the data from two studies performed by Stalmach et al. 
published in 2009 and 2014 with different doses.  
Table 4.3: Comparison of urinary metabolites in absolute excretion in µmol and as a 
percentage of the dose ingested of three studies with different amounts of caffeoylquinic 
acid and its derivatives ingested. For better comparability, only urinary metabolites 
analysed in the study described in this thesis are compared to the studies performed by 
Stalmach et al. and values are not taken into consideration calculating the excretion ratio 
(percentage of dose ingested). Moreover, urine in the study described in this thesis was 
collected for 36 hours after the consumption of coffee in contrast to 24 hours for the 
studies performed by Stalmach et al. . n.a. = compound not analysed in this study 
Compound Phase 1 Stalmach et al., 2009 
[7] 
Stalmach et al., 2014 
[16] 
 Amount 
in µmol 
Percentage 
of 
ingested 
dose 
Amount 
in µmol 
Percentage 
of 
ingested 
dose 
Amount 
in µmol 
Percentage 
of 
ingested 
dose 
CQAs ingested 
 
881.8  412.0  795.0  
Dihydrocaffeic 
acid-3-O-
sulphate 
60.2 6.8 37.1 9.0 47.9 6.0 
Feruloylglycine 51.7 5.9 20.7 5.0 27.2 3.4 
Vanilloylglycine 41.9 4.8 n.a. n.a. n.a. n.a. 
Ferulic acid-4-
O-sulphate 
40.7 4.6 11.1 2.7 16.1 2.0 
Dihydroferulic 
acid-4-O-
sulphate 
27.0 3.1 12.4 3.0 27.2 3.4 
Dihydroferulic 
acid 
19.2 2.2 9.7 2.4 10.6 1.3 
All metabolites 240.6 27.3 91.0 22.1 129.0 16.2 
 
The data presented in the previous table (Table 4.3) is conclusive. The most excreted urinary 
metabolites of ingested caffeoylquinic acid and its derivatives are dihydrocaffeic acid-3-O-
sulphate, feruloylglycine, vanilloylglycine, ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-
sulphate and dihydroferulic acid for the study described in this thesis. In contrast, Stalmach et 
al. did not analyse vanilloylglycine and found dihydroferulic acid-4-O-sulphate to be more 
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highly excreted compared to ferulic acid-4-O-sulphate in her 2009 and 2014 study. Moreover, 
due to the fact that in the study described in this thesis, urine was collected for 36 hours instead 
of 24 hours post coffee consumption, the overall percentage of urinary excretion of the dose 
ingested is 1.7-fold higher compared to the data from Stalmach’s study in 2014 [16]. 
Additionally, the studies performed by Stalmach included eleven participants, whereas the 
phase 1 of the study described in this thesis included 62 participants. Interestingly, the excretion 
ratios of the study described in this thesis show more similarity with the results from the 
excretion ratios of the 2009 study of Stalmach, however, the coffee beverage administered 
contained only 412 µmol compared to 882 µmol of caffeoylquinic acid and its derivatives. 
The interindividual variation is substantial with a factor of 8.3, 10.2 and 35.3 between the total 
excretion rate of the lowest excreter and the highest excreter of the three phases (82.9-693.2, 
55.1-562.3 and 17.9-631.9 µmol). These findings are, however, in accordance with previous 
publications [7, 15-17, 20].  
The advantage of the study described in this thesis is the fact that participants underwent three 
phases where they were asked to repeat the same procedure after at least six and twelve weeks.  
The results demonstrate major variation of the intraindividual excretion between the three visits. 
The sum of the total excretion of metabolites of caffeoylquinic acid and its derivatives varies up 
to four-fold. In order to better understand and assess the variation the coefficient of variation 
was calculated for the individual compounds for 36 people who completed all three phases of 
the study. Table 4.2 depicts the coefficient of variation of excretion for all the six metabolites 
namely dihydrocaffeic acid-3-O-sulphate, feruloylglycine, vanilloylglycine, ferulic acid-4-O-
sulphate, dihydroferulic acid-4-O-sulphate and dihydroferulic acid. Metabolites which are 
known to be formed in the colon of humans [26], e.g. dihydrocaffeic acid-3-O-sulfate, 
dihydroferulic acid-4-O-sulphate and dihydroferulic acid, showed the highest variation. This 
data leads to the suggestion that the colonic microbiota consisting of inter alia E. coli, B. lactis, 
and L. gasseri, change over the time range of several weeks. Previous studies investigated the 
effect of pre-/probiotics, antibiotic therapy and functional food consumption, leading to 
proliferation of intestinal microflora or hinderance of growth, respectively [82-84] and 
investigated the effect of either human faecal microbiota on polyphenols [85] or faecal slurries 
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on coffee caffeoylquinic acid and its derivatives [26]. Other studies quantitatively assessed food 
intake by means of food frequency questionnaires, detected and quantified the microbial strains 
faeces and correlated the results of both. A negative correlation was found between fibre intake, 
e.g. soluble pectin and B. coccoides and C. leptum, whereas a positive correlation was found 
between Akkermansia and B. coccoides with resistant starch. The only correlation analysed 
including a polyphenol was a negative correlation with orange-derived flavanone and B. 
coccoides and C. leptum. A longitudinal study over four weeks found a positive correlation 
between fructo-oligosaccharides intake and the quantity of bifidobacteria in healthy volunteers. 
Only a limited number of studies have been performed to investigate the longitudinal effect of 
tea polyphenols on gastrointestinal tract microbiota [86-88] , however, to our knowledge, 
neither a study has been performed to investigate the longitudinal changes of human faecal 
microbiota, nor has the intraindividual variation of absorption and excretion on coffee 
caffeoylquinic acid and its derivatives in vivo been described. Since participants were not 
requested to take a record of their diet in between the three phases, no effects of their diet on the 
absorption and excretion on coffee caffeoylquinic acid and its derivatives can be investigated 
further. Future, longitudinal studies on the intraindividual absorption and excretion, would 
require a detailed, quantitative recording of the food intake several weeks prior to and during the 
study.  
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Chapter 5: Correlation of urinary excretion of metabolites of 
caffeoylquinic acid and its derivatives, biomarkers of health, and food 
intake 
 
5.1 Abstract 
The following chapter links the data of urinary excretion of caffeoylquinic acid and its 
derivatives with biomarkers of health. The statistical analysis is described and is focused on the 
correlation between the excretion data presented in chapter 4, biomarker of health data, 
described in Ms Joana Amarante Encarnacao’s thesis, and data on food intake recorded by the 
means of a food frequency questionnaire. Several correlations are apparent. The main 
correlations are between the 0-36 hours excretion of dihydrocaffeic acid-3-O-sulphate after 
coffee consumption and plasma fasting insulin (rs=0.428, p=0.009), the 0-36 hours excretion of 
ferulic acid-4-O-sulphate after coffee consumption and plasma fasting insulin levels (rs=0.448, 
p=0.006), the 0-36 hours excretion of vanilloylglycine after coffee consumption and DL-
homocysteine (rs=0.432, p=0.010) and between the 0-36 hours excretion of dihydrocaffeic acid-
3-O-sulphate after coffee consumption with both the consumption of cups of coffee per week 
(rs=-0.434, p=0.008) and also the related coffee level, a measure of consumption of cups of 
coffee per week multiplied by the strength of the coffee (rs=-0.461, p=0.005).  
 
5.2 Introduction 
Over the past decade, the absorption, metabolism and excretion of coffee caffeoylquinic acid 
and its derivatives in humans have been intensively investigated. Several papers have presented 
data on absorption either assessed by pharmacokinetic studies [20, 21, 89], via the measurement 
of urinary excretion, or both [7, 16]. Chemically synthesised compounds and subsequently 
developed and validated analytical methods have improved the quality of the quantitative data 
substantially [30].  
Moreover, multiple epidemiological or meta-analysis papers have reported on the several health 
benefits of habitual, moderate coffee consumption including a reduced risk of diabetes type II 
[37], a lower risk of stroke and heart failure [90], a lower risk of coronary heart diseases in 
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women [91], and protective effects on hepatocellular and endometrial cancer [35]. Additionally, 
some studies reported acute health effects such as a reduced LDL oxidation in humans [42] and 
an amelioration of plasma antioxidant capacity, potentially ascribed to a reduced plasma uric 
acid level [92] post a single dose of coffee. However, up to date, no human study has been 
performed linking absorption, metabolism and excretion to biomarkers of health. This is of 
particular importance, since Stalmach et al. [7] confirmed a substantial interindividual variation 
in absorption of coffee caffeloylquinic acid and its derivatives in humans. The following chapter 
presents the linkage of the data of excretion of urinary metabolites of caffeoylquinic acid and its 
derivatives, described in detail in chapter 4, to biomarkers of health, i.e. thiols (L-cysteine, DL-
homocysteine, cysteinylglycine and L-glutathione), as an indicator of the plasma antioxidant 
status [93, 94], uric acid, primarily associated with gout [95], insulin and glucose, as markers 
for metabolic syndrome and type II diabetes [96]. The biochemical analysis was performed by 
Miss Joana Amarante Encarnacao and the data will be presented in her thesis in 2015.  
 
5.3 Statistical analysis 
 
IBM SPSS statistics 22 software (Armonk, NY, USA) was used for the statistical analysis of the 
data of urinary excretion of metabolites of caffeoylquinic acid and its derivatives and the 
correlation to the plasma biomarkers of health. Data was entered as mean values for the 
individual urinary metabolite of caffeoylquinic acid and its derivatives and coefficient of 
variation for the averaged sum of all urinary metabolites for participants who completed the 
three phases of the human study in order to take the intraindividual variation into account. Prior 
to correlation analysis by bivariate correlation testing, the normal distribution of the data was 
tested by means of a Shapiro-Wilk test. According to the outcome of the Shapiro-Wilk test, 
bivariate correlation is performed by a Pearson’s bivariate correlation test for normally 
distributed data and by a Spearman’s bivariate correlation test for the non-parametric data. 
Significant levels were defined as standard p≤0.05* and p≤0.01**.  
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5.3.1 Test for normal distribution 
Firstly, the average sum of six urinary metabolites, dihydrocaffeic acid-3-O-sulfate, 
feruloylglycine, vanilloylglycine, ferulic acid-4-O-sulfate, dihydroferulic acid-4-O-sulfate and 
dihydroferulic acid for each individual participant who completed all three phases were tested 
for normal distribution and the descriptive parameters including mean, standard deviation, and 
the confidence interval were determined.  
Secondly, the average concentrations of plasma thiols (L-cysteine, DL-homocysteine, 
cysteinylglycine and L-glutathione), plasma uric acid, plasma insulin and glucose for each 
individual participant who completed all three phases were tested for normal distribution and 
the descriptive parameters including mean, standard deviation, and the confidence interval were 
determined. 
Thirdly, the average intake of cups of coffee per week, the coffee level (cups of coffee per week 
multiplied by strength of coffee [weak=1, strong=3]), the intake of cups of black tea per week, 
portions of fruit per week, portions of vegetables per week, and portions of yoghurt per week 
for each individual participant who completed all three phases were tested for normal 
distribution and the descriptive parameters including mean, standard deviation, and the 
confidence interval were determined. 
Finally, the coefficient of variation for the averaged sum of all urinary metabolites excreted 
between 0-36 hours after coffee consumption for participants who completed the three phases of 
the human study was tested for normal distribution.  
 
5.3.2 Bivariate correlation of urinary excretion with biomarkers of health 
The normally distributed data of feruloylglycine was correlated with the normally distributed 
data of L-cysteine, cysteinylglycine, L-glutathione, uric acid, glucose and insulin using bivariate 
Pearson’s correlation. 
The non-normally distributed data of the average sum of six urinary metabolites, dihydrocaffeic 
acid-3-O-sulphate, vanilloylglycine, ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-sulphate 
and dihydroferulic acid was correlated with the normally distributed data of L-cysteine, 
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cysteinylglycine, L-glutathione, uric acid, glucose and insulin and with the non-normally 
distributed data of DL-homocysteine by means of Spearman’s bivariate correlation. The 
normally distributed data of feruloylglycine was correlated with the non-normally distributed 
data of DL-homocysteine using Spearman’s bivariate correlation.  
 
5.3.3 Bivariate correlation of urinary excretion with food intake 
The normally distributed data of feruloylglycine was correlated with the normally distributed 
data of the intake of portions of fruit per week using the Pearson’s bivariate correlation.  
The other urinary excretion data was correlated with the intake of cups of coffee per week, 
coffee level, the intake of portions of vegetables per week and portions of yoghurt per week by 
the means of the Spearman’s bivariate correlation.  
 
5.3.4 Bivariate correlation of the coefficient of variation for the average sum of 
all urinary metabolites of caffeoylquinic acid and its derivatives with the 
biomarkers of health  
The non-normally distributed data of the coefficient of variation (%) of the average sum of the 
excretion of all urinary metabolites for participants who completed three phases of the human 
study (n=36) was correlated with plasma L-cysteine, DL-homocysteine, cysteinylglycine, L-
glutathione, uric acid, glucose and insulin using the Spearman’s bivariate correlation.  
 
5.3.5 Bivariate correlation of the coefficient of variation for the average sum of 
all urinary metabolites of caffeoylquinic acid and its derivatives with food 
intake 
The non-normally distributed data of the coefficient of variation (%) of the average sum of the 
excretion all urinary metabolites for participants who completed three phases of the human 
study (n=36) was correlated with the intake of cups of coffee per week, the coffee level, the 
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intake of cups of tea per week, the portions of fruit per week, the portions of vegetables and the 
portions of yoghurt using the Spearman’s bivariate correlation.  
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5.4 Results 
 
5.4.1 Test for normal distribution 
Primarily, the average sum of six urinary metabolites, dihydrocaffeic acid-3-O-sulphate, 
feruloylglycine, vanilloylglycine, ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-sulphate 
and dihydroferulic acid for each individual participants who completed all three phases and the 
average sum of the individual metabolite for each individual participants were tested for normal 
distribution. The descriptive statistical parameters are summarized in Table 5.1. The null 
hypothesis of feruloylglycine (p=0.115) has been accepted, thus the data is normally distributed, 
whereas the null hypothesis for the average sum of all metabolites (p=0.001), dihydrocaffeic 
acid-3-O-sulphate (p=0.000), vanilloylglycine (p=0.000), ferulic acid-4-O-sulphate (p=0.004), 
dihydroferulic acid-4-O-sulphate (p=0.000) and dihydroferulic acid (p=0.000) has been rejected, 
thus the data is not normally distributed. 
Table 5.1: Summary of descriptive statistical parameters for averaged sum of all 
metabolites, dihydrocaffeic acid-3-O-sulphate, feruloylglycine, vanilloylglycine, ferulic 
acid-4-O-sulphate, dihydroferulic acid-4-O-sulphate and dihydroferulic acid for 
participants who completed three phases of the human study (n=36) 
Compound Mean 
(µmol) 
Standard  
deviation 
Confidence 
interval 
(95%) 
lower 
bound 
 
 
 
upper 
bound 
Shapiro-
Wilk 
significance 
Averaged sum 
of all 
metabolites 
238.19 120.42 197.44 278.93 0.001 
Dihydrocaffeic 
acid-3-O-
sulphate 
64.45 53.31 46.42 82.49 0.000 
Feruloylglycine 49.58 22.68 41.91 57.26 0.115 
Vanilloylglycine 40.43 30.76 30.02 50.83 0.000 
Ferulic acid-4-
O-sulphate 
38.04 23.02 30.25 45.83 0.004 
Dihydroferulic 
acid-4-O-
sulphate 
28.03 30.46 17.72 38.33 0.000 
Dihydroferulic 
acid 
17.66 13.68 13.03 22.28 0.000 
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Figure 5.1, Figure 5.2, Figure 5.3 depict the histograms for the average sum of six urinary 
metabolites, dihydrocaffeic acid-3-O-sulphate, feruloylglycine, vanilloylglycine, ferulic acid-4-
O-sulphate, dihydroferulic acid-4-O-sulphate and dihydroferulic acid for each individual 
participants who completed all three phases.  
Figure 5.1: Histogram of average sum of six urinary metabolites for participants who 
completed all three phases of the human study (n=36) 
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Figure 5.2: Histograms of average dihydrocaffeic acid-3-O-sulphate, feruloylglycine and 
vanilloylglycine for participants who completed all three phases of the human study 
(n=36) 
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Figure 5.3: Histograms of average ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-
sulphate and dihydroferulic acid for participants who completed all three phases of the 
human study (n=36). 
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In the histogram of the average sum of six urinary metabolites for 36 participants who 
completed the three phases of the human study (Figure 5.1), two statistical outliers of 593.4 and 
613.8 µmol were detected by box plot analysis (data not shown). Since the amounts excreted 
were equivalent to 67.2 and 69.6% of the dose ingested, and were therefore hypothetically 
possible, the values were not excluded for the subsequent correlation analysis. In the following 
histograms of the average dihydrocaffeic acid-3-O-sulphate, feruloylglycine and 
vanilloylglycine excretion for 36 participants who completed the three phases of the human 
study (Figure 5.2), three statistical outliers of 192.8, 217.7 and 258.2 µmol, one of 110.2 µmol 
and one of 123.11 µmol, respectively, were detected by box plot analysis (data not shown). In 
the histograms of ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-sulphate and dihydroferulic 
acid excretion for 36 participants who completed the three phases of the human study (Figure 
5.3) one statistical outlier of 111.8 µmol, three of 67.4, 77.2 and 172.7 µmol and one of 66.9 
µmol, respectively, were detected by box plot analysis (data not shown). The outliers were not 
excluded due to the reason mentioned afore. 
Secondly, L-cysteine, DL-homocysteine, cysteinylglycine, L-glutathione, uric acid, glucose and 
insulin for each individual participants who completed all three phases (n=36) were tested for 
normal distribution. The descriptive statistical parameters are summarised in Table 5.2. The null 
hypothesis of L-cysteine (p=0.385), cysteinylglycine (p=0.730), L-glutathione (p=0.123), uric 
acid (p=0.415), glucose (p=0.073) and insulin (p=0.118) has been accepted, thus the data is 
normally distributed, whereas the null hypothesis for the DL-homocysteine (p=0.000) has been 
rejected, thus the data is not normally distributed. 
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Table 5.2: Summary of descriptive statistical parameters for averaged L-cysteine, DL-
homocysteine, cysteinylglycine, L-glutathione, uric acid, fasting glucose and insulin for 
participants who completed three phases of the human study (n=36). 
Compound Mean 
(µM) 
Standard  
deviation 
Confidence 
interval 
(95%) 
lower 
bound 
 
 
 
upper 
bound 
Shapiro-
Wilk 
significance 
L-cysteine 259.41 22.68 251.74 267.09 0.385 
DL-
homocysteine 
9.51 4.08 8.13 10.89 0.000 
Cysteinylglycine 30.38 5.30 28.59 32.14 0.730 
L-glutathione 7.94 1.54 7.42 8.46 0.123 
Uric acid (mM) 0.26 0.05 0.24 0.28 0.415 
Glucose (mM) 4.76 0.32 4.66 4.87 0.073 
Insulin (mU/L) 9.16 2.39 8.35 9.97 0.118 
 
Figure 5.4 depicts the histograms of the average plasma L-cysteine, DL-homocysteine, 
cysteinylglycine, and L-glutathione, whereas Figure 5.5 shows the histograms of the average 
plasma uric acid, glucose and insulin for participants who completed all three phases of the 
human study (n=36).  
  
- 128 - 
Figure 5.4: Histograms of average plasma L-cysteine, DL-homocysteine, cysteinylglycine, 
and L-glutathione for participants who completed three phases of the human study 
(n=36).  
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Figure 5.5: Histograms of average plasma uric acid, fasting glucose and insulin for 
participants who completed three phases of the human study (n=36). 
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of the thiols were located outside the normal physiological ranges (DL-homocysteine: 6.5-11.9 
µM and L-glutathione: 4.9-7.3 µM) according to Bald et al. and Turell et al [93, 94], the 
outlying values were excluded and the normal distribution reanalysed. For DL-homocysteine, 
the null hypothesis was rejected again (p=0.018, n=35) and the data did not follow a normal 
distribution and thus was used for the subsequent non-parametric correlation analysis, whereas 
for L-glutathione the null hypothesis was accepted (p=0.265, n=33) again, thus the data 
remained normally distributed.  
In the histogram of plasma glucose and insulin for 36 participants who completed the three 
phases of the human study two statistical outliers of 5.50 and 5.59 mM, and 16.49 mU/L, 
respectively, were detected by box plot analysis (data not shown). The statistical outliers were 
not excluded, since these did not exceed healthy physiological ranges (glucose: ≤7.0 mM and 
insulin: ≥14 mU/L) according to Olokoba et al. and Weyer et al. [96, 97].  
Thirdly, the intake of cups of coffee per week, the coffee level (cups of coffee per week * 
strength of coffee [weak=1, strong=3]), cups of tea per week, portions of fruit per week, 
portions of vegetables per week, portions of fruit and vegetables per week and the portions of 
yoghurt per week for each individual participants who completed all three phases were tested 
for normal distribution and the descriptive statistical parameters are summarised in Table 5.3.  
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Table 5.3: Summary of descriptive statistical parameters for the intake of cups of coffee 
per week, coffee level, cups of tea per week, portions of fruit per week, portions of 
vegetables per week, and portions of yoghurt per week for participants who completed 
three phases of the human study (n=36). 
Compound Mean 
(Cups or 
portions) 
Standard  
deviation 
Confidence 
interval 
(95%) 
lower 
bound 
 
 
 
upper 
bound 
Shapiro-
Wilk 
significance 
Cups of coffee 
per week 
12.40 12.86 8.05 16.75 0.000 
Coffee level 32.83 39.94 19.32 46.35 0.000 
Cups of tea per 
week 
7.10 11.91 3.07 11.13 0.000 
Portions of 
fruit per week 
22.79 13.09 18.36 27.21 0.178 
Portions of 
vegetables per 
week 
21.83 15.37 16.63 27.03 0.000 
Portions of 
yoghurt per 
week 
2.44 3.02 1.42 3.47 0.000 
  
- 132 - 
Figure 5.6 and Figure 5.7 depict the histograms of intake of cups of coffee per week, coffee 
level, cups of tea per week, portions of fruit per week, portions of vegetables per week, portions 
of fruit and vegetables per week and portions of yoghurt per week. 
Figure 5.6: Histograms of intake of cups of coffee per week, coffee level, and cups of tea 
per week for participants who completed three phases of the human study (n=36). 
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Figure 5.7: Histograms of intake of portions of fruit per week, portions of vegetables per 
week, and portions of yoghurt for participants who completed three phases of the human 
study (n=36). 
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normally distributed, whereas the null hypotheses of cups of coffee per week (p=0.000), coffee 
level (p=0.000), cups of tea per week (p=0.000), portions of vegetables per week (p=0.000), and 
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Finally, the normal distribution was tested for the coefficient of variation for the averaged sum 
of all urinary metabolites excreted between 0-36 hours for participants who completed the three 
phases of the human study. The descriptive statistical parameters are presented in the following 
Table 5.4.  
Table 5.4: Summary of descriptive statistical parameters for coefficient of variation (%) of 
the average sum of all urinary metabolites for participants who completed three phases of 
the human study (n=36). 
Parameter Mean (%) Standard  
deviation 
Confidence 
interval 
(95%) 
lower 
bound 
 
 
 
upper 
bound 
Shapiro-
Wilk 
significance 
Coefficient of 
variation of the 
averaged sum 
of all urinary 
metabolites 
96.92 102.46 62.25 131.89 0.000 
 
The null hypothesis (p=0.000) of the Shapiro-Wilk test for normal distribution was rejected, 
thus the data is not normally distributed and the non-parametric Spearman’s correlation test was 
applied for subsequent correlations. Three statistical outliers were detected in the histogram by 
the means of box plot analysis, however, these were not excluded due to the fact that the effect 
of the high variation in excretion was tested on the biomarkers of health and food frequency 
data.  
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Figure 5.8: Histogram of the coefficient of variation (%) of the average sum of all urinary 
metabolites for participants who completed three phases of the human study (n=36). 
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Urinary excretion data was correlated with biomarkers of health either by the use of Pearson’s 
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Table 5.5: Summary of correlation coefficients, rS: Spearman’s coefficient, unless labeled by rp: Pearson’s coefficient, significant levels, p≤ 0.05*, p≤0.01** 
  Averaged 
sum of all 
metabolites 
DHCA-3-O-
sulfate 
FA-GLY VA-GLY FA-4-O-
sulfate 
DHFA-4-O-
sulfate 
DHFA 
L-cysteine rs 
Sig. 
N  
-0.132 
0.444 
36 
-0.266 
0.117 
36 
rp=-0.134 
0.437 
36 
0.238 
0.162 
36 
-0.163 
0.342 
36 
-0.235 
0.167 
36 
0.224 
0.189 
36 
DL-homocysteine rs 
Sig. 
N 
0.151 
0.387 
36 
-0.015 
0.933 
35 
0.150 
0.390 
35 
**0.432 
0.010 
35 
0.193 
0.266 
35 
-0.007 
0.967 
35 
0.118 
0.498 
35 
Cysteinylglycine rs 
Sig. 
N 
-0.294 
0.082 
36 
*-0.333 
0.047 
36 
rp=-0.121 
0.480 
36 
0.249 
0.143 
36 
-0.195 
0.254 
36 
-0.321 
0.056 
36 
-0.122 
0.479 
36 
L-glutathione rs 
Sig. 
N 
-0.009 
0.962 
33 
-0.026 
0.887 
33 
rp=-0.141 
0.434 
33 
0.116 
0.519 
33 
-0.074 
0.682 
33 
0.097 
0.590 
33 
-0.033 
0.853 
33 
Uric acid rs 
Sig. 
N 
0.141 
0.411 
36 
0.115 
0.505 
36 
rp=0.083 
0.631 
36 
0.016 
0.927 
36 
0.228 
0.181 
36 
0.268 
0.114 
36 
-0.151 
0.381 
36 
Glucose rs 
Sig. 
N 
0.123 
0.476 
36 
0.166 
0.334 
36 
rp=0.203 
0.235 
36 
0.036 
0.835 
36 
0.162 
0.345 
36 
0.023 
0.894 
36 
-0.006 
0.971 
36 
Insulin rs 
Sig. 
N 
*0.358 
0.032 
36 
**0.428 
0.009 
33 
rp=0.321 
0.056 
36 
-0.144 
0.401 
36 
**0.448 
0.006 
36 
0.309 
0.067 
36 
0.254 
0.135 
36 
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5.4.3 Bivariate correlation of urinary excretion with food intake 
Urinary excretion data was correlated with food intake data by the means of Spearman’s 
correlation for non-normally distributed data, whereas only the normally distributed excretion of 
feruloylglycine and the normally distributed data of the portions of fruit per day were correlated 
using a Pearson’s correlation. The results are presented in Table 5.6. Weak correlations were 
defined with r ≥0.300 - <0.400 and moderate correlations were defined with r ≥0.400 - <0.500. 
Several correlations were established between the excretion of urinary metabolites of caffeic 
acid and its derivatives and the weekly food intake. At a significance level of p≤0.01 a moderate 
negative correlation was detected between the 0-36 hours excretion of dihydrocaffeic acid-3-O-
sulphate, the intake of cups of coffee per week (rs=-0.434, p=0.008) and the 0-36 hours 
excretion of dihydrocaffeic acid-3-O-sulphate and the coffee level (rs=-0.461, p=0.005), 
respectively.  
Further weak, but statistically significant (p≤0.05), negative correlations were analysed between 
the averaged sum of all urinary metabolites of caffeoylquinic acid and its derivatives for 0-36 
hours and the intake of portions of fruit per week (rs=-0.341, p=0.042) and the averaged sum of 
all urinary metabolites of caffeoylquinic acid and its derivatives for 0-36 hours and the intake of 
yoghurt per week (rs=-0.348, p=0.038) , respectively.  
Additionally, at a significance level of p≤0.05, weak negative correlations were found between 
the 0-36 hours excretion of feruloylglycine and the intake of portions of fruit per week (rp=-
0.342, p=0.041) and a moderate negative correlation between the 0-36 hours excretion of 
feruloylglycine the intake of portions of yoghurt (rs=-0.409, p=0.013), respectively.  
Moreover, several weak, negative correlations at a significance level of p≤0.05 were established 
between the 0-36 hours urinary excretion of dihydroferulic acid-4-O-sulphate, the coffee level 
(rs=-0.379, p=0.023) and the intake of portions of yoghurt per week (rs=-0.363, p=0.029), 
respectively. No other statistically significant correlations were detected.  
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Table 5.6: Summary of correlation coefficients, rS: Spearman’s coefficient, unless labelled by rp: Pearson’s coefficient, significant levels, p≤ 0.05*, p≤0.01** 
  Average sum 
of all 
metabolites 
DHCA-3-O-
sulfate 
FA-GLY VA-GLY FA-4-O-
sulfate 
DHFA-4-O-
sulfate 
DHFA 
Cups of coffee per 
week 
rs 
Sig. 
N  
-0.301 
0.075 
36 
**-0.434 
0.008 
36 
-0.227 
0.183 
36 
0.269 
0.113 
36 
-0.254 
0.136 
36 
-0.327 
0.051 
36 
-0.227 
0.184 
36 
Coffee level rs 
Sig. 
N 
-0.317 
0.060 
36 
**-0.461 
0.005 
36 
-0.230 
0.177 
36 
0.285 
0.092 
36 
-0.312 
0.064 
36 
*-0.379 
0.023 
36 
-0.207 
0.225 
36 
Cups of tea per 
week 
rs 
Sig. 
N 
-0.069 
0.691 
36 
-0.015 
0.932 
36 
-0.015 
0.932 
36 
-0.037 
0.832 
36 
-0.003 
0.986 
36 
-0.011 
0.949 
36 
-0.223 
0.192 
36 
Portions of fruit 
per week 
rs 
Sig. 
N 
*-0.341 
0.042 
36 
-0.312 
0.064 
36 
rp=*-0.342 
0.041 
36 
0.016 
0.925 
36 
-0.231 
0.174 
36 
-0.199 
0.244 
36 
-0.238 
0.161 
36 
Portions of 
vegetables per 
week 
rs 
Sig. 
N 
-0.095 
0.582 
36 
0.000 
0.998 
36 
-0.248 
0.145 
36 
-0.228 
0.182 
36 
-0.079 
0.649 
36 
0.053 
0.759 
36 
-0.042 
0.804 
36 
Portions of 
yoghurt per week 
rs 
Sig. 
N 
*-0.348 
0.038 
36 
-0.319 
0.058 
36 
*-0.409 
0.013 
33 
0.045 
0.794 
386 
-0.238 
0.162 
36 
*-0.363 
0.029 
36 
-0.202 
0.236 
36 
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5.4.4 Bivariate correlation of coefficient of variation of the average sum of all 
urinary metabolites of caffeoylquinic acid and its derivatives with the biomarkers 
of health 
The non-normally distributed data of the coefficient of variation (%) of the average sum of the 
excretion of all urinary metabolites for participants who completed three phases of the human 
study (n=36) was correlated with plasma L-cysteine, DL-homocysteine, cysteinylglycine, L-
glutathione, uric acid, glucose and insulin using the Spearman’s bivariate correlation (Table 
5.7).  
A moderate, positive correlation at a significance level of p≤0.01 was detected between 
coefficient of variation of the average sum of all urinary metabolites of caffeoylquinic acid and 
its derivatives and L-cysteine (rs=0.457, p=0.005) and a moderate, negative correlation at a 
significance level of p≤0.01 was detected between the coefficient of variation of the average 
sum of all urinary metabolites of caffeoylquinic acid and its derivatives and plasma uric acid 
(rs=-0.443, p=0.007). No other statistically significant correlations were established.  
Table 5.7: Summary of correlation coefficients, rS: Spearman’s coefficient, significant 
levels, p≤ 0.05*, p≤0.01** 
  Coefficient of 
variation (%) 
L-cysteine rs 
Sig. 
N  
**0.457 
0.005 
36 
DL-homocysteine rs 
Sig. 
N 
0.131 
0.455 
35 
Cysteinylglycine rs 
Sig. 
N 
0.142 
0.409 
36 
L-glutathione rs 
Sig. 
N 
-0.053 
0.769 
33 
Uric acid rs 
Sig. 
N 
**-0.443 
0.007 
36 
Glucose rs 
Sig. 
N 
-0.069 
0.691 
36 
Insulin rs 
Sig. 
N 
-0.082 
0.635 
36 
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5.4.5 Bivariate correlation of coefficient of variation of the average sum of all 
urinary metabolites of caffeoylquinic acid and its derivatives with food intake 
The non-normally distributed data of the coefficient of variation (%) of the average sum of the 
excretion all urinary metabolites for participants who completed three phases of the human 
study (n=36) was correlated with the intake of cups of coffee per week, the coffee level, the 
intake of cups of tea per week, the portions of fruit per week, the portions of vegetables and the 
portions of yoghurt using the Spearman’s bivariate correlation (Table 5.8).  
No statistically significant correlations were analysed between the coefficient of variation of the 
average sum of all urinary metabolites of caffeoylquinic acid and its derivatives with the intake 
of cups of coffee per week, the coffee level, the intake of cups of tea per week, the portions of 
fruit per week, the portions of vegetables per week and the portions of yoghurt per week.  
Table 5.8: Summary of correlation coefficients, rS: Spearman’s coefficient, significant 
levels, p≤ 0.05*, p≤0.01** 
  Coefficient of 
variation (%) 
Cups of coffee 
per week 
rs 
Sig. 
N  
0.192 
0.262 
36 
Coffee level rs 
Sig. 
N 
0.231 
0.176 
36 
Cups of tea per 
week 
rs 
Sig. 
N 
-0.226 
0.184 
36 
Portions of 
fruit per week 
rs 
Sig. 
N 
0.026 
0.882 
36 
Portions of 
vegetables per 
week 
rs 
Sig. 
N 
-0.039 
0.821 
36 
Portions of 
yoghurt per 
week 
rs 
Sig. 
N 
0.230 
0.177 
36 
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5.5 Discussion 
In chapter 5, the data of urinary excretion of metabolites of caffeoylquinic acid and its 
derivatives over 36 hours after coffee consumption for participants who completed the three 
phases of the human study, presented in chapter 4, was linked to several baseline plasma 
biomarkers of health, analysed by Miss Joana Amarante Encarnacao and will be presented in 
her PhD thesis in 2015, and data of participant’s food intake, collected by the means of semi-
quantitative food frequency questionnaires (see appendix).  
Prior to correlation analysis by either Pearson’s correlation for normally distributed data or 
Spearman’s for non-normally distributed data, the normal distribution of the data of urinary 
excretion of metabolites of caffeoylquinic acid and its derivatives over 36 hours after coffee 
consumption for participants who completed the three phases of the human study, i.e. average 
sum of all urinary metabolites, its coefficient of variation between the three phases, 
dihydrocaffeic acid-3-O-sulphate, feruloylglycine, vanilloylglycine, ferulic acid-4-O-sulphate, 
dihydroferulic acid-4-O-sulphate and ferulic acid, was tested. The data of all parameters, but not 
the excretion of feruloylgycine, is skewed towards the higher end, which is in line with data of 
previous publications which reported on the interindividual excretion of urinary metabolites of 
coffee caffeoylquinic acid and its derivatives [7, 16]. Additionally, the data of the biomarkers of 
health was also tested for normal distribution and the plasma level of DL-homocysteine was the 
only one which did not follow a normal distribution. Outliers were detected in the data of DL-
homocysteine and L-glutathione. These outliers were excluded on the basis of their location 
beyond the normal physiological ranges. Further statistical outliers of the data of glucose and 
insulin were analysed, however, these were not excluded, as they lay within healthy 
physiological ranges. Furthermore the normal distribution for the data of food intake was 
investigated. All followed a non-normal distribution and were skewed towards the higher end, 
except for the portions of fruit per week. Several statistical outliers have been detected in the 
data of food intake, however, these have not been excluded due to the fact that the food intake 
depended on the participant’s dietary habits.  
Thereafter, the data of urinary excretion of metabolites of caffeoylquinic acid and its derivatives 
over 36 hours after coffee consumption for participants who completed the three phases of the 
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human study, i.e. average sum of all urinary metabolites, its coefficient of variation between the 
three phases, dihydrocaffeic acid-3-O-sulphate, feruloylglycine, vanilloylglycine, ferulic acid-4-
O-sulphate, dihydroferulic acid-4-O-sulphate and ferulic acid was correlated with biomarkers of 
health, i.e. plasma L-cysteine, DL-homocysteine, cysteinylglycine, L-glutathione, uric acid, 
glucose and insulin. All together four weak and one moderate correlation were found. However, 
the samples size calculation based on DL-homocysteine, described in chapter 4, required 52 
participants. The target of 52 participants has not been met, however, some of the results from 
the correlation between the urinary excretion of metabolites of caffeoylquinic acid and its 
derivatives over 36 hours after coffee consumption for participants who completed the three 
phases of the human study and biomarkers of health are statistically significant.  
The correlation between the data on urinary excretion of metabolites of caffeoylquinic acid and 
its derivatives over 36 hours after coffee consumption for participants who completed the three 
phases of the human study, i.e. average sum of all urinary metabolites, its coefficient of 
variation between the three phases, dihydrocaffeic acid-3-O-sulphate, feruloylglycine, 
vanilloylglycine, ferulic acid-4-O-sulphate, dihydroferulic acid-4-O-sulphate and ferulic acid, 
and the intake of cups of coffee per week, coffee level, the intake of cups of tea per week, the 
portions of fruit per week, the portions of vegetables per week and the portions of yoghurt per 
week showed some significant results. Both the cups of coffee per week consumed and the 
coffee level (cups of coffee per week multiplied by the strength of the coffee) showed weak or 
moderate negative correlations with the highest metabolite dihydrocaffeic acid-3-O-sulphate 
and dihydroferulic acid-4-O-sulphate. This is in accordance with previously published data by 
Stalmach et al. [16], they demonstrated that a lower proportion of a high dose of coffee 
caffeoylquinic acid and its derivatives ingested, is excreted in 0-24 hour urine post coffee 
consumption and Erk et al [17] argue that this might be due to enzyme saturation, limitation of 
substrates, limited transport capacities at the enterocytes (influx and efflux) or an influence of 
the gastrointestinal tract transit time. The general notion from the data is that habitual 
consumption of several cups of coffee per day attenuates the absorption of coffee caffeoylquinic 
acid and its derivatives and therefore their excretion as urinary metabolites.   
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Chapter 6: Summary and perspective on future research  
 
6.1 Summary 
Several hydroxycinnamic acids, the hydrolysis product of caffeoylquinic acid and its 
derivatives, have been chemically conjugated with glycine yielding vanilloylglycine, 3,4-
dimethoxybenzoylglycine, dihydroferuloylglycine, 3,4-dimethoxycinnamoylglycine, and 3,4-
dimethoxydihydrocinnamoylglycine. These have been characterized using 
1
H-NMR 
spectroscopy and MS
2
 and their physicochemical properties were determined. Subsequently, a 
liquid-liquid extraction based sample preparation method followed by a rapid LC-MS
 
method 
were developed and applied to quantitatively analyse urine samples collected at baseline, 0-4, 4-
8, 8-12, 12-24 and 24-36 hours after ingestion of a standardised coffee beverage containing 730 
µmol caffeoylquinic acid and its derivatives by six subjects. After the previously described 
feruloylglycine (39 µmol over 36 hours), vanilloylglycine (33 µmol over 36 hours) was also 
quantified in similar amounts in urine post coffee consumption, in contrast, the other glycine 
conjugates were only detected in trace amounts. The data suggests that hydroxycinnamic acids 
undergo beta-oxidation  and subsequent conjugation with glycine linked to the beta-oxidation in 
mitochondria, whereas previously detected plasma 3,4-dimethoxycinnamic acid and 3,4-
dimethoxydihydrocinnamic acid either undergo demethylation or are conjugated with other 
amino acids or peptides.  
Practical quantities of dihydrocaffeic acid-3-O-sulphate, ferulic acid-4-O-sulphate and 
dihydroferulic acid-4-O-sulphate were chemically synthesized, characterized by 
1
H-NMR, 
13
C-
NMR, IR and MS
2
, and their physicochemical properties described. Subsequently these 
standards were used, along with feruloylglycine, vanilloylglycine, dihydroferulic acid and 
sinapic acid to develop a quick sample preparation method, followed by a LC-MS based 
quantitative method for urine samples. In addition, 3-, 4-, and 5-caffeoylquinic acid, 3-, 4-, and 
5-feruloylquinic acid, 3,4-dicaffeoylquinic acid and 3,5-dicaffeoylquinic acid were 
quantitatively analysed in a standardised coffee beverage prior to administration to participants 
of a subsequent human study. Moreover, the in vitro effect of porcine pancreatin, a complex 
mixture of digestive enzymes including lipases, peptidases, amylases and non-specific 
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carboxylesterases secreted by the pancreas via the main pancreatic duct and the ampulla of 
Vater into the duodenum, on coffee, 3-, 4-, and 5-caffeoylquinic acid, and 3-, 4-, and 5-
feruloylquinic acid. At 0, 10, 20, 40, and 60 minutes aliquots were taken and free caffeic acid 
and ferulic acid, respectively, quantified. The enzymic rates for caffeic acid were determined 
with 203, 1.6, 2.4 and 5.4 pmol/(mg protein*min) for coffee, 3-, 4-, and 5-caffeoylquinic acid, 
respectively. No free ferulic acid was detected in coffee nor in 3-, 4-, and 5-feruloylquinic acid 
digestion mixtures. The data indicate that pancreatin has a substantial contribution to the 
hydrolysis of the ester bond between caffeic acid and the quinic acid moiety in caffeoylquinic 
acids, in particular on 5-caffeoylquinic acid, in the small intestine. 
Subsequently, a human study investigating the correlation of absorption of coffee caffeoylquinic 
acid and its derivatives, measured by means of quantitation of urinary metabolites over 36 hours 
after consumption of a standardised coffee beverage, to several biomarkers of health and food 
intake was undertaken. The study consisted of three phases and each phase included a 72 hour 
diet low in polyphenols, 36 hours prior to consumption of the coffee beverage (washout) and 36 
hours thereafter, collection of a baseline plasma and urine sample, consumption of a 
standardized coffee beverage and a breakfast and collection of all urine up to 36 hours 
thereafter. In urine samples, collected from 0-4, 4-8, 8-12, 12-24 and 24-36 hours after coffee 
consumption the five most excreted metabolites of caffeoylquinic acid and its derivatives were 
quantified with dihydrocaffeic acid-3-O-sulphate (60.2 µmol), feruloylglycine (51.7 µmol), 
vanilloylglycine (41.9 µmol), ferulic acid-4-O-sulphate (40.7 µmol), dihydroferulic acid-4-O-
sulphate (27.0 µmol), and dihydroferulic acid (19.2 µmol) adding up to 240.6 µmol which is 
equivalent to 27.3% of the ingested dose for 62 participants of phase 1. Similar results were 
found for phase 2 and 3 including 46 and 39 participants, respectively. Furthermore, the inter- 
and intraindividual variation was determined. In phase 1, phase 2 and phase 3 the total amount 
of metabolites of caffeoylquinic acid and its derivatives excreted over 36 hours vary 
interindividually by up to 8-fold, 10-fold and 35-fold, respectively, and for the participants who 
completed all three phases of the study the average intraindividual coefficient of variation was 
52.3, 51.8, 50.2, 46.1, 37.4 and 35.9% for dihydrocaffeic acid-3-O-sulphate, vanilloylglycine, 
dihydroferulic acid-4-O-sulphate, dihydroferulic acid, ferulic acid-4-O-sulphate and 
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feruloylglycine, respectively. The data indicates that vanilloylglycine is the third most excreted 
metabolite after dihydrocaffeic acid-3-O-sulphate and feruloylglycine. The interindividual 
variation is in line with previous publications [7, 16], however, the data on the intraindividual 
variation is novel and, according to our knowledge, has not been previously reported. 
Metabolites of caffeoylquinic acid and its derivatives formed and absorbed in the colon showed 
the largest coefficient of variation between the three visits which leads us to the conclusion that 
the colonic microflora involved in the catabolism of the afore mentioned compounds is prone to 
changes in quality and quantity within six and twelve weeks between phase 1 and 2 and phase 2 
and 3, respectively.  
Finally, the data of excretion of caffeoylquinic acid and its derivatives, used as a surrogate for 
the absorption, is correlated with biomarkers of health, e.g. L-cysteine, DL-homocysteine, 
cysteinylglycine and L-glutathione, uric acid, insulin and glucose in plasma and the food intake, 
assessed by semi-quantitative food frequency questionnaires, e.g. intake of cups of coffee per 
week, the coffee level (cups of coffee per week multiplied by strength), intake of cups of tea per 
week, portions of fruit per week, portions of vegetables per week and portions of yoghurt per 
week using a bivariate correlation test, e.g. Pearson’s or Spearman’s correlation test for 
normally or non-normally distributed data, respectively. Moderate correlations were found 
between the 0-36 hours excretion of dihydrocaffeic acid-3-O-sulphate after coffee consumption 
and plasma insulin levels (rs=0.428, p=0.009), the 0-36 hours excretion of vanilloylglycine after 
coffee consumption and DL-homocysteine levels (rs=0.432, p=0.010), the 0-36 hours excretion 
of ferulic acid-4-O-sulphate after coffee consumption and plasma insulin levels (rs=0.448, 
p=0.006), and between the 0-36 hours excretion of dihydrocaffeic acid-3-O-sulphate after coffee 
consumption and the consumption of cups of coffee per week (rs=-0.434, p=0.008) and the 
coffee level, a measure of consumption of cups of coffee per week multiplied by the strength of 
the coffee (rs=-0.461, p=0.005). It can be concluded that there is a reduced absorption of 
caffeoylquinic acid and its derivatives with increased, habitual coffee intake.  
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6.2 Perspective on future research 
Previously it has been shown that 3,4-dimethoxycinnamic acid and 3,4-
dimethoxydihydrocinnamic acid are readily absorbed after coffee consumption and circulate 
within the blood stream [28], however, their further fate is uncertain and only minor amounts 
were detected in urine. Recently, ferulic acid was incubated with hepatocytes and several 
metabolites of ferulic acid have been detected using high-resolution MS, inter alia a glutathione 
conjugate. This leads to the assumption that 3,4-dimethoxycinnamic acid and 3,4-
dimethoxydihydrocinnamic acid might be conjugated with glutathione, undergo the mercapturic 
acid pathway and are excreted as 3,4-dimethoxycinnamic acid-N-acetylcysteine and 3,4-
dimethoxydihydrocinnamic-N-acetylcysteine, respectively.  
Catabolic metabolism of caffeoylquinic acid and its derivatives was assessed recently and 
several free hydroxycinnamic acids and their dihydroforms were detected after in vitro 
incubation of coffee with fecal slurries [26], however, incubation and subsequent measurements 
were only performed at a single time point. The novel finding of the intraindividual variation in 
particular of colonic metabolites of caffeoylquinic acid and its derivatives within twelve weeks 
leads to suggestion of performing the mentioned afore experiment with fecal slurries from 
participants taken at two or more time points over several weeks, incubate coffee with these and 
quantify the metabolites of caffeoylquinic acid and its derivatives. Additionally, performing a 
human study, as described in this thesis, with additional, quantitative recording of food intake 
and stool samples collected at each visit including quantitation of the fecal microflora, would 
help to elucidate the effect of diet on the colonic catabolism of caffeoylquinic acid and its 
derivatives. 
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